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Abstract 
The neurodegenerative disease amyotrophic lateral sclerosis (ALS) is clinically characterized 
by the progressive loss of upper and lower motoneurons and pathologically by the presence of 
Tar DNA-binding protein of 43 kDa (TDP-43) positive aggregates. The cause of this fatal and 
rapidly progressing disease, for which effective treatments are lacking, remains still unknown. 
Increasing evidence points to altered RNA metabolism as a potential pathomechanism due to 
the high percentage of RNA binding proteins (RBP) encoded by disease causing genes and their 
aggregation in ALS patients. Mutations in the RBPs Heterogeneous nuclear ribonucleoproteins 
A1 (HNRNPA1) and HNRNPA2B1 were identified in ALS and Multisystem proteinopathy 
(MSP) patients. Another member of the HNRNPA family, HNRNPA3, was also linked to ALS 
due to its ability to bind Chromosome 9 open reading frame 72 (C9ORF72) repeats, and its 
localization to p62 positive TDP-43 negative C9ORF72 inclusions. The structural similarity of 
HNRNPA proteins to TDP-43, their ability to bind one another, and the presence of TDP-43 
aggregates in HNRNPA1 and HNRNPA2 mutation carriers, suggest common pathomechanisms 
of these proteins. To unravel the physiological function of HNRNPA1, HNRNA2B1, and 
HNRNPA3, and their association to ALS, this study aims to establish zebrafish loss of function 
mutants lacking the orthologues of the corresponding genes. Genetic analysis revealed that due 
to the teleost specific genome duplication zebrafish possess two HNRNPA1 orthologues named 
hnrnpa1a and hnrnpa1b, but no HNRNPA2B1 orthologue. In this thesis hnrnpa1a, hnrnpa1b, 
and hnrnpa3 zebrafish mutants were generated and characterized, and compared to the tardbp-
/-; tardbpl-/- mutant, which lacks the zebrafish TDP-43 orthologues.  
While single hnrnpa1a, hnrnpa1b, and hnrnpa3 knockout (KO) zebrafish are viable and fertile, 
double hnrnpa1a and hnrnpa1b KO mutants are embryonically lethal. Moreover, the double 
mutants are developmentally delayed, have shortened motoneuron axons, muscle defects, show 
vascular mispatterning with reduced or absent blood flow, have a thinned yolk extension and 
increased neutral lipid uptake from the yolk. Some of these phenotypic alterations, such as 
shortened motoneurons and degenerated muscles, are also present in tardbp-/-; tardbpl-/- mutants 
and are presumably a general phenomena preceeding the embryonic lethality. The impaired 
intersomitic vessels observed in both mutants show distinct characteristics, since hnrnpa1a-/-; 
hnrnpa1b-/- mutants only develop dorsal lateral lamellopodia, diverting from their physiological 
migration path and misconnect, whereas tardbp-/-; tardbpl-/- mutants additionally have ectopic 
endothelial sprouts from the dorsal aorta. 
RNA sequencing of hnrnpa1a-/-; hnrnpa1b-/- embryos revealed apolipoprotein (apoda.1) as one 
of the top downregulated genes. APOD is a lipid transporter and was previously shown to be 
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neuroprotective. Upon knockdown of apoda.1 in wildtype embryos we could mimic the lipid 
phenotype observed in hnrnpa1a-/-; hnrnpa1b-/- mutants. This finding points to a direct link 
between HNRNPA1 loss of function and downregulation of APOD. We hypothesize that 
HNRNPA1 ALS patients lack the neuroprotective upregulation of APOD, which contributes to 
disease progression and neurodegeneration.  
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Zusammenfassung 
Die neurodegenerative Erkrankung Amyotrophe Lateralsklerose (ALS) ist klinisch durch den 
Verlust der oberen und unteren Motorneuronen und pathologisch durch die Präsenz von 
Tar DNA-binding protein of 43 kDa (TDP-43) positiven Aggregaten gekennzeichnet. Die 
Ursache dieser unheilbaren und schnell fortschreitenden Krankheit ist bisher nicht bekannt. 
Mehrere Forschungsergebnisse, wie zum Beispiel der große Anteil an aggregierenden RNA 
bindenden Proteinen (RBPs) und Mutationen in den entsprechenden Genen als 
Krankheitsursache in ALS Patienten, deuten darauf hin, dass veränderter RNA Metabolismus 
eine große Rolle in der Krankheitspathogenese spielt. Mutationen in den RBPs Heterogeneous 
nuklear ribonukleoprotein A1 (HNRNPA1) und HNRNPA2B1 wurden in Multisystem 
Proteinopathy (MSP) und ALS Patienten identifiziert. Ein weiteres Mitglied der HNRNPA 
Protein Familie, HNRNPA3, wurde zudem mit ALS assoziiert, da es an Chromosome 9 open 
reading frame 72 (C9ORF72) Wiederholungssequenzen bindet und mit p62 positiven TDP-43 
negativen C9ORF72 Aggregaten kolokalisiert. Die strukturelle Ähnlichkeit der HNRNPA 
Proteine zu TDP-43, deren direkte Interaktion miteinander, sowie TDP-43 Aggregate in 
HNRNPA1 Patienten, suggerieren gemeinsame Pathomechanismen dieser Proteine.  
Zur Studie der physiologischen Funktion von HNRNPA1, HNRNPA2B1 und HNRNPA3, und 
deren Beitrag zu ALS, wurden Zebrafischmutanten generiert, in welcher die jeweiligen 
orthologen Gene defekt sind. Die genetische Analyse ergab, dass durch die Teleost spezifische 
Genomduplikation im Zebrafish zwei HNRNPA1 Orthologe existieren: hnrnpa1a und 
hnrnpa1b, jedoch kein HNRNPA2B1 Ortholog. Diese Dissertation widmet sich der Erstellung 
und Charakterisierung der hnrnpa1a, hnrnpa1b und hnrnpa3 Mutanten, sowie deren 
Gegenüberstellung mit der tardbp-/-; tardbpl-/- Mutante, in welcher die Zebrafisch TDP-43 
Orthologe defekt sind. 
Während die Einzelmutanten von hnrnpa1a, hnrnpa1b, und hnrnpa3 keine Auffälligkeiten 
zeigen, ist die Doppelmutante von hnrnpa1a und hnrnpa1b embryonal letal. Die 
Doppelmutante ist zudem entwicklungsverzögert, hat kürzere Motoneurone und degenerierte 
Muskeln, fehlentwickelte Gefäße mit stark verminderter oder fehlender Durchblutung, sowie 
eine dünnere Dottersackverlängerung und erhöhte Aufnahme von neutralen Lipiden aus dem 
Dottersack. Einige dieser phenotypischen Veränderungen, wie zum Beispiel die verkürzten 
Motoneurone und degenerierten Muskeln, sind auch in tardbp-/-; tardbpl-/- Mutanten präsent. 
Allerdings, kann man davon ausgehen, dass diese Veränderungen eine unspezifische Folge des 
sterbenden Embryos darstellen. Die in beiden Mutanten beobachtete Fehlbildung der Gefäße 
unterscheidet sich zudem, da hnrnpa1a-/-; hnrnpa1b-/- Mutanten laterale Lamellopodien dorsal 
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ausbilden, welche ihren physiologischen Migrationsweg verlassen und fehlerhafte 
Verbindungen bilden, wohingegen zusätzliche ektopische Endothelzellprozesse aus der 
dorsalen Aorta charakteristisch für tardbp-/-; tardbpl-/- Mutanten sind.  
RNA Sequenzierung der hnrnpa1a-/-; hnrnpa1b-/- Doppelmutante identifizierte apolipoprotein 
(apoda.1) als eines der Gene, dessen Expression am meisten reduziert ist. APOD ist ein 
Lipidtransporter und besitzt neuroprotektive Eigenschaften zu besitzen. apoda.1 knockdown in 
Wildtyp-Embryonen führte zu dem gleichen Lipidphenotyp, welcher in hnrnpa1a-/-; hnrnpa1b-
/- Mutanten beobachtet wurde. Diese Erkenntnis stellt eine direkte Verbindung zwischen 
HNRNPA1 Funktionsverlust und reduzierter APOD Expression dar. Wir nehmen an, dass 
HNRNPA1 ALS Patienten die neuroprotektiv wirkende vermehrte Expression von APOD fehlt, 
was zur Krankheitheitsenticklung und Neurodegeneration beisteuert. 
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1 Introduction 
 
According to a report by the United Nations in 2015, the world’s population age increased so 
drastically that the number of people aged 60 and over is predicted to more than double in the 
next 35 years [1]. This aging society is accompanied by an increased number of people 
suffering from neurodegenerative diseases, as aging represents the main risk factor for 
neurodegeneration. While Alzheimer’s disease (AD) is the most prevalent neurodegenerative 
disease, Parkinson’s disease (PD), Huntington’s disease (HD), prion disorders, tauopathies, 
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD) are also 
becoming more common [2]. Interestingly, in all these neurodegenerative diseases a subset of 
neurons becomes particularly susceptible to neurodegeneration, and most of them share the 
presence of distinct proteins aggregates [3] [4]. 
Thanks to enormous progress in the past years in identifying genetic variants, which modify 
or cause various diseases, exon sequencing and genome-wide association studies (GWAS) led 
to the discovery of thousands of phenotype-associated loci. Although several pathways, such 
as protein degradation or RNA metabolism could be associated with neurodegenerative 
diseases, little is known about the involved proteins’ role in disease and their physiological 
functions. Investigating the disease genes’ physiological functions and the impact of patient-
associated mutations in cell culture and animal models will help us to better understand the 
pathomechanisms in the future.  
Although many advances were made in the field, effective therapies are currently lacking, and 
drug development remains slow as clinicians and researchers are still challenged by the 
diversity of potential underlying disease mechanisms and overlapping clinical symptoms of 
different neurodegenerative diseases. While only 10% of the cases are familial, also in 
sporadic cases susceptibility genes are occasionally affected. In addition, there is evidence 
that not only single gene mutations cause neurodegeneration, but that environmental risk 
factors can also play a role in disease development [5]. Risk factor genes and environmental 
factors can for example act on a local level by affecting cell adhesion or neurotransmission; or 
influence the broader system by altering, for example, inflammation or metabolism [6] [7]. 
New approaches aim to specify patient subgroups and to identify the pathological 
mechanisms that are upstream and causative for pathology and clinical symptoms. Thereby 
individually tailored therapeutics depending on the underlying genetic causes and aggregated 
disease proteins may be established [8]. The identification of disease-related genes’ function 
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and their involvement in disease mechanisms allows for successful implementation of this 
goal.  
1.1 Aim of the project 
 
The aim of this PhD thesis is to characterize the functions and downstream targets of the 
ALS-associated proteins Heterogeneous nuclear ribonucleoprotein (HNRNP) HNRNPA1 and 
HNRNPA2B1 and HNRNPA3 in vivo. Mutations in HNRNPA1 and HNRNPA2B1 were 
found to be causative for ALS. Moreover, these two proteins mislocalize to the cytoplasm in 
muscle biopsies of Multisystem proteinopathy (MSP) patients and colocalize with the main 
ALS-associated protein Tar DNA-binding protein of 43 kDa (TDP-43) [9]. HNRNPA3 is 
linked to ALS due to its ability to bind Chromosome 9 open reading frame 72 (C9ORF72) 
repeats, the most common genetic cause of ALS, and the identification of HNRNPA3 
pathology in ALS patients with C9ORF72 repeat expansions [10] [11]. It is not clear yet 
whether the mutations and/or the mislocalization of these predominantly nuclear proteins to 
the cytoplasm resemble a gain or loss of function, or both. By generating loss of function 
zebrafish of the HNRNPA1 orthologues hnrnpa1a and hnrnpa1b, and the HNRNPA3 
orthologue hnrnpa3, I aim to generate an animal model that mimics the potential HNRNPA1, 
HNRNPA2B1 or HNRNPA3 loss of function scenario in ALS.  
First, general tools were established, such as zebrafish Hnrnpa1a, Hnrnpa1b, and Hnrnpa3 
specific antibodies, to provide the basis for this study. Next, I generate single hnrnpa1a, 
hnrnpa1b, and hnrnpa3 knockout (KO) zebrafish by genome editing, using the Clustered 
regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas)9/Cas9 
system. As these genes are highly similar in sequence and overlapping functions for the 
respective proteins were described, I incross the single KO to generate double or triple loss of 
function mutants. Zebrafish Hnrnpa1a, Hnrnpa1b, and Hnrnpa3 specific antibodies will 
demonstrate if the mutants are full loss of function alleles. After successful generation of 
these lines, I analyze them for phenotypical, biochemical and molecular alterations. My focus 
will be to thoroughly describe the obtained phenotype, analyze molecular changes, and 
correlate these findings with previously established Hnrnpa animal models. HNRNPA and 
TDP-43 are both members of the HNRNP protein family, are involved in ALS, and are 
structurally and functionally very similar. For successful comparison of molecular changes 
associated with Hnrnpa1a, Hnrnpa1b, Hnrnpa3 or TDP-43 loss of function in zebrafish, RNA 
sequencing is performed on the corresponding KO mutants. By determining the similarities 
between the Hnrnpa1 KO zebrafish and the previously generated Tdp-43 loss of function
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zebrafish I aim to identify disease related commonalities [12]. These might be ultimately used 
to design novel treatment options.  
1.2 Amyotrophic lateral sclerosis  
 
ALS, also known as Lou Gehrig disease, is an adult-onset neurodegenerative disease, which 
is characterized by the loss of upper (UMN) and lower motoneurons (LMN). The name 
derives from both the degeneration of corticospinal motoneurons, of which the descending 
axons in the lateral spinal cord are scarred (lateral sclerosis), and the loss of spinal 
motoneurons with secondary denervation and muscle wasting (amyotrophy) [13]. With an 
incidence varying from 0.3 to 2.5 cases per 100.000 people per year, ALS represents the most 
frequent motoneuron disease (MND) [14].  
1.2.1 ALS and closely associated diseases  
 
Neurodegenerative diseases are often characterized by the aggregation of proteins. This 
feature also helps to differentiate among other diseases, which is hardly possible according to 
clinical symptoms. Besides clinically pure forms of ALS, patients are often diagnosed with 
additional symptoms and there is significant clinical and pathological overlap to other disease 
entities. With advancing genome sequencing, clinical and pathological examination of ALS 
and other diseases it became clear, that ALS patients most frequently show additional features 
of FTLD and MSP. 
1.2.1.1 Frontotemporal lobar degeneration 
 
Historically, ALS and FTLD were thought two represent two distinct neurodegenerative 
disorders. With the discovery of common clinical, genetic, and pathological characteristics 
ALS and FTLD are now considered to be two extreme ends of a disease spectrum [15, 16]. 
FLTD describes a heterogenous group of diseases, which all primarily affect the frontal and 
temporal lobes of the brain, but are divers on a clinical, pathological, and genetic level. There 
are three major associated disorders including semantic dementia (SD), progressive non-
fluent aphasia (PNFA), and behavioral variant frontotemporal dementia (bvFTD), which is 
the most frequent variant accounting for 50% of FTLD patients. FTLD represents the second 
most common dementia after AD in patients under 65 years of age and has an incidence of 
3.5-4.1 per 100.000 people per year [17]. Next to FTLD related clinical features, neurological 
imaging obtained from magnetic resonance imaging (MRI), computed tomography (CT), and 
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positron-emission tomography (PET) allows FTLD diagnosis[18]. FTLD is characterized by 
behavioral changes such as neuropsychological, speech, and language deficits typical of 
frontotemporal dysfunction, and neuropathologically by deposits of mostly TDP-43 or Tau 
[19]. In few cases other proteins aggregate in FTLD patients leading to the establishment of 
FTLD subtypes according to the main deposited protein. Patients with Tau positive inclusions 
are referred to as FTLD-TAU, which make up 45% of all FTLD cases. Tau pathology 
negative cases include FTLD-TDP patients (45%), who show TDP-43 positive inclusions, and 
FTLD-FUS patients (9%) with Fused in Sarcoma (FUS) positive inclusions. Approximately 
1% of FTLD cases show inclusions for proteins of the ubiquitin-proteasome pathway, lacking 
TDP-43, FUS, or Tau pathology and are referred to as FTLD-UPS [20]. Patients with 
C9ORF72 mutations show apart from TDP-43 inclusions also aggregation of dipeptide repeat 
proteins (DPR) proteins [21] [22]. As TDP-43, DPRs, and FUS aggregates are likewise found 
in ALS cases, ALS and FTLD were pathologically connected [20]. This connection is further 
supported by the patients’ symptom overlap, as around 14% of ALS patients exhibit FTLD 
like symptoms and 30-50% of FTLD patients suffer from ALS associated movement 
disorders. Symptomatic subclasses reflecting ALS or FLTD or mixed forms were defined, 
such as ALS with cognitive and behavioral impairment (ALS-Ci/Bi), FTLD-MND for FTLD 
with motoneuron dysfunction, and ALS-FTLD for patients with similar portions of ALS or 
FLT related symptoms [23] [24] [25] [26]. The genetic overlap of ALS and FTLD is further 
supported by genetic studies, which revealed diseases causing mutations in the same genes, 
such as TDP-43 and FUS. The ultimate link is provided by C9ORF72 mutations, which cause 
ALS, FTLD, or ALS-FTLD in a similar frequent manner [21] [22]. Despite overlapping 
characteristics regarding ALS and FTLD genetics and pathology, some disease mutations and 
proteins exist that can be uniquely assigned to one of the diseases. Mutations in the 
microtubule-associated protein tau (MAPT) encoding the microtubule-associated protein Tau 
result in FTLD characterized by Tau positive aggregates, while mutations in SOD1 encoding 
the copper/zinc superoxide dismutase 1 are associated with pure ALS [29].  
1.2.1.2 Multisystem proteinopathy 
 
MSP is an inherited pleiotropic degenerative disorder that affects multiple tissues and organs, 
such as the muscle, bone, or the nervous system. The phenotype is highly variable and shares 
symptoms with inclusion body myopathy (IBM), FTLD, ALS or Paget’s disease of bone 
(PDB). Clinically, MSP is defined to include the diagnosis of at least two of the diseases 
IBM, PDB, and ALS/FTLD [30]. GWAS studies have for the first time linked ALS/FTLD to 
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MSP by the identification of Valosin-containing-protein (VCP) mutations in MSP and ALS 
patients [31] [32] [33]. Additionally, mutations in p62 were described for patients suffering 
from PDB, ALS, or FTLD providing another gene that links these diseases together [34]. 
Recently, rare mutations in HNRNPA1 and HNRNPA2B1 were identified in MSP families, 
which are also present in sporadic (sALS) and familial (fALS) cases of ALS. Postmortem 
tissues obtained from MSP patients show ubiquitin-positive inclusions that contain RBPs, 
such as TDP-43, HNRNPA1, or HNRNPA2B1 [35] [36]. Additionally, aggregates of proteins 
involved in ubiquitin-dependent autophagy, including P62/SQSTM1, VCP, OPTINEURIN, 
and UBIQUILIN-2 were found in these patients [37]. These findings support the involvement 
of disturbed RNA metabolism and autophagy as key contributors to pathogenesis related to 
HNRNPA1 or HNRNPA2B1 mutations. 
 
The common genetic mutations together with the overlapping clinical symptoms, and 
aggregated proteins among the disease spectra point to shared molecular mechanisms in ALS, 
FTLD and MSP. The phenomenon of ALS and its overlap to other diseases raises 
fundamental questions for seemingly distinct diseases, but also presents important 
opportunities for developing therapeutics for a broad spectrum of degenerative diseases.  
1.2.2 ALS clinical classification  
 
ALS belongs to the group of MNDs. Apart from ALS this category comprises several other 
diseases all sharing the characteristic of sequential degeneration of LMNs or UPMs. In 
contrast to ALS, in Primary lateral sclerosis (PLS) and Pseudobulbar palsy only UMN are 
affected, whereas Progressive muscular atrophy (PMA) and Progressive bulbar palsy (PBP) 
result only in LMN loss. ALS is a heterogeneous disease from a clinical point of view and 
subsets of the disease are classified by the degeneration of different sets of motoneurons and 
impairment of different body regions [38]. Most of the patients’ (approximately 70%) disease 
starts as degeneration of UMNs and LMNs in the limbs, resulting in limb muscle weakness 
and locomotion deficits. Around 25% of the patients present bulbar onset including UMNs 
and LMNs dysfunction of cranial nerve nuclei, causing in dysarthria and dysphagia. The 
remaining 5% of the patients show initial trunk or respiratory dysfunction [39]. Although, the 
clinical presentation and the disease course of ALS vary among patients, the mean onset is at 
55 years of age and the symptoms progressively spread to other parts of the body ultimately 
resulting in dysfunction of all voluntary muscle control. At late disease stage wasting of 
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respiratory muscles leads to patients death approximately three years after symptom onset due 
to respiratory failure [40].  
In order to diagnose a disease as ALS the El Escorial World Federation of Neurology Criteria 
of the Diagnosis of Amyotrophic Lateral Sclerosis developed standard criteria that have to be 
fullfilled [41]. The core of these criteria are the degeneration of LMN and UMN and the 
exclusion of other underlying diseases [42] [43]. The involvement of LMN is depicted by 
increasing muscle atrophy, muscle failing or muscle twitching (fasciculations) caused by 
spontaneous discharges of motor neurons. Fasciculations are often initially present at hand 
muscles, but electromyography (EMG) analysis is indispensable for final diagnosis. Signs of 
UMN degeneration are spasticity and degeneration in the motor cortex, which can be assessed 
by MRI and PET. Exclusion of other diseases via electrophysiology and cognitive testing 
leads to final ALS diagnosis [44].  
After the first description of ALS in 1869 by Jean Martin Charcot, nowadays there is still no 
cure for ALS and the majority of patients are treated with the FDA approved drug Riluzole 
(Rilutek, Sanofi-Aventis) or by symptomatic orientated therapy. Riluzol is a sodium channel 
blocker lowering glutamate effects and acts as a neuroprotector by decreasing glutamate 
mediated excitotoxicity. Upon Riluzole treatment the disease course of ALS is slightly 
modified and achieves only a modest improvement in survival of 3-6 months [45].  
1.2.2.1 Molecular pathology and genetics in ALS 
 
Over the past years ALS research lead to better understanding of disease mechanism by 
characterization of protein inclusions and the identification of their key components. While 
ubiquitin immunoreactive inclusions are found in all ALS cases [46, 47], pathological 
subtypes were established according to the major aggregating protein. TDP-43, which is 
found in inclusions in 97% of ALS, represents the most abundant aggregated protein (ALS-
TDP), while SOD-1 inclusion pathology is only seen in approximately 2% of ALS cases 
(ALS-SOD1). Approximately 1% of ALS cases (ALS-FUS) show inclusions of FUS protein 
[48] [19] (reviewed in [49]).  
Genetic studies further contributed to identify mutations in several genes that cause ALS. 
fALS is inherited by a dominant trait with high penetrance, while the remaining 90% are 
sALS patients who do not show a family history. Even though a high number of ALS genes 
was identified, understanding the precise mechanisms causing the disease remains a 
challenge.  
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The first genetic mutations, which were found to cause ALS, were identified in the SOD1 
gene in 1993 and account for about 12-20% of fALS cases and 1-2% of sALS cases [50]. 
SOD1 mutations cause pure ALS with SOD1 and ubiquitin aggregates, devoid of TDP-43 and 
FUS inclusions [51] [52]. The discovery of mutations in TARDBP (which encodes TDP-43) 
in autosomal dominant ALS and FTLD families identified the pathological hallmark of FTLD 
and ALS and make up to ~4% of fALS cases, which show TDP-43 positive inclusions [19]. 
FUS mutations account for 4% of fALS and 1% of sALS cases, which show FUS positive 
inclusions [53].  
As protein aggregates are the major hallmark of ALS pathology, defects in protein 
homeostasis were early suggested as a potential pathomechanism. Indeed, many mutations 
that cause ALS are involved in the protein degradation pathway. These mutations are thought 
to lead to a loss of function resulting in impaired protein degradation, which ultimately leads 
to pathological protein aggregates. Examples are mutations in the genes Sequestosome 
(SQSTM1), Optineurin (OPTN), Ubiquilin (UBQLN2), Valosin-containing protein (VCP) and 
Cyclin-F (CCNF) [54] [55] [56] [31] [57]. All these ALS cases share a common pathology 
characterized by inclusions of ubiquitinated proteins and TDP-43 aggregates. 
With the recent discovery of a GGGGCC (G4C2) hexanucleotide repeat expansion in the 
noncoding region of the C9ORF72 the most common genetic cause of ALS could be 
identified being responsible for 40%-50% of fALS cases and 8%-10% of sALS cases [21] 
[22]. While healthy individuals have 2 to 30 repeats, the repeat number expands to hundreds 
and thousands in C9ORF72 patients (C9-ALS) [58] [59]. C9ORF72 protein has been 
proposed to be a DENN (differentially expressed in normal and neoplastic cells) protein with 
a guanine exchange factor function for small GTPases based on sequence homology. 
Moreover, recent studies suggested a function for C9ORF72 in autophagy and stress granule 
(SG) formation [60] [61] [62] [63]. Loss of C9ORF72 function was early suggested as an 
underlying pathomechanism. While the repeat expansion suppresses the production of 
C9ORF72 protein by inhibiting transcription, several disease models could not identify a 
direct correlation between reduced C9ORF72 levels and neurodegeneration [21] [22], e.g. 
C9ORF72 deficient mice do not display neurodegenerative phenotypes [64] [65]. Moreover, 
no study could so far identify a pathway that links C9ORF72 activity to neuronal survival. 
Apart from C9ORF72 loss of function in ALS, two other disease mechanisms are under 
debate to cause C9-ALS. First, the repeat expansion generates DPRs that arise from non-ATG 
translation (RAN translation). Hereby all possible reading frames of the sense and anti-sense 
strand are translated giving rise to five different DPRs: GA, GR, GP, PR and PA [66] [67] 
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[68] [62]. The accumulation of transcripts with the long repeat sequence in RNA foci suggests 
toxic RNA gain-of-function pathomechanisms as these RNA foci are suggested to disrupt 
RNA metabolism and sequester RBPs. This is supported by the finding that RBPs, with the 
biggest group being HNRNPs including HNRNPA1, HNRNPA2/B1 and HNRNPA3, bind to 
G4C2 repeats and are sequestered in RNA foci in the spinal cord of ALS/FTLD patients, 
resulting in their cellular depletion and perturbed cellular RNA metabolism [21] [69] [70] 
[71]. Second, the DPR proteins are found in protein deposits, which are p62 positive and 
TDP-43 negative [62] [72] and are to different extents neurotoxic (reviewed in [73]). Poly GA 
aggregates, for example were found to recruit 26S proteasome complexes, providing a link of 
C9ORF72 repeats and protein aggregation due to an impaired proteasome function [72]. 
Additionally, in all C9-ALS cases pathological aggregation of TDP-43 can be found in the 
cortex and cerebellum [74]. So far only HNRNPA3 was identified to be contained in some 
p62 positive TDP-43 negative C9ORF72 specific inclusions [67]. Further evidence for a 
relationship between HNRNPA3 and C9ORF72 comes from in vitro studies. These showed 
that knockdown (KD) of HNRNPA3 in cell culture and primary fibroblasts from C9-ALS 
patients lead to DPR accumulation and an increase of repeat RNA foci [11]. Most likely all 
the C9 associated pathomechanisms are not mutually exclusive. 
1.2.2.2 The role of RBPs in ALS 
 
Apart from mutations in TDP-43 and FUS, mutations in other RBPs were identified, 
including TATA box-binding protein associated factor 15 (TAF15) [75], Ewing sarcoma 
breakpoint region 1 (EWSR1) [76], Matrin-3 (MATR3) [77], HNRNPA1, HNRNPA2B1 [9], 
and T-cell intracytoplasmic antigen (TIA1) [78]. In most of the cases these mutations cause 
aggregates of the respective protein in ALS patients’ brains. Motoneurons are the main 
affected cells in ALS and with their axons reaching lengths up to 1m they are dependent on 
transport of mRNAs along the cytoskeleton and local translation. Moreover, due to their non-
dividing nature they are dependent on tight mRNA homeostasis regulation [79]. These 
features make motoneurons especially vulnerable to dysfunctional RNA metabolism and 
potentially link the selective motoneuron degeneration observed in ALS to mutated and 
aggregated RBPs. 
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1.2.2.2.1 TDP-43 
 
TDP-43 is able to shuttle between the nucleus and the cytoplasm and has a variety of 
important functions in RNA metabolism ranging from transcription regulation, splicing, to 
microRNA (miRNA) processing [80]. TDP-43 was found to bind thousands of mRNAs by 
which it regulates their splicing and RNA stability suggesting potential impact on RNA 
metabolism on a broad scale [81] [82]. Additionally, TDP-43 regulates its own transcript 
levels through an autoregulatory feedback loop by binding to its own 3’ UTR [81] [83] [84]. 
Cytoplasmic mislocalized TDP-43 as observed in ALS, is heavily post-translationally 
modified via cleavage, phosphorylation, acetylation, and ubiquitination, and forms granular 
pathology that assembles to large inclusions [85]. These pathogenic variants are mostly 
located in the C-terminus of the protein, which allows ribonucleoprotein binding and is 
involved in splicing. At the C-terminus a prion like domain (PrLD) is present, which is 
enriched in uncharged polar amino acids and drives protein aggregation. The nuclear 
clearance of TDP-43 and its accumulation into aggregates suggests that loss of nuclear TDP-
43 function may lead to deleterious abnormal RNA metabolism [86]. Alternatively, toxic gain 
of function from increased normal TDP-43 activity or from a novel toxic cytoplasmic 
function may be culprit [87].  
1.2.2.2.2 TIA1 
 
TIA1 is structurally very similar to TDP-43 and HNRNPAs. Under normal conditions TIA1 is 
predominantly localized in the nucleus and functions in RNA metabolism including RNA 
splicing, and mRNA silencing [88]. Upon stress TIA1 translocates to the cytoplasm, where it 
suppresses RNA translation and functions in SG formation through self-association of its 
PrLD [89] [90]. Mutations in TIA1 were recently found in ALS patients, whereby all the 
mutations are found in the PrLD domain and cause impaired SG disassembly and promote 
accumulation of non-dynamic SGs that sequester TDP-43 [91] [92]. Patients with TIA1 
mutations do also show TDP-43 positive cytoplasmic inclusions in the CNS, however no 
aberrant accumulation was reported for TIA1 [93]. 
1.2.2.2.3 FET proteins 
 
Based on their similar structure - a zinc finger domain, a RNA recognition motif (RRM), and 
a N-terminal low complexity PrLD - FUS, EWSR1, and TAF15 proteins are grouped together 
and termed FET family [94]. The FUS protein is also a member of the HNRNP protein family 
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(sometimes referred to as HNRNP P2) and mutations in FUS are therefore hypothesized to 
lead to neuronal death via disturbed RNA metabolism. The majority of FUS mutations cluster 
at the C-terminus of the protein in the PY-NLS domain [95] and these mutations are thought 
to impair transport mediated nuclear import leading to redistribution of FUS to the cytosol 
[96] [97] where it  accumulates together with other FET proteins in SG as a cellular stress 
response [98]. Eventually, accumulated FUS transitions to stable inclusions, which represent 
the pathological hallmark in patients [95]. As FUS acts as a transcriptional regulator and 
controls RNA splicing of many genes, nuclear loss of function due to redistribution may lead 
to impaired RNA metabolism and detrimental effects in neurons. Due to the high similarity of 
its genomic sequence and protein structure to the previously identified FUS gene in ALS, 
EWSR1 was considered as a potential disease gene, of which two mutations were 
subsequently identified in sALS cases [78]. Moreover, mutations in sALS and fALS 
associated mutations were identified in TAF15, which functions in DNA repair, alternative 
splicing, transcription and RNA transport [75].  
1.2.2.2.4 HNRNPA proteins 
 
The latest discovery of mutations in RBPs was in 2013 in two other members of the HNRNP 
family – HNRNPA1 and HNRNPA2B1. Three HNRNPA1 mutations were linked to ALS 
(D262N; P288S) or MSP (D262V). Only one mutation in HNRNPA2B1 (D290V) was 
reported in a family with MSP, which is surprisingly homologue to the ALS associated 
HNRNPA1D262V mutation [9] [99]. Mutations in HNRNPA1 and HNRNPA2B1 show an 
autosomal dominant mode of inheritance in fALS and account for <1% of fALS and sALS 
cases, while they are also associated with the broader disease spectrum MSP [100]. The 
underlying disease mechanism connecting HNRNPA1 or HNRNPA2B1 mutations to 
neurodegeneration is not clear yet, but loss of function by mislocalization and/or aggregation 
or gain of function due to toxic aggregates or a combination of both was suggested. A loss of 
function mechanism was suggested by a group, which reported increased aggregation and 
localization of mutant HNRNPA2B1 to SGs in a cell-based system [101]. Evidence for only 
partial loss of function is supported by a study from Martinez et al., which revealed that the 
HNRNPA2B1D290V mutation is not equivalent to loss of HNRNPA2B1 protein in regard to 
alternative splicing changes [102].  
Evidence for a functional link between HNRNPA1 or HNRNPA2B1 and the main ALS 
associated protein TDP-43 comes from a study showing that the expression of HNRNPA1 
and HNRNPA2/B1 is altered in patients with FTLD-TDP, suggesting that perturbations in 
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RNA metabolism are not exclusively driven by TDP-43 loss of function [103]. Moreover, a 
direct interaction between HNRNPA1 and UBQLN1 was determined, which is dependent on 
the HNRNPA1 PrLD domain and reduced by HNRNPA1D262V mutations [104]. Lastly, 
HNRNPA1 and HNRNPA2 were linked to the ALS gene VCP as they were identified as 
VCP-associated phenotype suppressors when knocked down in a Drosophila VCP mutant 
model [105].  
The majority of the so far identified mutations in HNRNPA1 and HNRNPA2/B1 are localized 
in the PrLD. Under physiological conditions these HNRNPs were shown to self-aggregate 
and this behavior is increased by the disease-causing mutations. The mutated HNRNPA1 and 
HNRNPA2B1 form self-seeding fibrils that can recruit wildtype protein, which suggests 
prion-like properties [9]. RNA binding to HNRNPA1 further enhances fibrillization and 
formation of protein-rich droplets suggesting that HNRNPA1 interacts with RNA to mediate 
phase transition and that mutations promote fibrillization and alter the dynamics of 
membraneless organelles ultimately leading to SG formation [106]. An exception to these 
mutations is the P288S mutation, which was identified in a Chinese family with “Flail arm 
ALS”, an atypical ALS subtype with severe wasting and weakness of the arms without 
significant functional involvement of other regions [107]. The mutation localizes to the PY-
domain at the C-terminus of the protein [99]. It can be concluded that HNRNPA1 and 
HNRNPA2/B1 were clearly linked to ALS, while their genetic mutation frequency is low 
[108]. 
 
Disease causing mutations in the TDP-43, FUS, HNRNPA1, HNRNPA2B1, EWSR1, TAF15 
and TIA1 suggest that disturbed biology of RBPs plays a central role in ALS pathology 
(reviewed in [109]). The RBPs TDP-43, FUS, HNRNPA1, HNRNPA2B1, MATR3, and 
TIA1 in particular share common features. They are ubiquitously expressed and contain 
multiple RNA binding domains and a PrLD, which makes them aggregation prone. The 
majority of disease causing mutations is localized in the PrLD and impacts the domain’s 
aggregation potential inducing liquid-liquid phase transition and leading to altered SG 
kinetics [110]. By phase separation the local protein concentration is quickly increased, which 
causes recruitment of other proteins, and promotes their interaction within the SG. This 
process is very dynamic and can return into resting state quickly. Interestingly, disease-
causing mutations clustered in the PrLDs of TDP-43, FUS, HNRNPA1, and HNRNPA2B1 
enhance the prion like state of the protein, which promotes assembly into SG under stressors. 
During this process the prion domains form an abnormally strong interaction, which persists 
Introduction 
 12 
after stress relieve [111] [112] [113]. This leads to persistent sequestration of mRNA and 
impedes their translation [114]. Interestingly, increased formation of aggregates by liquid-
liquid phase transition was also observed by elevated protein concentrations due to 
cytoplasmic mislocalization linking nuclear loss of function and prion like behavior of the 
ALS associated proteins [115] [111].  
In conclusion, under physiological conditions the RBPs are found in RNA granules in the 
nucleus, but they mislocalize to the cytoplasm in disease state where they form inclusions 
[116] [117]. Due to their common nature and their similar behavior in disease state, 
researchers suggested a common pathogenic mechanism for these proteins in ALS, which 
causes loss or gain of function or a combination of both (reviewed in [109] [118]. 
1.3 HNRNP proteins 
 
HNRNP proteins are nuclear proteins that bind to nascent transcripts produced by RNA 
polymerase II and are mostly associated in RNA-protein complexes [119]. Historically,  
 
Figure 1.1 - Schematic illustration of the HNRNP family. Except of hnRNP E, K and U all members possess 
one or more RRM domains, which are involved for RNA/ssDNA binding. Glycine rich domains, which are 
found in HNRNPA/B, HNRNP H, HNRNP L, HNRNP U, FUS and TDP-43 and are highly aggregation prone. 
(Adapted from [120]) 
 
HNRNP proteins were grouped according to their RNA binding domains (RBD) composition 
[119]. The first list of HNRNPs was ultimately generated by co-immunopurification with 
monoclonal antibodies against HNRNPC, followed by two-dimensional gel electrophoresis, 
generating a group of 20 proteins that were named HNRNPs A-U (see Figure 1.1) [121]. 
Apart from various structural differences, all HNRNPs contain RBDs, many contain RGG 
boxes, consisting of repeats of Arg-Gly-Gly tripeptides, and most HNRNPs contain auxiliary 
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domains, such as proline-, glycine- or acid-rich domains [119] [122]. HNRNPs participate in 
many steps of nucleic acid processing, such as telomere maintenance, chromatin remodeling 
and DNA repair. Overall, HNRNPs can have overlapping functions, but some also have very 
specialized roles that are dependent on specific RNA-protein or protein-protein interactions 
[120]. As their function highly depends on their cellular localization, mechanisms that 
regulate their nucleo-cytoplasmic shuttling are of extreme importance [123]. 
1.3.1 Physiological function of HNRNPA proteins 
 
The HNRNPA/B subfamily consists of the proteins HNRNPA0, HNRNPA1, HNRNPA2B1 
and HNRNPA3. HNRNPA1, HNRNPA2B1, and HNRNPA3 (all three together are herein 
referred to as HNRNPA) proteins contain two N-terminal RRMs followed by a C-terminal 
Gly-rich domain (see Figure 1.1) [124] [125]. The RRM allows HNRNPA proteins to interact 
with single stranded nucleic acids, including RNA and single stranded DNA (ssDNA) to 
regulate transcription and splicing [126]. The RGG domain has a distinctive amino acid (aa) 
composition and allows protein-protein interactions. HNRNPA/Bs are present in molar excess 
over their high affinity binding targets and have multiple roles in RNA processes such as 
alternative pre-mRNA splicing, nuclear import, cytoplasmic trafficking of mRNA, mRNA 
stability and turnover, and translation [120]. They package nascent transcript in a non-
sequence specific manner, but have also distinct preferences for RNA sequences [119] [127, 
119]. HNRNPA1 and HNRNPA2/B1 have been well characterized as splicing repressors and 
promote distal splice site selection to regulate splicing of many mRNAs [128]. Like many 
other HNRNP proteins, HNRNPA proteins are predominantly located in the nucleus at 
steady-state but can shuttle between the nucleus and cytoplasm, which is controlled by the M9 
nuclear localization signal near the Gly-rich domain [129] [130]. Most studies have 
investigated the functions of HNRNPA1 and HNRNPA2/B1, while less is known about 
HNRNPA3. HNRNPA1 is one of the most abundant nuclear proteins and two gene variants 
generated by alternative splicing were so far experimentally validated: A1-B, which 
represents the full-length isoform and encodes a protein of 372 aa, and A1-A, the shorter 
variant, translates into a protein that lacks exon 8 resulting in a 320 aa protein. The shorter 
isoform was found to be 20-fold more abundant than the full-length transcript [120]. 
HNRNPA1 is able to negatively modulate its own pre-mRNA alternative splicing by 
inhibiting splicing of intron 10 [131]. It also has a role in stress response as it was shown to 
accumulate in cytoplasmic SG, in stress-activated cell, and is required for recovery from 
stress [132] [133].  
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HNRNPA2B1 is present in two distinct isoforms, A2 (341 aa) and B1 (353aa), which are both 
transcribed from the HNRNPA2B1 gene. Apart from its shared functions with HNRNPA1 and 
HNRNPA3 in RNA metabolism, HNRNPA2B1 has a role in trafficking mRNAs to neuronal 
dendrites, where HNRNPA2/B1 recognizes a 21-nucleotide A2 response element (A2RE) in 
target transcripts [134] [135]. HNRNPA3 and HNRNPA2/B1, but not HNRNPA1 act as 
mRNA trafficking trans-acting factors in neurons [136]. All three HNRNPAs bind to single 
stranded telomere DNA and telomerase RNA, and interact with telomere-binding factors, 
which suggests that they regulate access to telomeres to protect telomeres from degradation 
and thereby maintain genome stability [137] [138] [139] [140].  
1.3.2 Clinical significance of HNRNPAs 
 
Given their central role in gene expression and their multiple functions, it is not surprising 
that HNRNPAs were associated with a variety of diseases apart from ALS or MSP, such as 
cancer, Multiple Sclerosis (MS) [141] [141], and AD [142]. Sporadic AD (sAD) patients for 
example show a reduced expression of HNRNPA1 and HNRNPA2B1 in the entorhinal cortex 
and in an AD mouse model loss of HNRNPA1 or HNRNPA2B1 was associated with reduced 
cognitive function [143]. Additionally, HNRNPA1 was discovered to modulate alternative 
splicing of the APP gene, promoting the generation of toxic amyloid beta peptide, which is 
the core protein of amyloid plaques in AD brains [144].  
HNRNPAs were associated with cancer as they show aberrant expression in certain cancer 
types, e.g. HNRNPA1 expression is highly increased in lung cancer samples and is associated 
with tumor proliferation [145] [146]. Moreover, several oncogenes were identified as direct 
targets of HNRNPA1 [147]. Also HNRNPA2B1 was associated with cancer, as its KD in 
breast cancer cells induces apoptosis [148]. This data links HNRNPA mutations and protein 
levels to multiple diseases and hence implies a strong connection between HNRNPA 
homeostasis, neurological dysfunction, and cell proliferation. 
1.3.3 The interaction of HNRNPAs and TDP-43 in health and disease state 
 
TDP-43 and HNRNPA proteins belong to the large and complex HNRNP protein family and 
were both associated with ALS. While it is not yet understood how misfunction of these 
proteins causes the same disease, several lines of evidence point to cross-regulation among 
these proteins and suggest common disease pathways. The most striking finding is the 
similarity in structure of HNRNPAs and TDP-43 (see Figure 1.1). Buratti et al. could show 
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that HNRNPA proteins interact directly with TDP-43, and function cooperatively to regulate 
RNA metabolism. Moreover, an unbiased screen for disease modifiers of VCP-related 
degeneration in a Drosophila model of MSP identified the fly homologues of TDP-43, 
HNRNPA1, and HNRNPA2B1, pointing to a common physiological requirement in VCP 
associated neurodegeneration [149]. Functional interaction between HNRNPA1 and TDP-43 
was shown by Deshaies et al., who demonstrated that TDP-43 binds HNRNPA1 pre-mRNA 
and controls HNRNPA1 splicing. TDP-43 depletion thereby results in a longer HNRNPA1 
isoform, named HNRNPA1-B, which includes exon 8 and is hence aggregation-prone and 
negatively impacts cell survival [150]. The specific interaction between TDP-43 with 
HNRNPA1 and HNRNPA2B1 is further supported by the finding that pathological 
aggregation of these proteins was found in a MSP patient with the HNRNPA1D262V mutation, 
in the absence of FUS pathology. Double staining revealed that muscle tissue with TDP-43 
pathology typically also shows HNRNPA1 and HNRNPA2B1 pathology. In most instances 
the proteins were also colocalizing [101]. This is further evidenced by the finding that TDP-
43 redistribution to the cytoplasm and aggregation in spinal motor neurons (SpMN) from 
ALS patients was accompanied by loss of nuclear HNRNPA1 [151]. Interestingly, the 
majority of mutations so far identified in HNRNPA1, HNRNPA2B1, and TDP-43 locate 
within the C-terminal glycine-rich domain that has previously been found to be the site of 
HNRNP protein interaction [149] [152]. 
These findings further demonstrate cross-regulation between these ALS/FTLD relevant RBPs 
and supports the concept of impaired RNA metabolism in ALS/FTLD.  
1.3.4 The role of HNRNPA1 in the cell cycle 
 
The cell cycle is a highly regulated process, which involves complex feedback mechanisms 
and regulations of many proteins in order to control chromosome replication. The cell cycle 
control is highly conserved among eukaryotes [153] and its deregulation results in severe 
consequences for the cell resulting in hypoproliferation and apoptosis upon cell cycle arrest or 
in hyperproliferation ultimately leading to tumor formation. The somatic cell cycle is divided 
into two main phases: S-phase, during which DNA replication takes place and M-phase, 
during which mitosis occurs. These two main phases are separated by two so-called gap 
phases (G1 and G2), respectively. Another gap phase is assigned to non-dividing cells, such as 
neurons, known as G0. Cells that have entered G0 are terminally differentiated and are not re-
entering the cell cycle [154]. The crucial proteins that regulate the cell cycle are the cyclins 
and their associated cyclin-dependent kinases (CDK), whose expression and activity fluctuate 
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as the cell transitions from one cell cycle stage to the other [155]. For example, the activation 
of CyclinD-CDK4/6 complex is triggered by the presence of mitotic growth factors and 
controls the re-entry of resting cells into the G1 cell cycle phase. In order to transit from G1 to 
S-phase the CyclinE-CDK2 complex needs to be activated to phosphorylate Retinoblastoma-
like 2 (RBL2) upon which it dissociates from the transcription factor E2F2. The freed E2F2 
shuttles to the nucleus where it binds promoters that initiate transcription of S-phase genes 
[156]. The G1/S transition is tightly controlled by the CDK inhibitors p21 and p27, which 
inactivate the CyclinE-CDK2 and whose accumulation results in G1 arrest. In the presence of 
CyclinA, the cell divides and progresses to G2, whereas the cell goes down an apoptotic 
pathway in the absence of CyclinA [157]. Ultimately, the CyclinB-CDK1 complex initiates 
mitosis (see Figure 1.2).  
 
 
Figure 1.2 - Schematic illustration of the cell cycle. For explanation see text. 
 
HNRNPAs are associated with cell cycle abnormalities due to their role in cancer 
development (see section 1.3.2). It was shown that HNRNPA1 and HNRNPA2B1 but not 
HNRNPA3 are modulated during cell cycle progression with the most abundant expression of 
HNRNPA2B1 in G1 and S-phase and a high expression of HNRNPA1 during G2/M phase 
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transition [120]. Further evidence for a vital role of HNRNPA1 in cell cycle derives from 
studies demonstrating that KD of HNRNPA1 results in cell cycle arrest [146] [158].  
Several pathways are considered to mediate the arrest in cell cycle progression upon 
HNRNPA1 depletion. HNRNPA1 interacts with telomerase RNA and maintains length of 
telomeres, which is important for cell cycle progression [159]. Additionally, HNRNPA1 
reduction may inactivate the NF-κB pathway, which has been linked to cancer [160].  
1.3.5 Animal models of HNRNPA1 and HNRNPA2B1 
 
Some animal models of HNRNPA1 were so far generated to better understand the 
physiological function of HNRNPA1 and to thereby gain insights of molecular 
pathomechanisms that underlie HNRNPA associated ALS and MSP. The experimental 
approach and associated phenotypes of these models are summarized in Table 1.1. Drosophila 
null mutants for the HNRNPA1 orthologues Hrp36 and Hrp38 show slowed development 
with significant reduction in adult life span, decreased female fecundity, and high sensitivity 
to starvation [161]. So far no genetic zebrafish model lacking the HNRNPA orthologues was 
established, but two studies are published using hnrnpa1b specific morpholinos (MOs) that 
lead to phenotypic abnormalities in zebrafish upon hnrnpa1b KD [162, 163]. Chang et al. 
described vascular mispatterning and dorsal axis abnormalities, while Cartealy et al. report 
small and undeveloped embryos, which lack the midbrain-hindbrain boundary. The zebrafish 
KD models target only one hnrnpa1 orthologue and show conflicting results. This might 
potentially be due to off target effects, which are often seen with MO experiments. Also, so 
far no double KD or double KO has been generated. The generation of stable genetic loss of 
HNRNPA1 mutants lacking Hnrnpa1a and Hnrnpa1b will better capitulate full loss of 
HNRNPA1 in vivo. Chang et al. also established a mouse HNRNPA1 KO model by deletion 
of exon 2-7 with the Cre-loxP system. The majority of the homozygous HNRNPA1 KO mice 
are embryonically lethal. Further investigation of HNRNPA1 KO mice shows shortened body 
length, irregular tongue muscles, myofibril hypoplasia, and urinary bladder defects [162]. A 
mouse KD model for HNRNPA2B1 was published by Martinez et al., which lacks 75% 
HNRNPA2B1 protein after targeting of the HNRNPA2B1 transcript with antisense oligo 
nucleotides (ASO). Subsequent RNA sequencing revealed alterations in alternative splicing, 
including the skipping of an exon in the ALS-associated D-amino acid oxidase (DAO) that 
reduces D-serine metabolism [102]. Altogether, the lethality of HNRNPA1 KO mice points to 
an essential role of HNRNPA1 in embryonic development. This is further supported by the 
two independent zebrafish studies revealing severe phenotypes upon hnrnpa1b KD and 
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reduction in lifespan of drosophila upon KO of the two HNRNPA1 orthologues. Concluding, 
the animal models suggest a vital role of HNRNPA1 in embryonic development and so far no 
stable HNRNPA1 KO zebrafish model has been established. 
 
Publication Modification Phenotype 
Liu et al., 
2017 [162] 
Zebrafish:  
ATG MO 
hnrnpa1b KD; 0.15 mM 
- abnormal dorsal axis 
- heart edema 
- lateral asymmetry 
- intersegmental vessel defects 
Cartealy, 
2008 [163] 
Zebrafish:  
ATG MO 
hnrnpa1b KD; 3.5, 5, and 
7 ng 
- I: small and underdeveloped embryos 
- II: kinked body axis and disorganized somite 
- III: lack of midbrain-hindbrain boundary 
Liu et al., 
2017 [162] 
Mouse:  
HNRNPA1 KO Cre-loxP 
deletion of exon 2-7 
- embryonically lethal (62%) 
- shorter body length 
- hypoplasia of tongue muscles 
- dilation of ventricles 
- urinary bladder defects 
Martinez et 
al., 2016 
[102] 
Mouse:  
HNRNPA2B1 KD ASOs in 
lateral ventricles of mice 
- alternative splicing changes 
- skipping of a DAO exon  
- limited changes in gene expression 
Singh et al., 
2012 [161] 
Drosophila: 
P-element insertion 
hrp36 and hrp38 KO 
- delay in development 
- reduction in life span 
- decreased female fecundity 
- high sensitivity to starvation and thermal 
stress 
Table 1.1 - Overview of HNRNPA KD and KO animal models 
1.4 Zebrafish as a model organism 
 
Starting in the 1930s zebrafish (Danio rerio) as a small vertebrate has emerged to a classical 
developmental and embryological model in biomedical research [164]. The most important 
breakthrough in the 1980s was the production of clones of homozygous diploid zebrafish, 
which was the beginning of using this vertebrate model in genetics research [165]. In 2013 
sequencing of the zebrafish genome by the UK Sanger Institute was completed revealing 
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homology of approximately 70% in functionality of human and zebrafish genes [166]. Most 
importantly, about 80% of risk genes that are associated with human disorders have zebrafish 
orthologues [167]. These findings validate the approach of modeling human disease 
pathogenesis in zebrafish.  
The rapid development of zebrafish paired with high fecundity giving hundreds of eggs per 
spawning, promoted the rise of the zebrafish to an attractive research model. A zebrafish 
embryo completes its gastrulation within ten hours after fertilization and the heart beat starts 
at the end of one day post fertilization (dpf). Most organs are functionally developed within 
the first five days of development and zebrafish are fertile within three months. Apart from its 
advantages shared with invertebrates, such as inexpensive husbandry and the possibility of 
high-throughput drug screens, the zebrafish can be used for imaging studies due to the 
possibility to obtain transparent embryos and larvae by treating them with phenylthiourea 
(PTU). The existence of several fluorescent reporter lines labeling a specific cell type or 
subcellular structure via a fluorescent tag makes it possible to perform live imaging 
experiments and investigate cellular and subcellular processes in vivo [168]. Moreover, 
chemical screens can be easily performed by adding compounds to the water. Hereby, 
compounds of clinical relevance can be identified and their potential toxicity and 
teratogenicity can be determined [169]. The external development and thereby easy 
accessibility of the embryos allows minimally invasive manipulations, such as targeted 
mutagenesis and introduction of exogenic DNA or RNA. To date, zebrafish models for a 
variety of human diseases have been established, including cancer, inflammation, wound 
healing and regeneration, metabolic disorders, muscle diseases, and neurodegeneration 
(reviewed in [170]).  
Taken together, zebrafish have emerged to a great model system for studying vertebrate 
development, to examine the effect of mutagenesis, to investigate disease aspects, and to 
perform high-throughput chemical screens, due to zebrafish’ ease of genetic manipulation and 
its biological features.  
1.4.1 Genome editing in zebrafish 
 
In the past years a variety of genome editing tools were applied in fish mutagenesis with 
Zinc-finger nucleases (ZFNs), Transcription activator-like effector nucleases (TALENs) and 
CRISPR/Cas9 being the most successful ones for gene inactivation [171] [172] [173]. All 
these approaches share the feature of being nuclease-based genome editing tools as a nuclease 
is guided to a specific genomic region using different recognition modules where it then 
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induces a double strand break (DSB). Due to error-prone DNA repair at the site of interest by 
non-homologous end joining (NHEJ), insertion or deletion (indel) mutations are introduced, 
which can lead to frameshift mutations generating a KO allele. For knockin (KI) approaches, 
sequence templates, that carry homology arms and the desired genetic sequence (e.g. a patient 
mutation) can be co-injected and inserted at the targeted genomic site by the process of 
homology directed repair (HDR) [174] [175].  
As part of the CRISPR system, first a conserved set of genes adjacent to the spacers and 
repeats, named Cas genes, were identified, which serve as an antiviral defense mechanism in 
prokaryotes [176] [177] [178, 179]. Later, the last key component in CRISPR activation was 
identified, a non-coding trans-activating complementary RNA (tracRNA) allowing RNA-
guided binding to the nuclease Cas9 by base pairing to mature tracRNA [180]. Following 
research has further simplified the system for genome editing purposes to a single RNA 
system (instead of the two RNA system consisting of tracRNA and crRNA by identifying key 
components and thereby solely used an engineered 20 nucleotide (nt) long single guide RNA 
(gRNA), for sequence specific DSB by Cas9 [181]. The only sequence requirement for the 
gRNA target site is a three nucleotide NGG motif (for the Streptococcus pyogenes Cas9 
(SpCas9) protein), called protospacer adjacent motif (PAM) adjacent to the 20 nt target 
sequence (see Figure 1.3) [182]. The CRISPR/Cas9 system is a highly effective genome 
editing system, which differs from previous genome editing approaches since it uses an RNA 
entity to bind to the DNA. By specificity of the Watson and Crick base pairing the gRNA 
specifically directs the most widely used SpCas9 nuclease to the targeted genetic locus where 
it induces a DSB.  
The most common technique used in zebrafish for genome editing is microinjection of the 
Cas9 protein and a gRNA into the embryonic cell at the one cell stage. Upon injection into 
zebrafish embryos Cas9 and the gRNA form a complex with the targeted DNA site and Cas9 
protein induces a DSB at the targeted genomic site. In the past years generating specific KOs 
by NHEJ or KIs by HDR were successfully carried out in zebrafish (see section 1.4.2 for ALS 
related examples). Due to the ease of programmability of the gRNAs and the low workload, 
the CRISPR/Cas9 system is the most preferable genome editing system. Many websites give 
additional support for the design of sgRNAs with minimized off-target effects and closely 
located restriction endonuclease (RE) for easy analysis of successful genome editing. Suitable 
design websites include CHOPCHOP (www.chopchop.cbu.uib.no/), CRISPR Multitargeter 
(www.multicrispr.net/), and CRISPRdirect (www.crispr.dbcls.jp). The concern of a high 
probability of off target effects has been often raised due to the short target sequence. 
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However, the zebrafish model allows to eliminate unspecific side effects caused by off-target 
genomic modifications by outcrossing the mutated fish.  
In conclusion, the use of CRISPR/Cas9 in zebrafish allows fast, cheap, and high throughput 
genotype-phenotype correlations for candidate genes obtained from clinical genetics. 
 
 
Figure 1.3 - Schematic illustration of the CRISPR/Cas9 system. The Cas9 nuclease (green) is recruited to the 
genomic site via binding to a 20 nt long target sequence containing gRNA (yellow) next to the PAM. The red 
arrowheads indicate the approximate position of the induced double strand break. Upon creation of a DSB at the 
targeted site the site can be either repaired through NHEJ sometimes producing indel mutations leading to frame-
shift and loss of function mutants. Alternatively the double strand break can be repaired by HDR. For precise KI 
approaches sequence templates with homology arms can be co-injected and inserted at the targeted genomic site 
by the process of HDR. 
 
1.4.2 Modeling ALS in zebrafish 
 
Apart from the intensive research on ALS associated genes over the past years and the great 
advances in characterizing the pathological signature of the proteins derived from mutated 
genes, the physiological function of the encoded proteins remains largely unknown. Up to 
now a variety of model organisms were used in order to study genetic risk and disease-
causing genes in vivo by applying three main strategies. First, the gene of interest can be 
overexpressed in its wildtype or mutated form via RNA or DNA expression. However, this 
approach is highly critical due to the associated toxicity effects that may arise from 
abnormally high expression of proteins and protein mislocalization by ubiquitous expression 
of a protein that is normally only present in specific cellular compartments or cell types. 
Alternatively, the gene of interest can be transiently knocked down using MOs or stably 
knocked out using targeted mutagenesis (see section 1.4.1) in order to create a loss of function 
situation and hence determine the encoded protein’s physiological function. Lastly, the gene 
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of interest can be edited in such a way that it carries a specific patient mutation, to address the 
function of the encoded mutant protein in vivo.  
So far several studies have been performed in zebrafish that specifically address ALS 
associated genes and aim to recapitulate hallmarks of ALS. An overexpression (OE) model of 
SOD1 protein shows ALS like phenotypes, such as motoneuron loss, muscle atrophy, 
paralysis, and premature death [183]. A targeted induced local lesions in genomes (TILLING) 
zebrafish mutant expressing mutant Sod1 (T70I) protein at physiological levels, confirmed 
this finding, as it also showed key features of ALS: early neuromuscular junction (NMJ) 
phenotype, susceptibility to oxidative stress (OS), and an adult-onset MND phenotype [184]. 
In contrast to SOD1, many ALS associated genetic KD and KO models were established over 
the past years that lead to non-identical phenotypes upon KD or KO of the same gene. For 
example, KD of zebrafish Fus resulted in a motor phenotype that could be rescued by OE of 
wildtype human FUS but not with FUS carrying ALS-related mutations [185]. However, KO 
of Fus using ZFN mediated genome editing did not cause shortened motoneuron axons or 
related pathology [186]. KO of the two TARDBP orthologues tarbp and tardbpl in zebrafish 
by CRISPR/Cas9 resulted in lethality and embryos show shortened motoneurons, vascular 
mispatterning, and muscle defects [12]. While single tardbp or tardbpl KO zebrafish show no 
phenotypic abnormalities [12], MO-mediated KD of zebrafish tardbp only performed by 
another group, was shown to result in shortened SpMN axons [187]. Injection of wildtype and 
mutant TDP-43 mRNA into zebrafish embryos elicits similar motoneuron effects, with 
mutant TDP-43 causing more severe phenotypes [188]. A mutant zebrafish model carrying 
three ALS patient mutations (M337V, G348C, G290A) in the tardbp gene was recently 
generated in our laboratory. The zebrafish embryos are vital and elicit no motoneuron defects 
contrasting the severe phenotype observed in tardbp-/-; tardbpl-/- KO mutants. These 
preliminary results suggest that TDP-43 patient mutations do not cause a full Tdp-43 loss of 
function in zebrafish (personal communication, Özge Burhan and A. Hruscha and A. 
Gierson). Also, C9orf72 deficient zebrafish were generated using CRISPR/Cas9 system. The 
C9orf72 KO embryos show no difference in axon outgrowth length, but swimming behavior 
analysis revealed a higher locomotor activity upon darkness induced stimulation indicating a 
physiological requirement of C9orf72 for neuronal function [189] and (personal 
communication A.Hruscha). Another study established a Granulin (GRN) loss of function 
model in zebrafish by knocking out the zebrafish GRN orthologues grna and grnb using 
ZFNs. These fish contrast the phenotype of a previously MO induced grna and grnb KD 
embryos that shows SpMN axonopathies and a reduced number of myogenic progenitor cells 
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number. The phenotype discrepancy may probably be caused by unspecific toxicity of MOs 
[190] [191]. 
Overall, many zebrafish models for ALS associated genes were generated, including OE, KO, 
KD, and KI models. However, as described, transient KD or OE studies often display distinct 
phenotypes from persistent KO of the same gene. These discrepancies may arise from 
unspecific toxicity, due to off-target effects or global degradation machinery breakdown upon 
MO KD [192]. Rossi et al. revealed by KD or KO of two different genes that compensatory 
network are activated to buffer against deleterious mutations upon KO, but not KD. If this is 
the case in the ALS models, KD versus KO discrepancies remain to be resolved. Potentially, 
these discrepancies can also be eliminated by correct experiment design and using proper 
controls. Stanier et al have written a manual for MO usage that illustrates recommended 
guidelines for MO usage [193].  
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2 Material and Methods 
2.1 Material 
2.1.1 Zebrafish lines 
 
The following zebrafish lines were used in this study: 
Zebrafish line Origin (Reference) 
wildtype-line AB G. Streisinger, Institute of Neuroscience, 
University of Oregon, Eugene, USA  
wildtype-line TLF C. Nüsslein-Vollhard, MPI for 
Developmental Biology, Tübingen, Germany  
Tardbpmde159-/- (tardbp-/- in this thesis) B. Schmid & Hruscha, DZNE and LMU 
Munich, Germany [12]  
Tardbplmde222-/- (tardbpl-/- in this thesis) B. Schmid & Hruscha, DZNE and LMU 
Munich, Germany [12] 
Tg(fli1a:EGFP)y1Tg J. Bussmann, MPI for Molecular 
Biomedicine, Münster, Germany [194] 
2.1.2 Cell lines 
 
Cell line Origin 
HeLa cells DSMZ, #ACC 57 
2.1.3 Morpholinos 
 
MOs were purchased from GeneTools. Sequences are given in 5’-3’ orientation; e: exon; 
i: intron. 
 
apoda.1-e2i2 TCCATTGACTTGGTACTCACAGAAT 
2.1.4 Vectors and plasmids 
 
Vector Insert Origin Schmid laboratory 
database # 
pCS2+GW-GFP Apoda.1 L.Jansen N31 
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pcr8/GW/TOPO - Invitrogen - 
pCS2+GW-GFP HNRNPA1 L. Jansen N32 
pCS2+GW-GFP HNRNPA1D262V L. Jansen N33 
pCS2+ hnrnpa1a hnrnpa1a L. Jansen N34 
pCS2+ hnrnpa1+HA HA+hnrnpa1a L. Jansen N35 
pCS2+hnrnpa1b Hnrnpa1b L. Jansen N36 
pCS2+hnrnpa1b+HA HA+hnrnpa1b L. Jansen N37 
pCS2+ hnrnpa3 hnrnpa3 L. Jansen N38 
pCS2+ hnrnpa3+HA HA+hnrnpa3 L. Jansen N39 
2.1.5 Oligonucleotides 
 
Oligonucleotides were synthesized by Thermo Scientific. The sequences are shown in 5’-3’ 
orientation. The abbreviation letters and numbers in the oligonucleotide name refer to the 
Schmid laboratory database.  
 
Primer for cloning  
LJ-A01 hnrnpa1b F  GTCGGTAGGATGTCCAAAGAG 
LJ-A02 hnrnpa1b STOP R  TTAAAACCGTCTACCGCCAGAG 
LJ-A03 HA+hnrnpa1b F  TACCCATACGATGTTCCAGATTACGCTGCT
GGTAGGATGTCCAAAG 
LJ-A04 hnrnpa1b noStop R  GCTCTGGCGGTAGACGGTTT 
LJ-A05 hnrnpa1a F  CGTGACCGCCATGTCCAAAG 
LJ-A06 hnrnpa1a STOP R  ATCTAAAACCTCCGTCCGCC 
LJ-A07 HA+hnrnpa1a F  ATGTACCCATACGATGTTCCAGATTACGC
TGTGACCGCCATGTCCAAAGA 
LJ-A08 hnrnpa1a noStop R  GCTCTGGCGGACGGAGGTTT 
LJ-A09 hnrnpa3 F  GCGCAAAAGCTACAGCATGG 
LJ-A10 hnrnpa3 STOP R  ACTTACCACTCCAATTAATCTGCT 
LJ-A11 HA+hnrnpa3 F  ATGTACCCATACGATGTTCCAGATTACGC
TCGCAAAAGCTACAGCATGGA 
LJ-A12 hnrnpa3 noStop R  GTTACGGCTCCAGGAGATAT 
LJ-A13 apoda.1 F ATGAAGGTGTTTCTGGTCGTG 
LJ-A14 apoda.1 R TCAAAGTTTTTGGTCGCATC 
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Primer for Sequencing  
GATC M13-FP TGTAAAACGACGGCCAGT 
GATC M13-RP CAGGAAACAGCTATGACC 
GATC SP6 ATTTAGGTGACACTATAGAA 
GATC T7 TAATACGACTCACTATAG 
  
Primer for Genotyping  
LJ-B01 hnrnpa1b.ex2.KO.F – gRNA 1 CCTTGGTTTGATCTCCGTTACC 
LJ-B02 hnrnpa1b.ex2.KO.R – gRNA 1 TGTGTTTGGATCTTTCATCACCT 
LJ-B03 hnrnpa1b.ex9.KO.F – gRNA 2 GGCAATGGAAACTTTGGAGGT 
LJ-B04 hnrnpa1b.ex9.KO.R – gRNA 2 TCACGTCATTTATGCCTTTAGGA 
LJ-B05 hnrnpa1a.ex1.KO.F – gRNA 3 CCTTATTTGGGGGTAAAAACGTA 
LJ-B06 hnrnpa1a.ex1.KO.R – gRNA 3 CCTTATTTGGGGGTAAAAACGTA 
LJ-B07 hnrnpa1a.ex8.KO.F gRNA 4 GGCGGCGGCTATGATAACT 
LJ-B08 hnrnpa1a.ex8.KO.R gRNA 4 GCATTGCTCTGAATAAACCACTACA 
LJ-B09 hnrnpa3.ex2.F – gRNA 5 AGCATTATGCAACACATGGAGC 
LJ-B10 hnrnpa3.ex2.R – gRNA 5 CACGCAGTCTGTGAGTTTGC 
LJ-B11 hnrnpa3.Sanger.F CTGCAACAGGCTTCCATACA 
LJ-B12 hnrnpa3.Sanger.Wt.R TCCTCTCTTCTTCCCAGTCG 
LJ-B13 hnrnpa3.Sanger.Mu.R TCCTCTCTTCTTCCCAGTCT 
  
Primer for semiquantitative polymerase chain reaction (PCR) 
LJ-D01 pkma.exon203 F  CGGAGAGACCGCTAAAGGAGAT 
LJ-D02 pkma.exon203.R CCGGACCCAGTGAGCACTATAA 
LJ-D03 pkma.exon202.F AGTGATGTGGCCAATGCAGTTC 
LJ-D04 pkma.exon202.R CAGCATTTGAAGGAAGCCTCGAC 
  
Primer for quantitative realtime-PCR (qRT-PCR) 
KS-A11 Rpl13a_E3-4a_F ATTGTGGTGGTGAGGTGTGA 
KS-A12 Rpl13a_E3-4a_R CATTCTCTTGCGGAGGAAG 
KS-A13 Elf1a_2F AGCAGCAGCTGAGGAGTGAT 
KS-A14 Elf1a_2R GTGGTGGACTTTCCGGAGT 
KS A42 dr-vcam1 ex9-10 F CAAACGACCTGGGTTACGAA  
KS A43 dr-vcam1 ex9-10 R CAGCAGAACCTCCCAAGAAA 
Material and Methods 
 27  
KS A45 dr-itga4-ex2-3 F TGCAGTATGTTGAACAGCCAG 
KS A46 dr-itga4-ex2-3 R CAAACTCACACCCAGCCAC 
KS A47 dr-fn1a-ex3-4 F  TGTACTTGCATTGGCTCTGC  
KS A48 dr-fn1a-ex3-4 R GTCTCTGCCATGTGTCTCCA 
KS A49 dr-fn1b-ex39-40 F CATTGCCCTTCTGAATAACCA 
KS A50 dr-fn1b-ex39-40 R ATGACTGGGCAGGCTAGGTA  
LJ-C01 hnrnpa1b.F CCGTGTCTAGAGAGGATTCCAG 
LJ-C02 hnrnpa1b.R GTGACGAAGGCAAAGCCTCT 
LJ-C03 hnrnpa1a.F AAAGAGCAACAGACCCCTCG 
LJ-C04 hnrnpa1a.R TGACGAAGCCAAATCCCCTC 
LJ-C05 hnrnpa3.F TGGAGAGTCGCGACAGTAAG 
LJ-C06 hnrnpa3.R GAGTCCTCTCTGGAAACGGC 
LJ-C07 cdkn2a/b-F CAGCAGCCACCGGAAACATT 
LJ-C08 cdkn2a/b-R TCATCACCTGTATAGGCGTTCTTCT 
LJ-C09 rbl-F CCGCTTCTACAACCACGTCT 
LJ-C10 rbl-R GGAGTTTCAGCCTGCCCATT 
LJ-C11 cdkn1a-F TCCCGAAAACACCAGAACGA 
LJ-C12 cdkn1a-R TGGTAGAAATCTGTGATGTTGGTCT 
LJ-C13 gadd45-F ACTCGGTGATTAAGGCTCTGG 
LJ-C14 gadd45-R TCAGGGTCCACATTGAGGGA 
LJ-C15 ccne-F ACTTGCAGCTTCAGCACTCT 
LJ-C16 ccne-R ACCACTTCAGCCCTGAAACTT 
LJ-C17 gpnmb-F ACTTCATTACAGATAAGATTCCACT 
LJ-C18 gpnmb-R CCCTCTGACAAAGATGTTTCTG 
LJ-C19 p53-F ACTCAGGAAGGTCAGTTGCTG 
LJ-C20 p53-F TACGTTTGGTCCCAGTGGTG 
LJ-C21 apod-F AAAACAATTGACGGGACGGC 
LJ-C22 apod-R GCGTGTAGGGCAAAACATAGG 
LJ-C23 nampt-F TCAGCGACAGCTACGACATC 
LJ-C24 nampt-R TCCAGGACCTTGAGCACG 
  
Primer for gRNA synthesis  
M64 GCGTAATACGACTCACTATAG 
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gRNA oligo  
hnrnpa1a gRNA 3 ATGGCGGGTGGCATTGCTGCTGG 
hnrnpa1a gRNA 4 GCAGGAAACTTCGGAGGTGGCGG 
hnrnpa1b gRNA 1 CACGTGAGCCAGAGCAGCTGCGG 
hnrnpa1b gRNA 2 GGTGGTGGTGGCGGCAACAGTGG 
hnrnpa3 gRNA 5 GAGTCGCGACAGTAAGGAGCCGG 
N20: targeting oligo, bold letters indicate the PAM motif 
2.1.6 Bacteria 
 
Name Company 
One Shot TOP10 Chemically competent 
E. coli, C4040 
Invitrogen 
2.1.7 Antibodies 
 
For Western blotting (WB) and whole mount immunofluorescence stainings (IF) the 
following antibodies were used: 
Primary antibodies:   
Antibody (Species) Dilution Origin (Reference) 
α-Actinin IHC: 1:100 Sigma-Aldrich 
α-tubulin, T6199 (mouse) WB: 1:10.000 Sigma-Aldrich 
Calnexin, SPA-860 (rabbit) WB: 1:7000 Stressgen 
HA (mouse), MMS-101R WB: 1:200 Covance  
HNRNPA1 (rabbit),HA1-CT 
(VM) AN351 
WB: 1:1000 Gift from Douglas Black lab 
Myosin (ZE-BO-1F4) IHC: 1:1 Kremmer [195] 
Pcna (mouse) WB: 1:1000 
IHC: 1:100 
Santa Cruz 
TDP-43 N-term, SAB4200006 
(rabbit) 
WB: 1:10.000 Sigma-Aldrich 
znp-1 (mouse) 1:100 DSHB [196] 
 
Primary peptide antibodies generated by the IMI, Helmholtz Center Munich: 
Antibody (Species) Dilution Epitope 
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Hnrnpa1b Z1A1-2A7 (rat 
IgR2a) 
WB: 1:1 
IHC: 1:50 
MSKEGQPREPEQLR 
Tardbp antibody, 4A12-111 
(rat IgR2a) 
WB: 1:1 
IHC: 1:300 
TSTSGTSSSRDQAQTY 
Tarbpl antibody, 5F5-11 (rat 
IgR2a) 
WB: 1:1 FERSQYQFPSSHV 
Tardbpl_tv1 antibody, 16C8-
11 (rat IgR2a) 
WB: 1:1 SRQMMDRGRFGGYG 
Anti-rat (IgG2a), HRP 
conjugated 
WB: 1:10.000  
Secondary antibodies: 
Antibody Dilution Origin 
Alexa Fluor 488 anti-mouse 
A-11029 
IHC: 1:500 Invitrogen 
Alexa Fluor 488 anti-rabbit IHC: 1:10.000 Invitrogen 
A-11034   
Alexa Fluor 488 anti-rat 
A11006 
IHC: 1:10.000 Invitrogen 
Anti-mouse-HRP, W4021 WB: 1:10.000 Promega 
Anti-rabbit-HRP, W4011 WB: 1:10.000 Promega 
2.1.8 Chemicals 
2.1.8.1 Chemicals and reagents 
 
Acridine Orange, 235474 Merck 
Acrylamide / bis solution, 10681.03 Serva 
Agarose, 15510-027 Invitrogen 
Ammonium persulfate (APS), 9592.2 Roth 
Ampicillin, K029.2 Roth 
β-Mercaptoethanol, 4227.1 Roth 
Boric acid, 100165.1000 Merck 
Bromo phenol blue, 18030 Fluga 
Calcium chloride (CaCl2), 102382.0500 Merck 
Chloroform RothRoth 
Material and Methods 
 30 
Citric acid monohydrate Sigma-Alrich 
Collagenase, C9891 Sigma-Aldrich 
DanKlorix Colgate-Palmolive 
Deoxynucleoside triphosphates (dATP, dCTP, dGTP, 
dTTP) 
Thermo Fisher Scientific 
Diethylpyrocarbonate (DEPC), D5758 Sigma-Aldrich 
Dimethyl sulfoxide (DMSO), 317275 Merck 
Disodium hydrogen phosphate (Na2HPO4), 106580.5000 Merck 
Dithiothreitol (DTT) (100mM), Y00147 Invitrogen 
6x DNA loading dye, R0611 Thermo Fisher Scientific 
Dry ice - 
ECLplus (RPN2132) Amersham 
Ethylenediaminetetraactic acid (EDTA), 108418.1000 Merck 
80% Ethanol, UN1170 CLN 
Ethanol p.a., 100989.1011 Merck 
Fetal bovine serum (FBS), F7524 Sigma-Aldrich 
Formamide, F9037 Sigma-Aldrich 
Gelatin, 104080.0100 Merck 
GelRed, 41003 Biotium 
GeneRuler DNA ladder mix, SM0331 Thermo Fisher Scientific 
Glycerol p.a., 3783.2 Roth 
Glycine p.a., 04943 Roth 
5x GoTaq buffer Promega 
GoTaq DNA Polymerase, M830B Sigma-Aldrich 
I-Block (T2015) Thermo Fisher Scientific 
Isopropanol p.a., 109634.2511 Invitrogen 
Liquid nitrogen (liq. N2) Linde 
Magnesium chloride (MgCl2), 105833.1000 Merck 
Methanol p.a., 106059.2511 Merck 
MethaPhor agarose, 50185 Lonza 
Methyl cellulose, M0387 Sigma-Aldrich 
Milk powder, T145.2 Roth 
M-MLV reverse transcriptase, 28025013 Thermo Fisher Scientific 
5x M-MLV reverse transcriptase buffer, 18057018 Thermo Fisher Scientific 
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Monopotassium phosphate (KH2PO4), 104877.1000 Merck 
Natrium Chloride  Roth 
Natriumhydrogencarbonat, S5761 Sigma-Aldrich 
Newborn calf serum (NCS), N4762 Sigma-Aldrich 
Oil Red O, O1391 Merck 
Oligo(dT)12-18 Primer, 18418012 Thermo Fisher Scientific 
Opti-MEM, 51985-026 Gibco 
Paraformaldehyde (PFA), P6148 Sigma-Aldrich 
PCR nucleotide Mix, 11581295001 Sigma-Aldrich 
Phenol/chloroform/isoamylalcoohol, A156.1 Roth 
Potassium Chloride (KCl), 104936.1000 Merck 
Protease Inhibitor (PI) mix, 05056489001 Roche 
Pronase, 11459643001 Roche 
Proteinase K (PK), 03115852001 Roche 
Precision Plus Protein All Blue Standard, 161-0373 Bio-Rad 
PTU, P7629 Sigma-Aldrich 
Random hexamer primer, S0142 Thermo Fisher Scientific 
Random primer mix, S1330S NEB 
RiboLock RNase inhibitor (40U/µl), EO0382 Thermo Fisher Scientific 
RNAsecure, AM7010 Thermo Fisher Scientific 
RNase H, 18021071 Invitrogen 
SeeBlu Plu2 pre-stained standard, LC5925 Invitrogen 
SOC-Medium, 15544-034 Invitrogen 
Sodium chloride (NaCl), 3975.2 Roth 
Sodium dodecyl sulfate (SDS), 20765.03 Serva 
SP6 Polymerase, EP0131 Fermentas 
Spectinomycin, 85555 Fluka 
T7 Polymerase, EP0111 Fermentas 
Tetramethylethylenediamine (TEMED), 2367.3 Roth 
Tricaine, A5040 Sigma-Aldrich 
Tris, 08003 AppliChem 
Trisodium citrate Sigma-Aldrich 
Trizol Reagent, 15596026 Thermo Fisher Scientific 
Tropix I-block, T2015 Applied Biosytems 
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Turbo DNAse Thermo Fisher Scientific 
Tween 20, 822184.0500 Merck 
Xylene, 108681.1000 Merck 
2.1.8.2 Solutions and buffer 
 
All solutions and buffers were prepared by using H2O that was purified and desalted by a 
Milli-Q system (electric resistance 18.2Ωcm at 25°C). 
 
1-2% agarose 1%-2% agarose 
1xTBE 
Acridine Orange stock solution 3 mg/ml in dH2O 
Ampicillin stock 100 mg/ml dissolved in dH2O and sterile filtered 
10% APS (stock 10% APS in dH2O stored at -20°C 
Bleaching solution 600 ml tap water,  
 280 µl DanKlorix 
10x BSA stock 0.1 g/ml 
DEPC-dH2O 200 µl DEPC per 100ml dH2O 
incubate overnight (o/n) at 37°C and autoclave 
Deyolking buffer 55 mM NaCl 
1.8 mM KCl 
1.25 mM NaHCO3 
DMEM Glutamax, 61965 Gibco 
I-Block 0.2% Tropix I-Block 
0.1% Tween 
in 1xPBS 
4x Lämmli sample buffer 4 ml 20% SDS 
4 ml glycerol 
1 ml β-mercaptoethanol 
1.25 ml 1M Tris, pH 7.6 
1 pinch bromophenol blue 
0.2-1% low melting agarose (LMA) 
 
1%-2% MethaPhor agarose 
1xTBE 
Lysis buffer 10% PK stock in TE, pH 8.0 
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3% methyl cellulose 3% methyl cellulose in prewarmed H2O 70°C 
shake o/n at 4°C and centrifuge until every bubble is 
gone 
NCST 10% NCS stock 
0.1% Tween in 1xPBS 
PBS 0.14 M NaCl 
10 mM Na2HPO4 
2.8 mM KH2PO4 
2.7 mM KCl 
pH 7.4 
10x PBS 80 g NaCl 
17.8 g Na2HPO4x2H2O 
2.4 g KH2PO4 
2g KCl 
add dH2O up to 1l 
PBST 0.1% Tween in 1x PBS 
PBST milk 3% milk powder 
0.1% Tween in 1x PBS 
10x PCR buffer 100 mM Tris, pH8.3 
500 mM KCl 
15 mM MgCl2 
0.1% (w/v) gelatin 
in dH2O 
PCR mix 60 µl 100mM dATP 
60 µl 100mM dCTP 
60 µl 100mM dGTP 
60 µl 100mM dTTP 
6 ml 10x PCR buffer 
36.3 ml dH2O 
4% PFA 4% PFA in 1x PBS 
incubate approx. 5min at 80°C until PFA is 
dissolved 
cool to 4°C prior to usage or store at -20°C 
Proteinase K stock 17 mg/ml Proteinase K in dH2O 
Material and Methods 
 34 
Pronase stock 30 mg/ml pronase in dH2O 
10x PTU 0.3 mg/ml in E3 
Ringer solution 55 mM NaCl 
1.8 mM KCl 
1.25 mM NaHCO3 
RIPA 50 mM Tris-HCL, pH 8.0 
150 mM NaCl 
5 mM EDTA 1% NP-40 
0.5% Deoxycholat 
0.1% SDS 
10x running buffer 29 g Tris 
144 g glycine 
add dH2O up to 1l  
and autoclave 
SDS running buffer 0.1% SDS in 1x running buffer 
Spectinomycin stock 30 mg/ml dissolved in dH2O and sterile filtered 
Stacking gel buffer 1M Tris, pH6.8 
Stripping buffer 62.5 mM Tris 
2% SDS 
350 µl β-Mercaptoethanol 
adjust to pH6.7 
10x TBE 1080 g Tris 
550 g Boric acid 
400 ml 0.5M EDTA, pH8.0 
add 10l dH2O 
TE pH8.0 10 mM Tris 
1 mM EDTA 
adjust to pH 8.0 and autoclave 
10x transfer buffer 30.3 g Tris 
144 g glycine 
add dH2O up to 1l  
adjust to pH8.3 and autoclave 
50x tricain 2 g tricain 
 10.5 ml 1M Tris pH9.0 
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 Add 500 ml with dH2O 
 Adjust to pH 7.0 
Wash Buffer  110 mM NaCl 
3.5 mM KCl 
2.7 mM CaCl2 
10 mM Tris/Cl 
Adjust to pH 8.5 
2.1.8.3 Media 
 
Bacteria cultivation media was autoclaved before usage to prevent growth of undesired 
organisms. Sterile filtered antibiotics were added in the indicated concentration to the medium 
after cooling. 
Cell culture medium DMEM 
10% FBS 
1% Penicillin-Streptomycin 
E3 5 mM NaCl 
0.17 mM KCl 
0.33 mM CaCl2 
LB-Agar 1.5% Bacto Agar 
1% Bacto Trypton 
0.5% Yeast extract 
17.25 mM NaCl 
in dH2O 
Ampicillin 100 µg/ml or Spectinomycin 
100 µg/ml 
LB-Medium 1% Bacto Trypton 
0.5% Yeast 
17.25 mM NaCl 
in dH2O 
Ampicillin 100 µg/ml or Spectinomycin 
100 µg/ml 
Opti-MEM, 51985-026  Gibco 
SOC-Medium, 15544-034 Invitrogen 
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2.1.9 Kits 
 
BC Assay Protein Quantitation Kit, UP40840A Uptima 
Gateway LR Clonase II Enzyme Mix, 11791100 Invitrogen 
GoTaq DNA Polymerase, M3001 Promega 
iQ SYBR Green supermix, 170-8891 BioRad 
M-MLV Reverse Transcriptase, 28025-013 Invitrogen 
MEGAshortscript T7 Transcription Kit Ambion 
mMESSAGE Machine SP6 Kit, AM1340 Ambion 
mMESSAGE Machine T7 Kit, AM1344 Ambion 
NucleoBond Xtra Midi, 740410 Macherey-Nagel 
NucleoSpin Gel and PCR Clean-up, 740609 Macherey-Nagel 
NucleoSpin Plasmid, 740588 Macherey-Nagel 
pCR8/GW/TOPO TA Cloning Kit Invitrogen 
Pierce ECL Plus Western Blotting Substrate, 32132 Thermo Scientific 
RNAse-free DNase Set, 79254 Quiagen 
RNeasy Mini Kit, 74104 Quiagen 
SsoFast Eva Green Supermix, 172-5204 BioRad 
TRIzol Plus RNA Purification Kit, 12183555 Thermo Scientific 
2.1.10 Consumables 
 
0.2 ml Strip tubes, AB-0266 Thermo Fisher Scientific 
96-Well PCR Plate, AB-0600 Thermo Fisher Scientific 
Blotting Paper, MN 218 B Macherey-Nagel 
Borosilicate glass capillaries, 1B100F-4 World Precision Instruments 
Centrifuge tubes 15 ml, 50 ml Sarstedt 
Combitips Plus 0.5 ml, 5 ml Eppendorf 
Cover slip Thermo Fisher Scientific 
Hard-Shell 384-Well PCR Plates, HSP-3805 BioRad 
Microcentrifuge tubes 1.5 ml, 2.0 ml Sarstedt 
Microscope slide Thermo Fisher Scientific 
Microscope slide with wells Thermo Fisher Scientific 
Multi-well plates (12, 24, 48) Thermo Fisher Scientific 
PCR Film, AB-0558 Thermo Fisher Scientific 
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Petri dishes (60 mm, 100 mm) Sarstedt 
Pipette tips (10 µl, 10 µl long, 200 µl, 
1000 µl) 
Sarstedt 
Pipette tips with filter (10 µl, 20 µl, 100 µl, 
300 µl, 1000 µl) 
Sarstedt 
Polyvinylidenfluorid (PVDF) Membrane, 
Immobilon-P, IPVH00010IPVH00010 
Millipore 
Sterile serological pipettes (5 ml, 10 ml, 
25 ml) 
Sarstedt 
Transfer pipettes Sarstedt 
X-ray films Super RX, 47410 19236 Fujifilm 
2.1.11 Equipment 
 
Accu jet pro Brand 
Agarose gel documentation device Intas 
Agarose gel systems Peqlab 
Benchtop centrifuge Biofuge pico Heraeus 
Benchtop cool centrifuge 5427 R Eppendorf 
Benchtop cool centrifuge 5430 R Eppendorf 
C1000 Thermal Cycler Bio-Rad 
Cassette for x-ray film exposure Radiographic Products 
Casting stands Bio-Rad 
Casting frames Bio-Rad 
DMZ-Universal (needle) Puller Zeitz Instrumente 
Forceps Fine Science Tools FST 
Foam Pads Bio-Rad 
Freezer -20°C Liebherr 
Freezer -80°C Heraeus 
Fridge Liebherr 
Incubator 37°C, 55°C Binder or B. Braun Biotech International 
Kontes Pellet Pestle, 1.5 ml Thermo Fisher Scientific 
Kontes Pellet Pestle Cordless Motor, 
K749540-0000 
Thermo Fisher Scientific 
Microwave Sharp 
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Microinjector (Femto Jet) Eppendorf 
Microinjection molds Eppendorf 
Micro scales BP2215 Sartorius 
MilliQ academics Millipore 
Mini gel holder cassette, 180-3931 Bio-Rad 
Mini-PROTEAN Comb, 10-well  Bio-Rad 
Mini-PROTEAN 3 cell Bio-Rad 
Mini-PROTEAN Tetra cell Bio-Rad 
Mini trans-blot central core, 170-3812 Bio-Rad 
Multipipette plus Eppendorf 
NanoDrop IMPLEN 
PCR Plate Sealer Eppendorf 
PCR Thermocycler, nexus GSX1  Eppendorf 
pH Meter WTW 
Pipette 2.5 µl, 10 µl, 100 µl, 200 µl, 1000 µl Eppendorf 
Plate reader PowerWaveXS BioTek 
Rotors (A-2-MTP, Fa-45-48-11, F-35-6-30) Eppendorf 
Scales BP3100S Sartorius 
Schott bottles Schott 
Shaker cold room Bachofer 
Shaker RT Duomax 1030 Heidolph 
Short plates, 165-3308 Bio-Rad 
Spacer plates 1.5 mm 165-3312  Bio-Rad 
Stereo Microscope Stemi 2000 Zeiss 
Tea nets - 
Thermomixer comfort Eppendorf 
Thermomixer compact Eppendorf 
UV Detectionsystem Intas 
Vortexgenie2 Scientific Industries 
Waterbath GFL 
2.1.12 Microscopes 
 
Cell Observer CSU-X1 Yokogawa Spinning 
Disc AxioCam MRm 
Zeiss 
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Confocal laser scanning microscope LSM 
710 
Zeiss 
Fluorescence-Stereomicroscope Discovery 
V8 Aciocam 503 color/ Aciocam 506 mono 
Zeiss 
Stereomicroscope Zeiss Stemi 2000-C Zeiss 
Light microscope Axioscope A1 Zeiss 
2.1.13 Hardware and software 
 
Adobe Illustrator CS5 Adobe Systems Software 
Axiovision 4.0 Zeiss 
Bio-Rad CFX Manager 2.0 Bio-Rad 
CLC Main Workbench 6 CLC bio 
FileMaker Pro FileMaker 
GraphPad Prism 7 GraphPad Software 
ImageJ/Fiji NIH, USA 
LAS 400 Image Reader GE Healthcare Bio-Sciences AB 
iMac Apple 
Microsoft Office for Mac 2011 Microsoft 
ReadCube Labtiva 
EndNote Clarivate Analytics 
Zen Blue 2011 Carl Zeiss Microimaging 
  
2.2 Methods 
2.2.1 Zebrafish specific methods 
 
The following methods were mostly performed according to the Schmid laboratory methods 
manual. 
2.2.1.1 Zebrafish husbandry and handling of embryos 
 
Zebrafish husbandry, breeding, and mating were performed as described by Mullins et al. 
[197]. Until 5 dpf embryos and larvae were kept in an incubator holding 28.5°C in petri 
dishes containing E3 medium and no more than 30 embryos/larvae per dish. Zebrafish 
development stages were assigned as described previously by Kimmel et al. [198]. For in vivo 
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imaging and whole mount immunofluorescence experiments, zebrafish larvae and embryos 
were treated with 1xPTU before 24 hpf to prevent pigmentation [199].  
2.2.1.2 Bleaching of fertilized zebrafish eggs 
 
Bleaching of zebrafish eggs destroys pathogens, which may reside on the outer side of the 
chorion, to prevent contamination of the fish facility. Bleaching can be performed without 
harming the embryo in the time frame after epiboly until 1.5 dpf. The fertilized eggs were 
placed in a tea net and were held in bleaching solution for 5 min followed by a 5 min wash in 
tap water. This procedure was repeated once and bleaching solution was replaced every four 
runs. Afterwards the embryos were placed in a petri dish containing E3 medium with 10 µl 
pronase stock solution, which allows the embryos to hatch from the denatured chorion.  
2.2.1.3 Mating of adult zebrafish 
 
In the evening pairs of one female and one male adult zebrafish were transferred from tanks to 
mating boxes containing dividers to separate males and females overnight. In the following 
morning dividers were removed in parallel allowing simultaneous spawning of several pairs 
yielding age matched zebrafish embryos. Eggs were transferred to a petridish containing E3 
medium. In the afternoon unfertilized and debris eggs were removed and the fertilized eggs 
were kept in the incubator at 28.5°C until further analysis or raising.  
2.2.1.4 Microinjection into zebrafish eggs 
 
Injection needles were pulled using a needle puller with the program P(A)60. By filling a 
petri dish with 1.5% agarose in E3 and placing the microinjection molds into the drying 
agarose, injection dishes with agarose rills were generated. In the morning freshly laid eggs 
were placed into the agarose rills and were injected at a 1-cell stage with a mix of each 1.5 µl 
Cas9 protein (0.5 µg/µl) and 1.5 µl gRNA (1-3 µg/µl). Alternatively a plasmid or a MO was 
injected. The rest of the spawned eggs was placed in a separate petri dish containing E3 
medium and served as a control for proper development. DNA and RNA with Cas9 protein 
were injected into the cell, while RNA only was injected into the yolk. After injection the 
eggs were kept in the incubator at 28.5°C in E3 medium. In the afternoon the eggs were 
screened for normal development and unfertilized eggs and debris were removed. 
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2.2.1.5 KD of genes in zebrafish embryos using morpholinos 
 
Establishment of apolipoprotein d (apoda.1) KD A MO targeting the exon 2-intron 2 
junction was ordered at GeneTools. 1 mM stocks were prepared by solubilizing the 
lyophilized solid in sterile dH2O. 10 µl aliquots were prepared and stored at RT for immediate 
injection or at -20°C for later injections. 1 mM, 0.5 mM or 0.25 mM concentrations were 
injected into 1-cell stage AB embryos as described in section 2.2.1.4 The MO was designed to 
block the exon-intron boundary. Thereby three scenarios are possible depending on the 
sequence: Intron retention, skipping of an exon, or usage of a cryptic splice site resulting in 
either intron retention or partial intron inclusion. The altered transcripts are in most cases 
degraded by nonsense-mediated decay. Alternative, the transcripts are transcribed and result 
in the synthesis of a truncated protein [200]. The injected embryos were observed for 
phenotypic abnormalities from 1 dpf to 5 dpf and KD efficiency represented by exon 
exclusion or intron retention was evaluated by PCR. RNA was extracted from a pool of 10 
embryos and transcribed into cDNA, which was amplified by apoda.1 full length spanning 
primer. The obtained PCR product was separated by gel electrophoresis, bands were excised 
and DNA was purified, followed by sequencing. Injection of 1 mM led to the greatest KD 
efficiency, without causing unspecific toxicity, and was thereby chosen for conduction of the 
following experiments.  
2.2.1.6 Quantification of rescue capacity of Apoda.1 and KD of Apoda.1 to mimic the 
Hnrnpa1 loss of function phenotype 
 
1 mM apoda.1 MO was injected into AB embryos for KD of apoda.1. After 30 hpf, the 
timepoint when hnrnpa1a-/-; hnrnpa1b-/- embryos can be firstly distinguished from their 
wildtype looking siblings, images were taken using the Axioscope. To address the previously 
observed lipid phenotype the yolk extension area of injected embryos and their uninjected 
siblings was measured using Fiji. The average area size was calculated and subjected to 
statistical analysis.  
2.2.1.7 Fin biopsies of adult zebrafish 
 
Fin biopsies are taken from adult zebrafish to genotype single fish. Adult zebrafish were 
individually anesthetized in fish facility water containing 3% tricaine stock solution.  After 
confirming successful anesthetization, which can be tested by touching of the fish gently and 
confirmation of lack of movement, the fish was placed on a cutting board and a small piece 
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from the most caudal part of the tail fin was cut and fixed in 100% methanol. Immediately 
after the zebrafish was transferred into a labeled single box allowing to specifically attribute 
the fish to its fin until completion of genomic analysis. The fish was observed until full 
recovery.  
2.2.1.8 Fixation and storage of zebrafish samples 
 
For protein analysis or mRNA isolation embryos, larvae and dissected tissue were placed in a 
microcentrifuge tube and after having removed all liquid they were quickly frozen in liq. N2. 
Snap frozen samples were stored at -80°C until usage.  
For whole-mount immunohistochemistry 30 hpf anesthetized PTU treated and dechorionated 
embryos were transferred to 4% PFA in microcentrifuge tubes and were fixed o/n at 4°C. The 
PFA solution was then removed and samples were washed four times for 5 min with PBST at 
room temperature (RT). For immunofluorescence stainings samples were serially washed for 
10 min in increasing concentrations of methanol (25% methanol in PBST, 50% methanol in 
PBST, 75% methanol in PBST, 100% methanol) followed by two additional washes for 10 
min in 100% methanol prior to being stored in 100% methanol at -20°C until usage. Embryos, 
larvae and fin tissue biopsies for individual genotyping were stored at -20°C in 100% 
methanol until usage.  
2.2.1.9 Lämmli lysis of zebrafish samples 
 
For protein isolation from embryos or zebrafish brains, shock frozen samples were 
homogenized in 4x Lämmli Buffer using a tissue homogenizer. Brains were lysed in 250 µl, 
one embryo was lysed in 15 µl and more embryos in an equivalent volume. Samples were 
then boiled for 5 min at 95°C and centrifuged for 15 min at 13000 rpm to pellet debris. 
Samples were stored at -20°C and were reused after 5 min boiling at 95°C and followed 
centrifugation of 1 min at 13000 rpm.  
2.2.1.10 In vivo imaging of zebrafish embryos  
 
For live imaging PTU treated anesthetized embryos were embedded in 0.8% LMA in E3 
containing 1x tricaine. To prevent drying out the agarose was covered with 1x PBST 
containing 1x tricaine. For long term imaging 24 hpf old embryos were then imaged with the 
spinning disc cell observer for 20 h. Acridine Orange stained embryos were imaged with the 
confocal laser scanning microscope using the 488 nm laser.  
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2.2.1.11 Whole mount immunofluorescence staining 
 
For whole mount immunofluorescence (IF) stainings PFA fixed embryos stored in methanol 
were used. Samples were washed 2x 10 min in PBST and were serially rehydrated by 
washing them 5 min at RT in decreasing methanol concentrations (75% methanol in PBST, 
50% methanol in PBST, 25% methanol in PBST, 100% PBST). The samples were then 
washed 3x5 min in PBST at RT. 30 hpf embryos used for caudal primary (CaP) motoneuron 
staining with Znp-1 antibody were permealized for 10 min with 1 mg/ml collagenase in PBST 
at RT. Collagenase was removed by washing in PBST for 3x5 min at RT. For Proliferating 
cell nuclear antigen (Pcna) staining, embryos were kept in 100% aceton for 20 min at -20°C 
instead of collagenase treatment. After the samples were blocked for 1 h in NCST on a shaker 
at RT. Then the primary antibodies were added in NCST followed by an overnight incubation 
step on a shaker at 4°C. The next day the primary antibodies were removed and kept for 
further usage at 4°C. Samples were then washed for 3x40 min with PBST on a shaker at RT 
followed by a blocking step with NCST for 2x30 min at RT. Afterwards the secondary 
antibody diluted in NCST was added and incubated at 4°C on a shaker o/n. After removal of 
the secondary antibody samples were washed with PBST for 3x40 min. The samples were 
imaged with the spinning disc cell observer microscope using the 488 nm laser. 
2.2.1.12 Motoneuron analysis 
 
After whole mount IF stainings with Znp-1 antibody, which detects CaP motoneurons, SpMN 
axons were analyzed. To correlate genotypes of the embryos to the motoneuron analysis, the 
heads of 30 hpf embryos were biopsied after the IF staining and individually collected in 
microcentrifuge tubes containing TE/Proteinase K buffer to lyse them. The extracted DNA 
was subject for genotyping procedure using allele specific primers or restriction digest. 
Immunostained tails of the embryos were stored in PBST until completion of the genotyping. 
10 embryos per genotype in 3 different clutches were imaged and morphology and length 
analysis were done for motoneuron axons.  
2.2.1.13 Lysis of zebrafish samples 
 
For the extraction of protein RIPA lysis was used. After shock freezing embryos, larvae or 
adult tissue in microcentrifuge tubes, these were kept on ice until radioimmunoprecipitation 
assay buffer (RIPA) buffer containing 1x Proteinase and Phosphatase Inhibitor (PI) was 
added to the samples and tissues. They were immediately homogenized using a pestle mixer 
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and centrifuged for 15 min at 4°C at 13.000 rpm. The supernatant containing the protein was 
transferred to a microcentrifuge tube and was used in a BCA assay to determine the protein 
concentration. As a next step ½ volume of 2x Lämmli buffer was added prior to incubation 
for 5 min at 95°C and centrifuged for 15 min at 13.000 rpm to pellet debris. 5-20 mg sample 
was used for SDS-page. Samples were stored at -20°C and reused after incubating them for 5 
min at 95°C and centrifuging for 1 min at 13.000 rpm.  
2.2.1.14 Deyolking of zebrafish embryos and sample preparation for mass spectrometry  
 
For the proteomic analysis the yolk was removed from the embryos to prevent that the 
abundant yolk proteins mask the detection of proteins. 30 hpf embryos were dechorionated 
and pools of 10 embryos were transferred to a microcentrifuge tube filled with deyolking 
buffer. By pipetting up and down with a 200 µl pipette the yolk was mechanically removed. 
Deyolked embryos were then transferred to a new microcentrifuge tube containing 200 µl 
deyolking buffer. The embryos were shaken at 1100 rpm for 5 min at 4°C on a thermoblock 
followed by a 30 sec centrifugation at 300 g. The supernatant was discarded and 1 ml washing 
buffer was added. The washing and centrifugation steps were repeated three times before 
transferring the embryos to a Protein LoBind tube. Embryos were then frozen in liq. N2 and 
stored for further usage at -80°C.  
Sample preparation for mass spectrometry was performed as described by Sielaff et al. [201]. 
An amount of 20 µg of protein per sample was subjected to proteolytic digestions using a 
modified protocol with an additional benzonase digest step in the beginning for single-pot 
solid-phase enhanced sample preparation (SP3). The protein lysate was diluted 1:2 with 
water. A volume of 10 µL 100 mM MgCl2, and 25 units Benzonase (Sigma Aldrich, US) were 
added followed by an incubation for 30 min at 37°C at 1400 rpm in a Thermomixer 
(Eppendorf, Germany).  
2.2.1.15 Acridine Orange staining 
 
To estimate the number of cells undergoing cell death in the zebrafish embryos Acridine 
Orange staining was performed [202]. Dechorionated anaesthetized 30 hpf PTU treated 
embryos were incubated for 30 min in 3 µg/ml Acridine Orange in E3 containing 1x tricaine. 
After 3 washes for 5 min in E3 1x tricaine the embryos were embedded in 0.8% LMA and 
imaged immediately by the confocal laser-scanning microscope using a 488 nm laser.  
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2.2.1.16 Oil-Red-O staining 
 
For staining of lipids in zebrafish, PTU treated embryos at 30 hpf were fixed by placing them 
in a microcentrifuge tube containing 4% PFA at 4°C o/n. On the next day the embryos were 
rinsed 3x10 min in PBST. Afterwards 0.5% oil red O (ORO) solution (diluted in 100% 
isopropanol) was diluted to 0.3% in sterile H20 and centrifuged for 5 min at 11.000 rpm. 
Subsequently, 500 µl Osolution taken from the top of the microcentrigue tube were added to 
stain the embryos for 1 h at RT on a shaker. The embryos were then washed 3x10 min with 
1xPBST before they were embedded in in 1.5% LMA in PBST and imaged using the Axio 
Scope A1 microscope.  
2.2.2 Cellbiological methods 
 
The following methods were mostly performed according to the Schmid laboratory methods 
manual. 
2.2.2.1 Cell cultivation 
 
Human cervical carcinoma cells (HeLa) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with Glutamax supplemented with 10% fetal calf serum (FCS) and 1% 
penicillin/streptomycin at 37°C and 5% CO2.  
2.2.2.2 Transfection of cells 
 
After plating the cells they were kept for 24 h before they were transfected. The cells were 
seeded in 12 well cell culture dishes and transfected by inverse transfection. Per well, 2 µl 
lipofectamin 2000 and 125 µl optiMEM were incubated for 5 min before the mix was 
combined with 0.8 µg of DNA mixed with 125 µl optiMEM. Next, the DNA/lipofectamin 
transfection mix was transferred to a new 12 well plate prior splitting cells to 150000 cells in 
500 µl per well. Cells were incubated in transfection mix o/n followed by an exchange of 
media by DMEM/Glutamax/FCS/penicillin/streptomycin the next day. Cells were culture and 
harvested 48 hpf later (see section 2.2.2.3) 
2.2.2.3 Harvesting of HeLa cells and whole cell lysis 
 
Cells were washed 2x in PBS prior to being detached from the dish using a cell culture 
spatula. Cells were then centrifuged at 3500 x g and the pellet was lysed in 250 µl ice-cold 
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RIPA lysis buffer containing 1x Proteinase and PI by incubation on ice for 10 min. 
Afterwards the DNA was sheared by vortexing and after a centrifugation step for 15 min at 
13000 rpm at 4°C the remaining debris was pelleted. The supernatant was transferred to a 
new microcentrifuge tube and protein concentration was determined by BCA assay 
measurement. Next, cell lysates were mixed with 4x Lämmli sample buffer, boiled at 95°C 
for 5 min and centrifuged for 1 min at 11000 rpm. Until usage for immunoblotting, cell 
samples were stored at -20°C.  
2.2.3 Molecular biological methods 
The following methods were mostly performed according to the Schmid laboratory methods 
manual. 
2.2.3.1 Isolation of genomic DNA 
 
For genotyping of individual embryos or adult fish, genomic DNA from embryos or fin 
biopsies was isolated (for fin biopsies see section 2.2.1.7). The methanol from fin biopsies 
was removed and the remaining methanol evaporated by incubating the samples at 55°C. 
Embryos were anesthetized in 1x tricaine.  Fin biopsies or embryos were then lysed in each 
50 µl lysis buffer containing 10% PK. Samples were first digested at 55°C at 750 rpm for 1 h 
before inactivating PK at 95°C for 10 min. To pellet remaining tissue debris the samples were 
centrifuged for 5 min at 13.000 rpm. The genomic DNA containing supernatant was used for 
further analysis by PCR.  
2.2.3.2 Isolation of RNA 
 
Isolation of RNA using RNeasy Mini Kit For isolation of RNA from zebrafish embryos or 
adult brain the RNeasy Mini Kit including on column DNase treatment (RNase-free DNase 
Set) was used according to the technical handbook. 30 embryos were pooled or one brain was 
placed in one microcentrigue tube. For RNA sequencing of hnrnpa1a-/-; hnrnpa1b-/- and their 
wildtype siblings 20 embryos were pooled respectively. After removal of the water, 2x 350 µl 
RLT buffer containing 10% β- mercaptoethanol was added and embryos were disrupted with 
a tissue homogenizer. RNA was eluted in 30 µl RNase free water, and RNA quality was 
evaluated by gel electrophoresis (2 µl loaded), and the concentration was measured with a 
NanoDrop device. RNA was then stored at -80°C. 
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Isolation of RNA using Trizol RNA from zebrafish adult brains derived from hnrnpa1a-/-, 
hnrnpa1b-/- or hnrnpa3-/- mutant fish that was sent for RNA sequencing was isolated 
according to the TRIzol Plus RNA Purification Kit. This method allows the extraction of a 
variety of RNA species of large and small molecular size. Each brain was homogenized in 
1 ml TRIzol. RNA was eluted in 30 µl RNAse free water, RNA integrity was checked by gel 
electrophoresis (2µl loaded), and RNA concentration was determined with a NanoDrop 
device. RNA was stored at -80°C. 
2.2.3.3 cDNA synthesis 
 
cDNA was synthetized as described in the M-MLV Reverse Transcriptase Kit. Additionally 
RiboLock RNase Inhibiter was used for RNase inhibition. For cDNA, which is later used in 
qRT-PCRs 0.5 µg of total RNA was mixed with 2.5 µl random hexamer primers and 1 µl 10 
mM dNTPs in a volume of 12 µl H2O. For cDNA used for cloning of hnrnpa constructs 5 µg 
of total RNA were mixed with 2.5 µl of oligo (dT) primers instead that selectively enrich for 
mature mRNAs. The cDNA transcription was followed by 20 min RNase H digest at 37°C to 
remove RNA-DNA hybrids. Efficient cDNA transcription was determined by performing a β-
actin PCR according to section 2.2.3.4.1 on the samples.  
2.2.3.4 PCR 
 
Oligonucleotides used for PCR are listed in section 2.1.5. Pairs of oligonucleotides were 
designed to have a similar annealing temperature not differing more than 2°C in the range of 
50°C to 70°C to allow successful amplification of the spanned genomic region. The following 
components were mixed in a PCR tube: 
 PCR mastermix / reaction 17.5 µl PCR mix 
     0.5 µl forward primer (10 µM) 
     0.5 µl reverse primer (10 µM) 
     0.1 µl GoTag DNA Polymerase 
     
1 µl DNA or cDNA was added to 17.5 µl mastermix and the following PCR program was 
used after identifying the optimal oligonucleotide annealing temperature using a gradient PCR 
(see section 2.2.3.4.5). The number of cycles was initially set to 34 and adjusted depending on 
the band intensity:  
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PCR products were analyzed by agarose gel electrophoresis. 
2.2.3.4.1 Control PCR 
 
To proof efficient synthesis of cDNA a β-actin PCR was performed. The PCR mix was used 
in combination with primers oA03 β-actin F and oA04 β-actin R, which specifically amplify 
β-actin. In one reaction 1 µl of cDNA and 17.5 µl of mastermix were used in the following 
PCR program:  
 
PCR products were analyzed by agarose gel electrophoresis. 
2.2.3.4.2 PCRs for sequencing hnrnpa1a, hnrnpa1b, and hnrnpa3 
 
To verify published hnrnpa1a, hnrnpa1b, and hnrnpa3 sequences in our AB fish line and to 
identify naturally occurring single nucleotide polymorphisms (SNPs) in our fish population, 
hnrnpa1a, hnrnpa1b, and hnrnpa3 genes were sequenced from 2 dpf AB cDNA. For 
amplification of full-length hnrnpa genes the following primer combinations were used:  
Cycle Step Temperature Time No. of cycles 
Initial Denaturation 95°C 2 min 1 
Denaturation 95°C 30 s xz 
Annealing 50-70 °C 30 s xz 
Extension 72°C xy min  xz 
Final extension 72°C 5 min 1 
 
Cycle Step Temperature Time No. of cycles 
Initial Denaturation 95°C 2 min 1 
Denaturation 95°C 30 s 34 
Annealing 65.3 °C 30 s 34 
Extension 72°C 1 min  34 
Final extension 72°C 5 min 1 
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Amplicon F Primer R-Primer Annealing Temp 
hnrnpa1a LJ-A05 LJ-A06 70.0 
hnrnpa1b LJ-A01 LJ-A02 66.4 
hnrnpa3 LJ-A09 LJ-A10 63.8 
 
The primer pairs listed in the table were used in combination with the PCR mix whereby each 
reaction contained 1 µl genomic cDNA and 17.5 µl mastermix. The annealing temperature 
was specifically selected for each primer pair as shown in the above table. The extension time 
was 1 min and 30 sec and the number of cycles was 34. PCR products were analyzed by 
agarose gel electrophoresis prior to purification and being sent for sequencing to GATC.  
2.2.3.4.3 Screening/ genotyping PCR for hnrnpa CRISPR/Cas9 mutants 
 
For screening/genotyping PCRs the PCR mastermix was used with the respective primer pairs 
listed in the table below. The annealing temperature and number of cycles for each primer 
pair are listed in the table below. For sequencing of the mutant allele the PCR product was 
digested by RE digest and separated on an agarose gel. The mutant band was cut out from the 
gel, purified according to the NucleoSpin Gel Clean-up protocol and sent for GATC 
sequencing.  
 
Amplicon F-Primer R-Primer Annealing 
Temp 
(°C) 
Cycle 
# 
RE T 
(°C) 
Buffer 
hnrnpa1a ex2 LJ-B05 LJ-B06 58.0 32 Fnu4HI 37.0 Cutsmart 
(CS) 
hnrnpa1a ex8 LJ-B07 LJ-B08 64.0  36 MnlI 37.0 CS 
hnrnpa1b ex2 LJ-B01 LJ-B02 68.3 34 PvuII 37.0 CS 
hnrnpa1b ex9 LJ-B03 LJ-B04 68.3 34    
hnrnpa3 ex2 LJ-B09 LJ-B10 58.8 34 Fnu4HI 37.0 CS 
hnrnpa3 Sa LJ-B11 LJ-B12 
/LJ-B13 
68.8 30    
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2.2.3.4.4 PCRs for cloning HA tagged wildtype hnrnpa1a, hnrnpa1b, and hnrnpa3  
 
For amplification of wildtype HA-tagged hnrnpas, referred to as HA+hnrnpa1a, 
HA+hnrnpa1b, HA+hnrnpa3, the primer pairs listed in the table were used in combination 
with the general mastermix. The annealing temperature was specifically selected for each 
primer pair as shown in the table below. The extension time was 1 min and 30 sec and the 
number of cycles was 34. PCR products were analyzed by agarose gel electrophoresis prior to 
purification and being sent for sequencing to GATC.  
 
2.2.3.4.5 Gradient PCR 
 
In order to determine the optimal annealing temperature of a primer pair gradient PCRs were 
performed using the general mastermix. Thereby a temperature gradient for the annealing 
temperature with a range from 50-70°C was tested. The extension time was adjusted 
according to the expected PCR product size. As a last step the PCR products were analyzed 
by agarose gel electrophoresis.  
2.2.3.4.6 Colony PCR 
 
Single clones from a previously plated agar plate were picked with pipette tips and inoculated 
with 30 µl LB medium containing the appropriate antibiotic. Bacterial colonies were then 
incubated at RT for 30 min and stored at 4°C. Appropriate primers, which allow the 
verification of the successful integration of the insert in the plasmid and its orientation, were 
selected for the PCR. For one reaction 1 µl colony LB culture and 17,5 µl mastermix were 
used. Annealing temperature and extension time were adjusted according to the temperatures 
of the primers used and the expected PCR fragment size. PCR products were analyzed by 
agarose gel electrophoresis.  
2.2.3.4.7 qRT-PCR 
 
The primers used for qRT-PCR all spanned an exon-exon junction with an intron longer than 
1 kb to exclude amplification of genomic DNA and had an amplicon size of 80-150 bp. To 
Amplicon F Primer R-Primer Annealing Temp 
HA+hnrnpa1a LJ-A03 LJ-A06 66.2 
HA+hnrnpa1b  LJ-A07 LJ-A02 78.3 
HA+hnrnpa3 LJ-A11 LJ-A10 60.0 
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test the specificity of the primers they were analyzed on wildtype cDNA and validated by the 
presence of a single band of the predicted size upon agarose gel electrophoresis. The obtained 
PCR products were additionally sent for sequencing and aligned to their target sequence. 
qPCR was performed in 384-well format on a C1000 Thermal Cycler. One reaction contained 
2 ng cDNA, 2.5 µl SYBR Green, 0.25 µl 10 µM forward primer, and 0.25 µl 10 µM reverse 
primer. To establish a standard curve total cDNA of all samples were pooled and a dilution 
series of 1:1, 1:10, 1:100, 1:1000 was set up. Each reaction was conducted as a technical 
triplicate and for each primer pair a no reverse transcriptase and no template control were 
included. The PCR program was run on a C1000 Thermal Cycler with the following steps: 
30 s at 95°C, 55 cycles of 5 s at 95°C and 10 s at 60°C and a melting curve from 60°C to 
95°C with an increase of 0.5°C every 5 s. Relative gene expression of each gene was 
calculated by ∆∆CT-method and the normalized fold expression was determined by 
normalizing individual gene expression to the reference genes rflp13a and elf1a2.  
2.2.3.4.8 Semiquantitative PCR 
 
Semiquantitative PCR was performed for pkma. 1 µl cDNA, 17.5 µl PCR mix, 0.5 µl 10 µM 
forward primer, and 0.5 µl 10 µM reverse primer were subjected to the following PCR 
program:  
 
Cycle Step Temperature Time No. of cycles 
Initial Denaturation 95°C 2 min 1 
Denaturation 95°C 30 s  
Annealing 63.8 °C 30 s 25/29/33/27 
Extension 72°C xy min   
 
Four PCRs were set up with different cycle numbers (25, 29, 33, 37) to identify the number of 
cycles that leads to accumulation of the PCR product just below saturation level so that 
linearity is fullfilled. For all PCR products the same volume was analyzed via agarose gel 
electrophoresis.  
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2.2.3.5 Cloning of zebrafish hnrnpa1a, hnrnpa1b, and hnrnpa3 constructs 
 
A variety of hnrnpa1a, hnrnpa1b, and hnrnpa3 constructs were cloned using TOPO cloning 
(see section 2.2.3.8) and Gateway technology (see section 2.2.3.9). For cloning full-length 
hnrnpa1a, hnrnpa1b, and hnrnpa3, primers were designed that specifically amplify the full-
length gene. After amplification of the genes via PCR from 2 dpf AB zebrafish cDNA pools, 
the genes were cloned into pCR8/GW/TOPO vectors, which serve as entry vectors. The 
sequence of the vector insert was verified via GATC sequencing. Subsequently, expression 
vectors were generated via gateway reaction with pCS2+ plasmids, which contain pCS2+ 
cytomegalovirus (CMV) promoter as an expression control. Also, destination vectors with a 
GFP tag 5’ of the gateway sites allow for N-terminal fusion of the gene of interest with GFP. 
These vectors were utilized to N-terminally tag HNRNPA1 and HNRNPA1D262V with GFP. 
These plasmids were used to analyze the localization of HNRNPA1 protein in zebrafish in 
wildtype form or when carrying the D262V patient mutation in vivo. 
 
2.2.3.6 Agarose gel electrophoresis 
 
For separation of PCR products by their size to analyze restriction enzyme digests for 
genotyping, or to determine RNA quality, agarose gel electrophoresis was performed. A 1-2% 
agarose gel (agarose in 1xTBE buffer) depending on the size of the PCR product analyzed 
was poured containing Gel Red (1:20000) to visualize the DNA. The samples were mixed 
with 5 µl loading dye and 1 µl DNA-ladder was placed next to the samples. Electrophoresis 
was run in 1xTBE buffer until PCR bands of interest were fully separated. The gel was then 
documented using a UV detection system. 
2.2.3.7 DNA gel extraction and PCR purification 
 
DNA extraction from an agarose gel was performed according to the NucleoSpin Gel Clean-
up protocol. Purified DNA was eluted in 30 µl water and was either used for cloning into 
TOPO vector or analyzed by sequencing.  
2.2.3.8 TOPO cloning 
 
Entry clones were cloned using the pCR8/GW/TOPO TA Cloning Kit. The topoisomerase 
reaction in the kit requires the existence of sticky ends on the PCR product. Freshly generated 
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PCR products can be directly used for further cloning when kept on ice whereas stored PCR 
or cut out PCR bands from agarose gels need addition of adenosines at the ends. Adenosine 
overhangs were added in the following reaction: 20 µl PCR product, 5 µl 5x GoTaq Buffer, 
0.5 µl 10 mM dATP, 0.3 µl GoTaq DNA Polymerase were incubated for 15 min at 72 °C. 1-4 
µl of this fresh PCR product were then used in a TOPO cloning reaction according to the 
cloning kit’s manual. The TOPO cloning reaction was incubated at RT before being 
transformed in chemically competent E. coli cells (see 2.2.5.10). 
2.2.3.9 Gateway cloning 
 
For transfer of DNA fragments from entry clones to expression clones the Gateway cloning 
system was used. 150-500 ng pCR8/GW/TOPO vector containing the DNA insert was used as 
an entry clone and 150 ng of pCS2+GW vector containing a Gateway cassette served as a 
destination vector. The Gateway cloning reaction was performed according to the user manual 
of the Gateway LR clonase II Enzyme Mix. Subsequently 2 µl LR Clonase reaction were 
utilized for transformation to chemically competent E. coli cells (see section 2.2.3.10).  
2.2.3.10 Chemical transformation of bacteria 
 
For transformation of plasmid DNA into bacteria, chemically competent TOP10 E.coli cells 
were used. E. coli cells were thawed on ice prior to adding 2-4 µl of TOPO cloning reactions, 
2 µl of LR Gateway cloning reactions, or 10 pg- 100 ng plasmid DNA. In the next step, the 
cells were incubated on ice for 30 min, heat-shocked at 42°C for 30 s and then quickly chilled 
on ice for 3 min. To allow growth of bacteria, 250 µl SOC medium were added and bacteria 
were incubated at 37°C for 1 h at 200 rpm. Then 10-200 µl of the transformed cells were 
plated out on a pre-warmed LB agar plate containing the appropriate antibiotic to allow 
growth of cell clones expressing resistance genes due to successful integration of the desired 
DNA fragment. LB agar plates were incubated o/n at 37°C. The following day bacteria 
colonies were selected if present and analyzed for correct plasmid integration by colony PCR 
(see section 2.2.3.4.6).  
2.2.3.11 Cultivation of bacteria and plasmid DNA isolation 
 
For plasmid isolation bacteria carrying the plasmid of interest were cultivated in different 
scales depending on the subsequent usage. For miniprep plasmid isolation single clones were 
picked from an LB-agar plate and individually transferred to 3-5 ml LB medium containing 
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the appropriate antibiotic.  The bacteria culture was then incubated o/n at 37°C at 200 rpm. 
The next day plasmid DNA was isolated according to the NucleoSpinPlasmid protocol.  
For midiprep plasmid isolation a single clone from an LB agar plate was inoculated in 200 ml 
LB medium containing the appropriate antibiotic and incubated o/n at 37°C at 200 rpm. On 
the following day plasmid DNA extraction was performed as described by the NucleoBond 
Xtra midi protocol. The concentration was measured with a NanoDrop device and stored for 
later usage at -20°C. Plasmids were sent for sequencing at GATC and entered to the Schmid 
laboratory plasmid database. 
2.2.3.12 RE digest 
 
RE digest is a useful tool for plasmid linearization, screening and genotyping. The optimal 
buffer and temperature were chosen according to the manufacturers protocol.  
For plasmid linearization 10 µg of DNA were digested in 50 µl H2O reaction containing 5 µl 
buffer and 1 µl RE. For screening and genotyping 3 µl PCR product were added to 7 µl of the 
following RE mastermix: 
RE mastermix / reaction  1.0 µl buffer 
      0.1 µl RE 
      6.0 µl sterile dH2O 
The digestion reaction for any of the above applications was incubated for at least 2 h at the 
optimal temperature and was subsequently analyzed by agarose gel electrophoresis. 
Linearized plasmids were purified with Nucleospin PCR clean up, eluted in 25 µl H2O, 
treated with RNA secure, and the concentration determined by NanoDrop. 
2.2.3.13 In vitro mRNA synthesis and purification 
 
gRNAs for injection were transcribed from a gRNA template oligonucleotide. First, the 
gRNA oligonucleotide (oligo) was annealed to the T7 oligo by setting up the following 
reaction in a microcentrifuge tube: 4.3 µl of 100 mM T7 oligo, 1 µl 10x Annealing Buffer, 
0.4 µl RNA secure and 4.3 µl gRNA oligo. After RNA secure treatment of the reaction for 10 
min at 60°C the oligos were denatured in a 95°C waterbath for 5 min. The waterbath was 
slowly cooled down over three hours. In the next step the in vitro transcription was set up in a 
microcentrifuge tube containing the following reagents: 2 µl T7 10x reaction Buffer, 4 µl 
H2O, 2 µl ATP, 2 µl CTP, 2 µl GTP, 2 µl UTP, 4 µl annealed oligos and 2 µl T7 enzyme mix. 
The reaction was mixed and spun down before being incubated for 4 hours at 37°C.  
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RNA that was used for OE of human HNRNPA1D262V and H2B1 was transcribed from a 
linearized template pCS2+ plasmid containing a CMV promoter. 1 µg linearized plasmid was 
mixed in a microcentrifuge tube with 10 µl 2xNTP/CAP, 2 µl 10x reaction buffer, filled up 
with nuclease free H2O to 20 µl, and 2 µl enzyme mix (SP6/T7). The reaction was then 
incubated for 2h at 37°C.  
For degradation of remaining DNA 2 µl TURBO DNAse were added to the reaction followed 
by another incubation step for 15 min at 37°C. Next, for gRNAs used for injection, 115 µl 
nuclease-free H2O and 15 µl ammonium acetate stop solution were added before RNA was 
precipitated by the addition of 300 µl 100% ethanol. In the case of RNAs used for OE, the 
reaction was stoped by adding 30 µl nuclease free H2O and 30 µl lithium chloride. For better 
RNA yields RNA was precipitated overnight at -20°C. On the next day, the reaction was 
centrifuged for 30 min at 4°C at 14.000 xg and the supernatant was discarded. The remaining 
RNA pellet was washed with 800 µl 70% ethanol and centrifuged for another 30 min at 4°C 
at 14.000 x g. Next, the supernatant was discarded and the remaining ethanol was removed by 
evaporation. The RNA was then resuspended in 10 µl RNAse-free H2O and RNA 
concentration was measured using a NanoDrop. Additionally, RNA integrity was analyzed by 
agarose gel electrophoresis. RNA was immediately divided to 1.5 µl aliquots and kept for 
later use at -80°C.  
2.2.3.14 Determination of protein concentration 
 
Protein concentration of zebrafish brain lysates was measured by a BC assay according to the 
user manual of the BC Assay Protein Quantification Kit. To set up a standard curve BSA was 
taken. The reaction was measured with a plate reader at 562 nm.  
2.2.3.15 SDS-polyacrylamide gel electrophoresis 
 
Proteins were separated on a SDS-polyacrylamide gel according to their molecular weight 
(MW). The percentage of the gel was chosen according to the expected MW of the studied 
protein (https://www.thermofisher.com/content/dam/LifeTech/global/Forms/PDF/protein-gel-
electrophoresis-technical-handbook.pdf). 
Gels were prepared according to the following recipe (calculated for three separating gels and 
three stacking gels): 
 10% 12% Stacking gel 
40% acrylamide 6.3 ml 7.6 ml 560 µl 
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The polyacrylamide gel electrophoresis (PAGE) equipment was assembled according to the 
manufacturer’s instruction (Mini Protean Tetra Cell System, BioRad) and SDS running buffer 
was added to the chamber. Before loading the protein samples gel wells were rinsed with SDS 
running buffer. For determination of protein molecular weight Precision Plus ProteinTM All 
Blue Standard was loaded. Electrophoresis was started at 80 V until proteins started to 
separate and continued at 120 V until the proteins of interest were separated sufficiently. Gels 
were subsequently used for Western blotting (see section 2.2.3.16).  
2.2.3.16 Protein transfer to PVDF-membrane (Western blotting) 
 
For transfer immobilization of proteins on a PVDF membrane wet Western blotting was 
performed. Prior to blotting, the PVDF membrane was activated by pre-wetting the 
membrane in methanol. The membrane was then washed in dH20 before being incubated in 
1x transfer buffer. The gel together with the membrane was assembled between Whatman 
paper and foam pads in a holder cassette. Transformation of proteins from the gel to the 
membrane was performed in 1x transfer buffer at 400 mA for 60 min before membranes were 
used for immunodetection.  
2.2.3.17 Immunodetection of proteins 
 
After successful transfer of proteins to the membrane, the Western blotting membranes were 
incubated at RT for 1 h on an orbital shaker in I-Block. The membrane was then incubated in 
primary antibody undiluted or diluted in I-Block on a shaker at 4°C o/n. On the next day, the 
primary antibody was removed and kept for further use at 4°C. Remaining antibody was 
removed by washing 4x15 min in PBST. The secondary antibody was applied diluted in 
PBST for 1 h at RT. After removal of the secondary antibody the membrane was washed 6x 
for 15 min with PBST. Immunodetection was performed using ECL Plus as indicated in the 
manual. Hereby ECL Plus substrate reacts with the HRP conjugate of the secondary antibody 
1M Tris pH 8.8 12.5 ml 12.5 ml - 
1M Tris pH 6.8  - 750 µl 
10% SDS 0.25 ml 0.25 ml 60 µl 
dH2O 5.7 ml 4.4 ml 4,54 ml 
10% APS 67.5 µl 67.5 µl 22.5 µl 
TEMED 67.5 µl 67.5 µl 22.5 µl 
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and produces a strong chemiluminescent signal that can be detected upon exposure of X-ray 
films. After immunodetection the membrane was washed 3x5 min with PBST and dried for 
storage or later reusage between Whatman papers. Before immunodetection of a previously 
used and stored membrane the membrane was reactivated in methanol. The membrane was 
then incubated in 50 ml stripping buffer containing 350 µl β-mercaptoethanol in a shaking 
water bath at 50°C for 30 min. After rinsing the membrane 4x5 min in PBST on a shaker at 
RT the membrane was ready for another round of immunodetection, which was performed as 
described above. 
2.2.4 General methods 
2.2.4.1 Generation of zebrafish specific Hnrnpa specific monoclonal antibodies 
 
Zebrafish specific monoclonal antibodies detecting Hnrnpa1a, Hnrnpa1b and Hnrnpa3 
proteins were generated by the service unit monoclonal antibodies at the Core Facility 
Monoclonal Antibodies, Institute for Molecular Immunology, Helmholtz Center Munich. Rats 
and mice were immunized using peptides that are N- or C-terminally conjugated with 
ovalbumin by the Specialty Laboratories GmbH. The screening process for monoclonal 
antibodies (mAbs) is described in further detail in the result section. 
2.2.4.2 Databases, alignments and primer design 
 
The Ensembl Genome Browser (http://www.ensembl.org/index.html) or NCBI 
(http://ncbi.nlm.nih.gov/) was used for genome and transcript analysis. Sequence alignments, 
mapping of restriction enzymes. and construction of plasmids maps and knockin constructs 
were performed using the CLC Main Workbench. For primer design, Primer 3 
(http://primer3.ut.ee/) was applied followed by a specificity analysis by Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Blast searches of unknown gene and 
transcript sequences were performed on NCBI (https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
2.2.4.3 gRNA design 
 
For successful generation of KO lines a suitable gRNA sequence, which specifically targets 
the genomic region of interest, is suitable for CRISPR/Cas9 genome editing and which allows 
genotyping by restriction fragment length polymorphism (RFLP) needs to be designed. A 20 
nucleotide long sequence followed by a NGG PAM motif for Cas9 recognition was chosen, 
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which lies close the genomic locus of interest. Additionally, a RE site should be present close 
to the NGG motif for convenient genotyping purposes. Ultimately, the chosen gRNA 
sequence was blasted against the zebrafish genome on the NCBI website 
(https://blast.ncbi.nlm.nih.gov/) to identify potential off targets. gRNAs with a low number of 
off targets were then in vitro transcribed as stated in section 2.2.3.13 and used for zebrafish 
zygote injection. The results section depicts further evaluation of gRNAs and their usage for 
mutant generation in vivo. 
2.2.4.4 Image acquisition, processing and analysis 
 
Images were taken by Zeiss spinning disc cell observer, Zeiss Axio Scope A1 microscope, 
Zeiss Stereo discoveryV8, and Zeiss confocal laser scanning microscope. Zebrafish embryos 
were embedded in 1.5% (for fixed embryos) or 0.8% (for live imaging) LMA in PBST for 
immobilization and imaged on glass bottom microscope dishes.  
Images were processed using ZEN blue and Fiji to linearly adjust image brightness, contrast, 
and size. For quantification of Western blots, the LAS 400 image reader was used to depict 
band intensities in a linear manner for later analysis in Fiji.  
2.2.4.5 Statistics 
 
GraphPad Prism was used for calculations and for generating the graphs, which are shown in 
this thesis. The statistical tests used in specific experiments are indicated in the respective 
figure legend. The level of significance shown in the graphs is depicted by asterisks: *p<0.05; 
**p<0.01; ***p<0.001. In case no significant difference was observed, the abbreviation n.s. is 
used.  
 
Western Blot analysis: 
In order to quantify western blot bands, all protein levels to be quantified were adjusted to the 
corresponding control protein levels (Calnexin or Tubulin). To be able to compare different 
blots to each other the mean of all wildtype values on a blot was set on the same level with a 
specific multiplication factor for each blot as these are considered to be the same in each 
experiment. According to the calculated factor all loaded KO values on the blot were 
multiplied to obtain comparable values from one blot to the other. As a next step the means of 
wildtype and KO samples from technical replicates were taken. Ultimately, all values were 
divided by the wildtype mean, to obtain the change from wildtype to KO values.  
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3 Results 
3.1 Characterization of zebrafish Hnrnpas 
3.1.1 HNRNPA orthologues and their expression in zebrafish 
 
Zebrafish has become a popular organism for genetic studies of vertebrate gene function due 
to its short generation time, transparency and other features that facilitate and accelerate 
genetic studies. However, for effective modeling of the human gene function, it is important 
to understand the extent to which orthologues zebrafish genes are related to human genes. 
Zebrafish belong to the teleostei class, which underwent an additional round of whole genome 
duplication (WGD) called the teleost-specific genome duplication (TSD) [203]. According to 
Ensembl Compara 71.4% of human genes have at least one zebrafish orthologue and 
reciprocally 69% of zebrafish genes have at least one human orthologue [204].  
The Ensembl database (http://www.ensembl.org/index.html) indicates that the Hnrnpa/b 
family in zebrafish consists of several proteins: two Hnrnpa0, two Hnrnpab, two Hnrnpa1, 
and one Hnrnpa3. The two Hnrnpa1, referred to as Hnrnpa1a and Hnrnpa1b, are both the 
orthologues of human HNRNPA1 and the orthologue of human HNRNPA3 is Hnrnpa3. 
There is no zebrafish orthologue for HNRNPA2. Zebrafish Hnrnpa1a, Hnrnpa1b, and one 
Hnrnpa3 share the main protein domains, such as two RRM domains followed by a RGG 
domain, with HNRNPA1 and HNRNPA3 (see Figure 3.1). 
 
 
Figure 3.1 - Schematic illustration of the human HNRNPA and zebrafish Hnrnpa domain structures. 
Black numbers: amino acids. RRM: RNA recognition motif 1 and 2. RGG: Arginine-Glycine-Glycine rich 
domain. The M9 domain, which is required for nuclear shuttling is indicated in pink. 
 
I amplified hnrnpa1a, hnrnpa1b, and hnrnpa3 from cDNA of 2 dpf embryos to verify the 
genetic sequence of respective genes and to identify SNPs in our zebrafish population. 
Hnrnpa1a is located on chromosome 11 and consists of 10 exons with an open reading frame
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 (ORF) of 1167 bp that encodes a 388 aa protein with a theoretical molecular weight of 
38.5 kDa. The longer hnrnpa1a isoform encoding 411 aa (with additional 23 aa at the N-
terminus) with an ORF of 1236 bp and a theoretical MW of 41.02 kDa could also be 
amplified. hnrnpa1b is located on chromosome 23 and consists of 11 exons with an ORF of 
1269 bp coding for 422 aa protein with a calculated MW of 42.6 kDa. A shorter isoform that 
lacks 19 aa at the N-terminal part was also amplified and has a calculated MW of 40.5 kDa. 
Hnrnpa3 is located on chromosome 9 and consists of 11 exons with an ORF of 1023 bp, and 
is translated into a 340 aa protein with a theoretical molecular weight of 35.6 kDa. Hnrnpa1a, 
hnrnpa1b and HNRNPA1 share a conserved genome environment, a phenomenon described 
as synteny [205]. The shared synteny between hnrnpa1a and hnrnpa1b with HNRNPA1 is 
depicted in Figure 3.2. indicates that hnrnpa1a and hnrnpa1b are orthologues of HNRNPA1. 
Additionally, the shared synteny between hnrnpa3 and HNRNPA3 is 
 
 
Figure 3.2 - Synteny between human and zebrafish HNRNPA1 and HNRNPA3. A: Human HNRNPA1 is 
located on chromosome 12. In zebrafish two hnrnpa1 genes have evolved by genome duplication: hnrnpa1a and 
hnrnpa1b that are located on chromosome 11 and chromosome 23, respectively. The neighbouring genes of 
human HNRNPA1 are SMUG1 and CBX5 at the 5’ site and NFE2 and COPZ1 at the 3’ site. In zebrafish smug1 
is located 5’ of hnrnpa1a,  cbx5 is located 5’ of hnrnpa1b, and nfe2 is located 3’ of hnrnpa1b. B: Human 
HNRNPA3 is located on chromosome 2 and zebrafish hnrnpa3 is located on chromosome 9. The genes situated 
5’ and 3’ of HNRNPA3 and hnrnpa3 are highly similar (HOXD and hoxd, NFE2l2 and nfe2l2a, AGPS and agps) 
indicating shared synteny.  
shown, providing the evidence that hnrnpa3 is the HNRNPA3 orthologue (see Figure 3.2). 
Sequence analysis revealed 67% sequence identity between human HNRNPA3 and zebrafish 
Hnrnpa3. In human two HNRNPA1 forms exist, which are generated by alternative splicing: 
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A1-B, which represents the full-length isoform of 372 aa, and A1-A, the shorter variant, 
which lacks exon 8 resulting in a 320 aa long portein. Alignment of Hnrnpa1a and Hnrnpa1b 
to HNRNPA1-A or HNRNPA1-B using the UniProt alignment tool (www.uniprot.org/align) 
gave sequence identity percentages. The analysis revealed the highest sequence identity 
between hnrnpa1a (63-66 %) and hnrnpa1b (61-65 %) when compared to HNRNPA1-B. 
Comparison of zebrafish hnrnpa1a and hnrnpa1b to HNRNPA1-A revealed only 55-58 % 
and 53-57 % sequence identity, respectively. Based on sequence comparison, the zebrafish 
hnrnpa1s are more similar to human Human HNRNPA1-B.  
3.1.2 Screening for zf-Hnrnpa antibodies 
 
In order to detect Hnrnpa proteins by Western blotting and to thereby confirm the absence of 
protein in our mutants and to analyze changes in protein expression levels, monoclonal 
antibodies were generated. Hnrnpa proteins are similar in their amino acid sequence, 
especially Hnrnpa1a and Hnrnpa1b. To reduce the likelihood of cross-reactivity of these 
antibodies I selected unique sequences as specific epitopes for immunization (see Figure 3.3).  
 
 
 
Figure 3.3 - Schematic illustration of the Hnrnpa1a, Hnrnpa1b, and Hnrnpa3 antibody epitope. The 
location of the antibody epitopes are indicated by a red line. 
The monoclonal antibody (mAb) unit (IMI, Helmholtz Center Munich) used conjugated 
peptides to immunize mice and rats (peptides and their conjugates are listed in table 3.1). 
Subsequently, lymphocytes were taken from these animals and fused with myeloma cells to 
hybridomas to generate mAbs [206]. Pooled supernatants of the hybridoma cells were 
screened by an enzyme-linked immunosorbent Assay (Elisa) using bovine serum albumin 
(BSA) or biotin-conjugated peptides for positive mAbs.  
I then tested positive pools by Western blotting of HA-tagged zf-Hnrnpa proteins, which were 
derived from OE in HeLa cells. Successful OE of these constructs was confirmed by Western 
blot with the HA antibody and I found HA-Hnrnpa1a migrating on a SDS-PAGE at a MW of 
approximately 40 kDa, HA-Hnrnpa1b migrating on a SDS-PAGE at a MW of approximately 
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40 kDa and HA-Hnrnpa3 at a MW of approximately 38 kDa (see Figure 3.4). All three 
proteins run at a slightly higher MW than expected probably due to the HA tag (3.56 kDa) or/ 
and posttranslational modifications. The different splice variants of Hnrnpa1a and Hnrnpa1b 
could not be detected as they run at similar molecular heights, which require greater 
separation by a higher percentage gel. 
 
 
 
Figure 3.4 - HA-tagged Hnrnpa1a, Hnrnpa1b and Hnrnpa3 are successfully overexpressed in HeLa cells. 
Hnrnpa1a, Hnrnpa1b, and Hnrnpa3 run at a slightly higher MW than expected probably due to the HA tag and/or 
posttranslational modification. Hnrnpa1a is detected at approximately 40 kDa and Hnrnpa3 runs at 
approximately 38 kDa. Hnrnpa1b is lower expressed and can be only detected after longer exposure time at 
approximately 40 kDa. 
As a next step, the hybridoma supernatant pools were tested on their ability to detect 
overexpressed zf-Hnrnpa1a, zf-Hnrnpa1b, or zf-Hnrnpa3. 24 out of 151 tested pools directed 
to Hnrnpa1b and 31 out of 44 pools directed to Hnrnpa3 detect Hnrnpa1b or Hnrnpa3 in cell 
culture, respectively (see Figure 3.5 and Table 3.1). Unfortunately, none of the Hnrnpa1a 
antibodies was positive for Western Blotting  
Taken together, zebrafish specific mAbs detecting overexpressed Hnrnpa1b and Hnrnpa3 in 
HeLa cells were successfully generated, while no mAb could be established that specifically 
detects Hnrnpa1a. 
 
Peptide name Peptide sequence No. of positive / No. of all 
hybridoma tested 
Z1A2 (Hnrnpa1a) OVA-C- MTEKNSDKRRGF  0/16 
Z1A1 (Hnrnpa1b) MSKEGQPREPEQLR-C-OVA  24/151 
Z1A3 (Hnrnpa3) OVA-C-KALPKQEMQSSSNQRYRGG 31/44 
Table 3.1 - Peptides for mAb generation and summary of hybridoma pools tested. Peptides for 
immunization were conjugated to OVA N- or C-terminally via an added cysteine (-C-). 
Results 
 63  
 
Figure 3.5 - Overexpressed HA tagged Hnrnpa1b and Hnrnpa3 are specifically detected on Western Blot. 
Hnrnpa1b is detected at approximately 40 kDa and Hnrnpa3 runs at approximately 38 kDa. Absence of a band in 
the control untransfected cells show specificity of the antibodies.  
Hnrnpa3 antibody 
 
While an antibody was identified that detects overexpressed Hnrnpa3 protein, none of the 
positive mAbs directed to Hnrnpa3 detected endogenous zebrafish Hnrnpa3. However, I 
identified an antibody (Tardbpl_tv1 16C8-11), which next to its targeted protein Tardbpl_tv1 
also seemed to detect Hnrnpa3. To further confirm this initial observation I conducted several 
control experiments. First the cross-specificity of the antibody was tested on adult Hnrnpa3 
KO brains compared to wildtype brains. While in Western blots a band was present at the 
expected height of 35.6 kDa in samples obtained from wildtype brains, this band was absent 
 
Figure 3.6 - The monoclonal antibody raised against Tardbpl_tv1 detects also Hnrnpa3 but not Hnrnpa1a 
or Hnrnpa1b A: anti-Tardbpl_tv1 16C8-11 detects a band at the expected size of Hnrnpa3 at 35.6 kDa in the 
zebrafish wildtype brain but not in the brain of hnrnpa3-/- fish. B: No crossreactivity of the antibody with 
Hnrnpa1a or Hnrnpa1b on hnrnpa1a-/- and hnrnpa1b-/- brains. No band at the expected size for Hnrnpa3 was 
detected in hnrnpa3-/- brains, while this band was unchanged in hnrnpa1a-/- and hnrnpa1b-/- brains. C: Hnrnpa3 
was detected in hnrnpa3 transfected HeLa cells at a higher molecular weight (38 kDa) due to HA tag. No band 
was detected in hnrnpa1a or hnrnpa1b transfected HeLa cells.  
in samples derived from Hnrnpa3 KO brains (see Figure 3.6A). No cross-reactivity with 
Hnrnpa1a or Hnrnpa1b was further confirmed by the presence of this band in hnrnpa1a-/- and 
hnrnpa1b-/- mutant brains (see Figure 3.6B). Moreover, the antibody was tested on HeLa cells 
overexpressing HA tagged hnrnpa3, which was clearly detected at the expected size. No 
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bands at the expected height were detected in HeLa cells overexpressing HA tagged 
Hnrnpa1a or Hnrnpa1b (see Figure 3.6C). It can be concluded that the antibody directed to 
Tardbpl_tv1 (16C8-11) also specifically detects zebrafish Hnrnpa3 but not Hnrnpa1a or 
Hnrnpa1b. 
3.1.3 Hnrnpa1b and Hnrnpa3 expression throughout development 
 
Having identified Hnrnpa1b and Hnrnpa3 specific mAbs, these were used to determine 
Hnrnpa1b and Hnrnpa3 protein expression throughout development by immunoblotting. A 
distinct Hnrnpa1b band was clearly visible above 37 kDa at all developmental stages that 
were analyzed upon immunoblotting with the Hnrnpa1b antibody.  
 
 
Figure 3.7 - Hnrnpa1b and Hnrnpa3 protein expression during development. A: Hnrnpa1b protein is 
expressed at 2 hpf to 4 dpf visualized by Hnrnpa1b mAb marked by a black arrow B: Hnrnpa3 protein levels 
were below the detection limit from 2 hpf to 4 dpf. Calnexin served as a loading control. Note that the Calnexin 
band was masked by huge amounts of yolk proteins at 1 dpf. One embryo per lane was loaded. Asterisk marks 
longer exposure time. 
Hnrnpa3, which runs at approximately 37.5 kDa could not be detected at any analyzed 
developmental stage from 2 hpf to 4 dpf. This may be due to low expression of Hnrnpa3 
during development, which is below detection limit of the antibody. The protein expression 
levels of Calnexin served as a loading control.  
Concluding one can say that Hnrnpa1b protein is expressed at all developmental stages 
analyzed (2 hpf, 1 dpf, 2 dpf, 3 dpf, and 4 dpf). Hnrnpa3 is not detectable by Western blot in 
early developmental stages pointing to either low Hnrnpa3 expression, absence of Hnrnpa3 
during early developmental stages or masking of the epitope during development due to 
posttranslational modifications.  
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3.2 HNRNPA1D262V protein localization 
 
HNRNPA1 shuttles between the nucleus and cytoplasm under normal conditions with a 
predominant nuclear localization [207]. In healthy muscles, HNRNPA1 is predominantly 
localized to the nucleus. In contrast, mutations in HNRNPA1, including the D262V patient 
mutation, cause depletion from nuclei and are found in sarcoplasmic inclusions of HNRNPA1 
in degenerating muscle of sporadic IBM and MSP patients [208]. Moreover, the 
 
Figure 3.8 - HNRNPA1D262 does not mislocalize or aggregate in vivo. A: Schematic illustration of HNRNPA1 
expression constructs in neurons. HNRNPA1 coding sequences (blue) are fused to GFP (green) under the control 
of the CMV promoter (grey). H2B1 coding sequence (light brown) is fused to mRFP (red) under the control of 
the CMV promoter (grey). B: Representative images of HNRNPA1wildtype and HNRNPA1D262V protein 
expression and RFP nuclear labeling in 2 dpf zebrafish embryos. Scalebar=10 µm. 
 
HNRNPA1D262V disease mutation is located in the PrLD of HNRNPA1 and is predicted to 
enhance aggregation propensity according to prion domain prediction algorithms [101].  
To investigate whether the patient mutation affects nuclear transport of human HNRNPA1 
protein resulting in HNRNPA1 redistribution to the cytosol and/or HNRNPA1 aggregation, 
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localization of HNRNPA1 wildtype and mutant protein was analyzed in vivo. Therefore, I 
cloned two reporter constructs fusing human HNRNPA1wildtype or HNRNPA1D262V to a GFP 
tag. Additionally, I cloned a reporter construct fusing H2B1 to a RFP tag, which stains the 
nuclei in red. All three constructs were under the control of a CMV promoter (see 
Figure 3.8A). These plasmids were injected in 1-cell stage zebrafish embryos resulting in a 
mosaic expression pattern and immunofluorescence staining was performed at 2 dpf. Stained 
cells were analyzed for HNRNPA1 localization changes or aggregation. From the staining it 
becomes evident that HNRNPA1wildtype and HNRNPA1D262V are both restricted to the nucleus 
in neurons (see Figure 3.8B) and do not differ in their subcellular localization.  
It can be concluded that the D262V patient mutation does not seem to cause nuclear shuttle 
defects and HNRNPA1D262V expression is indistinguishable from HNRNPA1wildtype.  
3.3 Generation of hnrnpa1a, hnrnpa1b, hnrnpa3 loss of function mutants 
 
Mutations in HNRNPA1 and HNRNPA2B1 were identified in patients suffering from ALS and 
MSP, but the effect of these mutations on protein function is not clear [101]. In order to study 
their protein function in zebrafish, I generated hnrnpa1a and hnrnpa1b loss of function 
zebrafish. As another member of the HNRNPA protein family, HNRNPA3 was associated 
with ALS as it was found to aggregate in motoneurons of patients carrying C9ORF72 repeats 
[70]. Hnrnpa3 is furthermore highly similar in structure to HNRNPA1 and HNRNPA2B1 and 
was shown to bind G4C2 repeats found in ALS patient’s C9ORF72 gene [70]. I therefore 
generated an additional zebrafish line that is deficient of Hnrnpa3. In this study I generate 
protein loss of function mutants by CRISPR/Cas9 genome editing, as these are stable and 
inherited so that studies can be also performed in adult zebrafish.  
3.3.1 gRNAs targeting hnrnpa1a, hnrnpa1b, and hnrnpa3 
 
To generate mutations, I targeted hnrnpa1a, hnrnpa1b, and hnrnpa3 with a gRNA that was 
designed as described in section 2.2.6.3 and Cas9, and screened injected embryos for indel 
mutations by RFLP. I designed two gRNAs for each gene to target two different loci of each 
gene and to thereby create two independent loss of function lines for the hnrnpa1a and 
hnrnpa1b. An additional fish line was obtained from the Sanger center, which was N-ethyl-N-
nitrosourea (ENU) mutagenized. It contains a point mutation in the hnrnpa3 gene at aa 140 
that is predicted to result in a premature termination codon (PTC). 
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For each gene one gRNA targets the 5’ end of the ORF as frame shift mutations in this region 
are likely to result in loss of function as mutated mRNAs may be recognized by the NMD 
machinery leading to translation of a truncated protein. The second gRNA targets the gene 
close to the patient mutation site more towards the 3’ end of the ORF and was initially 
designed to introduce patient mutations at this locus by targeted KI. By targeting the genes at 
two different loci at distinct ends of the gene (one at the 5’ end and the other towards the 3’ ed 
of the ORF) independent KO lines for the same genes were generated (see Figure 3.9). Two 
independently generated alleles reduce the probability of identical off-target effects. gRNAs 
 
 
 
Figure 3.9 - Localization of gRNA target sequences in hnrnpa1a, hnrnpa1b, and hnrnpa3 A: Schematic 
illustration of the hnrnpa1a genomic exon/intron structure. gRNA3 targets the first coding exon. Induced 
mutations are detected with the restriction endonuclease (RE) Fnu4HI. gRNA4 targets the ninth coding exon 
close to the patient mutation site and induced mutations are detected with the RE MnlI. B: Schematic illustration 
of the hnrnpa1b genomic exon/intron structure. gRNA1 targets the second coding exon and induced mutations 
are detected with the RE PvuII. gRNA2 targets the ninth coding exon close to the patient mutation site and 
induced mutations are detected with the RE Fnu4HI. C: Schematic illustration of the hnrnpa3 genomic 
exon/intron structure. gRNA5 targets the second coding exon and induced mutations are detected with the RE 
Fnu4HI. Red lines: binding and cut sites of the RE. Purple: gRNA target sequence. Bold: PAM motif. Scale bar: 
100 bp – Schematic illustrations were genered with http://wormweb.org/exonintron 
were designed manually in CLC by choosing the target locus and designing the gRNA close 
to the next available PAM NGG motif. For later genetic screening purposes only those NGG 
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motifs were chosen that additionally have a RE cutting site close to them with the additional 
limitation that the chosen enzyme does only cut once in the region in such manner 
(approximately 150 bp up- and downstream of the NGG site) that the digested (wildtype 
unmodified allele) and undigested (modified KO allele) PCR product can be separated 
according to their length by gel electrophoresis). Selected gRNAs were then checked for their 
GC content using the online tool Multiple Primer Analyzer by Thermofischer and a GC 
content of 40 to 60% was considered suitable. Furthermore, the gRNA was tested for 
specificity in a BLAST search (http://blast.ncbi.nlm.nih.gov/blast.cgi). All the chosen gRNAs 
had off-target coverage below 70% upon Blast search against the zebrafish genome, thereby 
reducing the likelihood of off-target binding. As a next step the gRNAs were injected together 
with Cas9 protein by microinjection into the cell of zebrafish eggs at the 1-cell stage (see 
Figure 3.10).  
 
 
 
Figure 3.10 - Schematic illustration of gRNA+Cas9 protein injection into zebrafish eggs. Injection of 
hnrnpa1a, hnrnpa1b, or hnrnpa3 targeting gRNAs with Cas9 protein and the resulting mosaic P0 generation. 
Colored dots in P0 fish indicate mosaic expression of different induced mutations.  
3.3.2 Screening for hnrnpa1a, hnrnpa1b, and hnrnpa3 mutations 
 
For identification of successfully edited zebrafish eggs, screening assays were established that 
allow the detection of mutations that are induced by the cell`s error prone repair mechanism 
NHEJ after induction of a DSB. The screening assay not only functions as a read out of the 
gRNAs` efficiency can additionally be used for screening of edited alleles. Genomic DNA of 
2 dpf old injected fish or finclip material of adult fish was amplified by PCR using primer that 
span the target site of the gRNA. Subsequently, the PCR product was digested with the 
respective RE (see Table 3.2) and separated on an agarose gel side by side to the undigested 
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Table 3.2 – PCR band pattern for screening CRISPR/Cas9 induced hnrnpa mutations. For explanation see 
text. 
PCR product. In the wildtype situation the PCR product that was treated with the respective 
RE is completely digested resulting in digested bands that run at a lower MW than the 
undigested PCR product. In case that the RE cuts once in the PCR product two bands are 
present in the digested PCR product (see Figure 3.11C+D+E), whereas more smaller bands 
are present in case that the enzyme cuts multiple times in the PCR product (see Table 3.2). 
Mutations altering the RE recognition motif prevent binding of the enzyme and the PCR 
product remains undigested. The amoung of undigested PCR product is proportional to the 
amount of edited alleles deleting the restriction recognition site. In embryos that were injected 
with gRNA3 (see Figure 3.11A) and gRNA 4 (see Figure 3.11B) targeting hnrnpa1a, the PCR 
band at 296 bp or 396 bp respectively was only partially digested showing successful 
induction of mutations in the P0 generation in the hnrnpa1a gene. The PCR product at 346 bp 
and 305 bp is also only partially digested in embryos that were injected with gRNA1 and 
gRNA2, respectively, pointing towards successfully induced hnrnpa1b mutations in the P0 
generation (see Figure 3.11C+D). Additionally, in embryos injected with gRNA5, which 
targets hnrnpa3, the PCR band at 232 bp was only partially digested from which it can be 
concluded that some cells of the P0 embryos carry mutations in the hnrnpa3 gene (see Figure 
3.11E).  
Altogether, I established genotyping assays to introduce and screen for mutation. Moreover, I 
generated hnrnpa1a, hnrnpa1b, and hnrnap3 mutations in injected P0 fish. Next, these 
mutation carrier fish will be screened for successful germline transmission. 
 
 
gRNA set PCR 
product 
[bp]  
RE RE (No. of 
cut sites) 
Band pattern in 
digested wt [bp] 
Band pattern in 
digested mutant 
[bp] 
gRNA1 346 PvuII 1 108+238 346 
gRNA2 305 Fnu4HI 1 126+179 305 
gRNA3 296 Fnu4HI 2 201+7+88 289+7 
gRNA4 P0 
gRNA4 F1 
396 
396 
AciI 
MnlI 
1 
10 
297+99 
32+3+3+3+12+3+ 
153+65+7+21+90  
396 
32+3+3+3+12+3+2
18+7+21+90 
gRNA5 232 Fnu4HI 1 98+136 232 
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Figure 3.11 - Screening assays for CRISPR/Cas9 P0 induced hnrnpa mutations. Uninjected and injected P0 2 
dpf embryos were tested. PCR and corresponding RE-digested samples were separated on agarose gels A: 
Injection with hnrnpa1a gRNA3 targeting exon 1. RE: Fnu4HI. B: Injection with hnrnpa1a gRNA4 targeting 
exon 8. RE: AciI. C: Injection with hnrnpa1b gRNA1 targeting exon 1. RE: PvuII. D: Injection with hnrnpa1b 
gRNA 2 targeting exon 9. RE: Fnu4HI. E: Injection with hnrnpa3 gRNA5 targeting exon 1. RE: Fnu4HI. The 
red asterisks (*) mark the band size in the RE-digested sampled that remained in gRNA injected samples only 
indicative of an undigested band due to an induced mutation by CRISPR/Cas9. 
3.3.3 Screening for hnrnpa1a, hnrnpa1b, and hnrnpa3 mutants 
 
Genetically edited P0 fish are mosaic, meaning that not every cell has the same mutation 
and/or that some cells have no mutation at all. In order to obtain a F2 zebrafish that carries a 
single mutation in every cell the following screen (see Figure 3.12) was performed: 
Having identified a mosaic P0 fish using the RFLP assay after injection of hnrnpa1a, 
hnrnpa1b or hnrnpa3 targeting gRNA and Cas9, this fish was outcrossed to a wildtype fish. 
The heterozygous F1 generation was analyzed for successful germline transmission of 
mutations and the region around the target site of the mutant allele was sequenced to 
determine the introduced mutation. For each of the targeted loci frameshift mutations were 
identified resulting in mutations leading to either a PTC, deletion of the translation initiation 
codon ATG, or deletion of splice target sites.  
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Figure 3.12 - Schematic illustration of breeding P0 mosaic mutation carrier to homozygousity. The Figure 
shows the process of generating hnrnpa1a, hnrnpa1b and hnrnpa3 homozygous mutation carriers from mosaic 
mutation carriers obtained by CRISPR/Cas9 genome editing in zebrafish. 
 
The ratio of frameshift mutations in contrast to in frame mutations was quite variable for each 
locus (see Table 3.3). Upon identification of mosaic founder fish, these were outcrossed with 
a wildtype fish and the offspring was analyzed using finclip material for genotyping. 
hnrnpa1a exon 1 targeted founder fish resulted in 23 % mutation carrying offspring of which 
67% had frameshift mutations. hnrnpa1a exon 8 targeted founder fish resulted in 14 % 
mutation carrying offspring of which only 40% had frameshift mutations. All offspring of 
hnrnpa1b exon 2 targeted founder fish had mutations (100 % germline efficiency), of which 
60% caused frameshifts. The majority of offspring (79%) obtained from hnrnpa1b exon 9 
targeted founder fish had mutations, which resulted in frameshift mutations in 67% of the 
fish. Only a small part (13%) of the offspring obtained from hnrnpa3 exon 2 targeted founder 
fish showed mutations of which 67% caused a frameshift. With the assumption that the 
identified mutations will result in nonfunctional protein, zebrafish siblings carrying the same 
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mutation were incrossed to obtain a homozygous F2 generation and outcrossed to wildtype 
fish to establish the line. For each gRNA target site one allele was chosen for further 
experiments (see Figure 3.13) and was bred to homozygosity. For these alleles genotyping 
assays were established, which are depicted in Figure 3.14. Primer flanking the mutation site 
are used for PCR amplification followed by an analytic RE digest. A wildtype allele becomes 
fully digested while a mutated allele stays undigested. The digestion pattern depicts 
homozygous wildtype (fully digested PCR product), heterozygous (50% digested PCR 
product), or homozygous KO (undigested PCR product).  
 
Gene 
(exon#) 
# tested for 
mutation 
# positive 
for mutation 
% positive 
for mutation 
% inframe 
alleles 
% 
frameshift 
alleles 
hnrnpa1a (1) 291 68 23 33 67 
hnrnpa1a (8) 257 37 14 60 40 
hnrnpa1b (2) 94 94 100 40 60 
hnrnpa1b (9) 48 38 79 33 67 
hnrnpa3 (2) 120 15 13 33 67 
Table 3.3 - Allele frequencies in F1 after targeting hnrnpa loci – For explanation see text. 
The genotypes were detected by the same readout used for detection of mutations in P0 
generation (see Table 3.3, Figure 3.14A+C+E+F). Two exceptions are mutants that carry 
mutations in exon 9 of hnrnpa1 or mutations in exon 8 of hnrnpa1b. For these fish new 
screening assays were developed as either the mutation cannot be detected by the initial RE 
assay or the mutation induced such large deletion that can be already detected by a band shift 
in the PCR product (see Figure 3.18B+D). The genotype of hnrnpa1a exon 9 targeted 
zebrafish can be detected by mutation spanning PCR amplification resulting in a 396 bp PCR 
product. Upon digest of the PCR product with the RE MnlI a band is obtained at 218 bp and 
and some small digest products in the wildtype allele. In the homozygous allele one enzyme 
binding site is mutated resulting in a band at 218 bp and some small digest products (see 
Figure 3.14B). The genotype of hnrnpa1b exon 8 targeted zebrafish can be detected by 
mutation spanning primer that amplify the wildtype and mutated allele resulting in a 305 bp 
PCR product in the wildtype allele and a 252 bp PCR product in the mutated allele carrying a 
53 bp deletion (see Figure 3.14D). The hnrnpa3 allele obtained from the Sanger Center can be 
genotyped by mutation specific primer pairs, which specifically either amplify the wildtype or 
the mutated allele. Only in heterozygous samples each PCR reaction results in a PCR product, 
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whereas in homozygous mutation carriers or wildtype, only the mutation or wildtype specific 
PCR reaction results in a PCR product (see Figure 3.14F).  
 
 
 
Figure 3.13 - Genomic sequences of selected alleles. (A-F): Top rows depict the wildtype nucleotide and aa 
sequence. The lower sequence depicts the respective mutant allele. A: hnrnpa1a wildtype exon 1 region and the 
mutated allele leading to ATG deletion B: hnrnpa1a wildtype exon 9 region and the mutated allele containing a 
10 bp insertion C: hnrnpa1b wildtype exon 2 region and the mutated allele contains a 5 bp deletion. D: 
hnrnpa1b wildtype exon 9 region the mutant allele has a 53 bp deletion spanning an exon-intron site and leads to 
translation of the previous intron and a PTC stop. E: hnrnpa3 wildtype exon 2 region the mutant allele contains 
a 7 bp deletion. F: hnrnpa3 wildtype exon 4 region the sanger mutant containing point mutation that leads to a 
PTC codon. Blue: exonic sequence.. black: intronic sequence. ∆: deletion. +: insertion. Exon-intron boundary 
underlined. *: Stop.  
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Figure 3.14 - Genotyping assays in F2 to discriminate between different genotypes. A: hnrnpa1a edited 
exon 1 locus. Mutation spanning primer amplify the wildtype and mutated allele. Wildtype alleles are fully 
digested by the RE resulting in a fully digested PCR product. The mutation results in loss of the RE cutting site 
whereby an undigested PCR product remains. Heterozygous mutation carriers are recognized by a partially 
digested PCR product. RE: Fnu4HI. B: hnrnpa1a edited exon 8 locus. RE: MnlI. C: hnrnpa1b edited exon 2 
locus. RE: PvuII. D: hnrnpa1b edited exon 9 locus. Mutation spanning primer allow to distinguish between the 
wildtype and mutated allele. The mutated allele carrying a 53 bp deletion can be detected by a band shift of 53 
bp downwards on an agarose gel. E: hnrnpa3 edited exon 2 locus. RE: Fnu4HI F: hnrnpa3 edited exon 4 locus. 
Mutation specific primer either recognize the mutant or wildtype allele. For each sample two PCR reactions 
were performed. Only in heterozygous samples each PCR reaction results in a PCR product, whereas in 
homozygous mutation carriers or wildtype only the mutation or wildtype specific PCR reaction results in a PCR 
product, respectively. The red asterisks (*) mark the band that remains in the edited allele only. 
In summary, gRNAs led to mutations in the germline, which are thereby transmitted to the 
next generation. Zebrafish carrying mutations that result in a frameshift or splice alterations 
leading to a PTC, or delete the translation initiation ATG codon, were identified using the 
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screening assay described in Table 3.2 and were bred to homozygousity. These mutations are 
likely to result in loss of protein function.  
3.3.4 hnrnpa1b and hnrnpa3 mutants are loss of function mutants 
 
The generated KO lines required confirmation that they are loss of function alleles and that no 
functional protein is produced by the selected alleles. The mutant mRNA containing a PTC is 
likely to be degraded by NMD [209]. If mutant mRNA is targeted to NMD was assayed by 
qRT-PCR and loss of protein by immunoblot. 
As no Hnrnpa1a specific antibody is available, mRNA levels of brains derived from 
hnrnpa1ains10-/- brains were analysed by qRT-PCR, which revealed that hnrnpa1a mRNA 
levels are reduced to 30% compared to wildtype siblings, which is a significant decrease (see 
Figure 3.15A). The remaining 30% of hnrnpa1a mRNA point to partial degradation of 
hnrnpa1a mRNA by NMD. It has to be further confirmed whether the remaining hnrnpa1a 
 
 
 
Figure 3.15 - The selected hnrnpa1a, hnrnpa1b, and hnrnpa3 alleles are loss of function alleles A: hnrnpa1a 
mRNA levels were measured in hnrnpa1ains10-/- mutants as no Hnrnpa1a specific antibody is available. 
Hnrnpa1a mRNA levels are significantly reduced in the brains of hnrnpa1b-/- mutants. (*p<0.02) n=4. Error bar 
indicates S.E.M. Normalized to rflp13a and elf1a2. Student’s t-test. B: The Hnrnpa1b specific band is absent in 
all brain samples derived from hnrnpa1b-/- mutants, whereas an Hnrnpa1b specific signal was detected in brain 
samples of hnrnpa1b+/+ siblings. C: The Hnrnpa3 specific band was absent in all brain samples derived from 
hnrnpa3-/- mutants, whereas an Hnrnpa3 specific signal was detected in brain samples of hnrnpa3+/+ siblings. 
mRNA levels are translated into a functional protein. Antibodies against Hnrnpa1b and 
Hnrnpa3 were used in Western blot analysis in order to confirm Hnrnpa1b absence in the 
hnrnpa1b∆5-/- and hnrnpa1b∆53-/- zebrafish and Hnrnpa3 absence in hnrnpa3∆7-/- and 
hnrnpa3Sa-/- zebrafish brains, respectively. On immunoblots against Hnrnpa1b a band is 
present at 42.6 kDa in wildtype brain samples, which is not detectable in brain samples from 
hnrnpa1b-/- mutants. The Hnrnpa3 specific signal is present in wildtype brain samples at 35.6 
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kDa but not in hnrnpa3-/- mutant brain samples. Given the absence of the Hnrnpa1b and 
Hnrnpa3 specific band in brain samples of hnrnpa1b-/- and hnrnpa3-/- mutants it can be 
concluded that the respective proteins are no longer produced or degraded (see Figure 
3.15B+C).  
In summary, Hnrnpa1a loss of function could only be assessed on mRNA level and revealed a 
70% decrease in hnrnpa1a mRNA levels compared to wildtype. All selected alleles for 
hnrnpa1b and hnrnpa3 are loss of function alleles whereby the respective protein is no longer 
produced or degraed.  
3.4 Basic characterization of single hnrnpa1a-/-, hnrnpa1b-/- and hnrnpa3-/- 
mutants 
 
The aim of this study was to establish stable KO lines for Hnrnpa1a, Hnrnpa1b and Hnrnpa3 
to study the function of these proteins in vivo. Having generated these lines I next addressed 
the consequences of protein loss of function in single and double mutants. For further analysis 
only one allele of each gene was taken: hnrnpa1ains10; hnrnpa1b∆53, and hnrnpa3Sa. 
3.4.1 hnrnpa-/- single mutants are viable and fertile 
 
Single hnrnpa1a-/-, hnrnpa1b-/-, and hnrnpa3-/- mutants were examined for viability from 
hatching until adulthood. For all in- and outbreedings natural occurring egg lay numbers were 
obtained with a majority of fertilized eggs. Among all the crosses, expected ratios of 
Mendelian inheritance were obtained (see Table 3.4). All embryos were raised to adulthood 
with an indistinguishable lifespan between mutants and wildtype siblings.  
 
Incross of hnrnpa1a +/-, (n=302 
Genotype hnrnpa1a +/+ hnrnpa1a +/- hnrnpa1a -/- 
Examined Ratio 24,42% ± 0.04 52,94% ± 0.04 22,64% ± 0.02 
Expected ratio 25% 50% 25% 
 
Incross of hnrnpa1b +/-, (n=150) 
Genotype hnrnpa1b +/+ hnrnpa1b +/- hnrnpa1b -/- 
Examined Ratio 21.88% ± 0.02 48.25%  ± 0.02 29.87% ± 0.03 
Expected ratio 25% 50% 25% 
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Incross of hnrnpa3 +/-, (n=156) 
Genotype hnrnpa3 +/+ hnrnpa3 +/- hnrnpa3 -/- 
Examined Ratio 23.96% ±0.01 48.89% ± 0.03 27.15% ± 0.02 
Expected ratio 25% 50% 25% 
Table 3.4 - Mendelian laws apply for incrosses of single hnrnpa-/- mutants - for each clutch 40 eggs 
analyzed. n=number of embryos analyzed (obtained from at least 3 different clutches). ± : standard deviation. 
 
To analyze the single mutants in further detail I examined them for obvious morphological 
changes. Thereby the body shape, body length, eye, brain and yolk were observed throughout 
the development from embryo stage up to adult hood. The analysis revealed no morphological 
differences among mutants and wildtype siblings. Representative images are depicted in 
Figure 3.16. In summary, hnrnpa1a-/-, hnrnpa1b-/-, and hnrnpa3-/- single mutants are hetero- 
and homozygous viable and fertile and have no obvious morphological phenotype.  
 
 
Figure 3.16 - hnrnpa-/- single mutants show no obvious morphological phenotype. Images of 5 dpf old 
wildtype, hnrnpa1a-/-, hnrnpa1b-/- and hnrnpa3-/- mutants. Lateral view. Anterior to the left. Images were taken 
with Axio Scope A1. Scalebar represents 500 µm. 
3.4.2 hnrnpa-/- single mutants have no morphological phenotype in ALS associated cells 
or tissues 
 
One central characteristic for ALS is the degeneration of upper and lower motoneurons and 
subsequent muscle wasting [41]. As a first step hnrnpa1a-/-, hnrnpa1b-/-, and hnrnpa3-/- single 
mutants were therefore analyzed for changes in ALS related tissues, such as motoneurons and 
muscles. Maternal mRNA, provided to the eggs by the mother allows embryos to synthesize 
proteins before the onset of their own zygotic transcription. Therefore Hnrnpa1a, Hnrnpa1b, 
or Hnrnpa3 protein translation from maternal mRNA at the earliest stages of development 
could potentially preclude identification of early phenotypes [210]. To exclude maternal 
contribution embryos used for the analysis of ALS related phenotypes originate from 
incrosses of homozygous mutants.  
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3.4.2.1 hnrnpa-/- single mutants mutants have no motoneuron phenotype 
 
The SpMN axon of the Cap motoneuron axon, which project ventrally from the spinal cord to 
innervate muscles, is frequently used as a neuron vulnerability readout in zebrafish. In the 
past a variety of zebrafish KO models were analyzed for SpMN axon morphology by 
quantifying the SpMN axonal outgrowth length and branching [211] [212] [12] [190].  
 
 
 
Figure 3.17 - hnrnpa-/- single mutants show normal SpMN axon outgrowth. A: Schematic illustration of a 
30 hpf embryo with the analyzed region in detail (red box). SpMNs and their axons are illustrated in white and 
the red line marks the measured axon length for SpMN axon 1. Grey: spinal cord. B: Examples of whole-mount 
IF stainings of 30 hpf wildtype, hnrnpa1a-/-, hnrnpa1b-/-, and hnrnpa3-/- mutants stained with znp-1 antibody. 
The four SpMN axons anterior to the end of the yolk extension are shown. Images are taken with the spinning 
disk cell observer. Maximum intensity projection. Lateral view. Anterior to the left. Scale bar: 25 µm C: A 
comparison of the SpMN axon lengths of wildtype (orange), hnrnpa1a-/- (turquoise) (p(1-4)>0.34, n=7), 
hnrnpa1b-/- (blue) (p(1-4)>0.23, n=7), and hnrnpa3-/- (green) (p(1-4)>0.99, n=7) embryos at 30 hpf revealed no 
significant difference in the SpMN axon length when compared to wildtype. S.E.M. Two-way ANOVA. 
Bonferroni post-test.  
SpMN were visualized by immunohistochemical staining of 30 hpf old PTU treated embryos 
using a znp-1 antibody. Quantification of the SpMN axon length of the Cap, which is defined 
as the length from the ventral side of the spinal cord to the end of the growth cone, revealed 
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no significant length difference in hnrnpa1a-/-, hnrnpa1b-/- and hnrnpa3-/- mutants compared 
to age matched wildtypes (see Figure 3.17), indicating normal SpMN axon outgrowth in 
hnrnpa1a-/-, hnrnpa1b-/- and hnrnpa3-/- mutants.  
3.4.2.2 hnrnpa-/- single mutants mutants have no muscle defects 
 
 
Figure 3.18 - hnrnpa-/- single mutants show no morphological muscle defects A: Schematic illustration of the 
assayed region (red box) B: Antibody staining of 30 hpf wildtype, hnrnpa1a-/-, hnrnpa1b-/-, and hnrnpa3-/- 
mutants with the Actinin specific antibody (green). C: Antibody staining of 30 hpf wildtype, hnrnpa1a-/-, 
hnrnpa1b-/-, and hnrnpa3-/- embryos with the myosin specific antibody ZE-BO-1F4 (green). B and C: Pictures 
taken by confocal laser scanning microscopy using the 488 nm laser. Lateral view. Anterior to the left. Scale bar 
represents 25 µm. 
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To visualize the muscle fibers I performed immunohistochemistry on 30 hpf old PTU treated 
hnrnpa1a-/-; hnrnpa1b-/- and hnrnpa3-/- embryos using α-actinin and ZE-BO 1F4 antibodies. 
α-actinin is a marker for Z-discs, while ZE-BO 1F4 binds to smooth muscles, striated skeletal 
and heart muscles (fast-twitch muscle fibers) [213] [195]. hnrnpa1a-/-, hnrnpa1b-/- and 
hnrnpa3-/- mutants showed no difference in muscle patterning using α-actinin (see Figure 
3.18B) and ZE-BO 1F4 (Figure 3.18C) antibodies compared to age-matched wildtype 
embryos. These findings implicate normally developed Z-discs and fast-twitching muscle 
fibers and that the muscle is morphologically wildtype at 30 hpf in hnrnpa1a-/-, hnrnpa1b-/- 
and hnrnpa3-/- mutants.  
3.4.3 Tdp-43 variant protein levels are not changed in hnrnpa-/- single mutants 
 
The lack of any obvious phenotype in single hnrnpa1-/-, hnrnpa1b-/-, and hnrnpa3-/- mutants 
prompted us to investigate potential crossregulation of HNRNP family members. Since TDP-
43 is the key aggregating protein in ALS we asked if TDP-43 levels change upon depletion of 
 
 
 
Figure 3.19 – Tdp-43 variant levels are not changed in brains of hnrnpa-/- single mutants A: Tardbp levels 
were not changed in hnrnpa1a-/- (p>0.13, n=4), hnrnpa1b-/- (p>0.52, n=8), and hnrnpa3-/- (p>0.51, n=4) 
mutants. B: Tardbpl levels were not changed in hnrnpa1a-/- (p>0.99, n=8), hnrnpa1b-/- (p>0.57, n=4), and 
hnrnpa3-/- (p>0.76, n=8) mutants. C: Tardbpl_tv1 levels were not changed in hnrnpa1a-/- (p>0.90, n=8), 
hnrnpa1b-/- (p>0.09; n=8), and hnrnpa3-/- (p>0.93; n=4) mutants. Normalized to control. Student’s t-test. Error 
bars indicate S.E.M. Calnexin served as a loading control. 
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HNRNPA proteins. In order to address this question Tdp-43 protein levels were examined in 
brain samples derived from hnrnpa1a-/-, hnrnpa1b-/- and hnrnpa3-/- mutant zebrafish. In 
zebrafish two isoforms of TDP-43, named tardbp and tardbpl, are present. Furthermore, our 
group and others described another tdp-43 transcript variant, named tardbpl_tv1, which is 
generated by alternative splicing of tardbpl upon tardbp depletion [12]. Our laboratory 
developed antibodies that specifically detect Tardbp, Tardbpl, and Tardbpl_tv1. Upon usage 
of these antibodies by immunoblotting no differences in Tardbp, Tardbpl or Tardbpl_tv1 
protein levels were observed in hnrnpa1a-/-, hnrnpa1b-/- or hnrnpa3-/- brain samples (see 
Figure 3.19).  
It can be concluded that loss of Hnrnpa1a, Hnrnpa1b, or Hnrnpa3 protein function does not 
affect the protein levels of Tdp-43 in zebrafish.  
3.4.4 Differentially expressed RNAs in single mutants 
 
In order to identify differentially expressed genes in hnrnpa1b-/- and hnrnpa3-/- mutants an 
unbiased approach was chosen by sending hnrnpa1b-/- and hnrnpa3-/- brains (six months) for 
RNA sequencing (total RNA including small and noncoding RNAs, paired end, 35 Million 
reads/sample).  
3.4.4.1 Differentially expressed genes in hnrnpa1b-/- zebrafish brain 
 
NGS revealed 45 genes with p-value smaller than 0.01 and a positive or negative fold change 
greater than one between mutants and wildtype siblings. Of these genes 26 were upregulated 
and 19 were downregulated. hnrnpa1b itself is downregulated by 1.23 (p-adj.=2.91E-41), 
supporting the successful KO of hnrnpa1b previously shown by Western blot. Interestingly, 
nine lincRNAs were identified with these settings whereby all of them were upregulated.  
 
Gene Ensembl ID 
Human 
Orthologue 
log2fold 
change 
p-adjusted 
CU929061.1 ENSDARG00000107933 n.a. 5.10 8.07E-4 
si:dkey-240n22.3 ENSDARG00000095013 n.a. 3.70 1.28E-6 
si:ch211-196h24.2 ENSDARG00000100341 n.a. 3.53 1.08E-3 
si:dkey-165o8.1 ENSDARG00000098369 n.a. 2.45 4.44E-3 
si:ch211-227e10.1 ENSDARG00000104968 n.a. 2.17 1.87E-5 
si:ch211-205a14.1 ENSDARG00000102713 n.a. 2.04 3.791E-7 
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cyp2aa6 ENSDARG00000103590 n.a. 1.68 4.00E-10 
si:ch211-106j21.2 ENSDARG00000102575 n.a. 1.52 4.74E-3 
si:ch211-232d10.2 ENSDARG00000100348 n.a. 1.49 1.70E-6 
BX322575.1 ENSDARG00000095595 n.a. 1.42 6.13E-3 
 
si:dkey-207l24.2 ENSDARG00000101688 n.a. -7.70 3.48E-6 
BX649431.1 ENSDARG00000098522 n.a. -7.19 5.68E-5 
BX004873.8 ENSDARG00000108677 n.a. -2.91 5,38E-7 
N.A. ENSDARG00000102102 n.a. -2.78 1.46E-3 
rnf17 ENSDARG00000056387 RNF17 -2.50 4.85E-6 
si:dkey-14o6.1 ENSDARG00000098383 n.a. -2.44 8.90E-4 
BX004873.5 ENSDARG00000101310 n.a. -2.40 3.74E-3 
si:dkey-16p6.1 ENSDARG00000088245 n.a. -2.37 5.33E-3 
si:dkey-16b10.1 ENSDARG00000096139 n.a. -2.26 2.61E-3 
znf1105 ENSDARG00000104887 n.a. -2.09 1.78E-05 
Table 3.5 – Top 10 differentially expressed genes and the respective human orthologues in hnrnpa1b-/- brains. 
For zebrafish genes lacking a human orthologue the abbreviation not available (n.a.) is used.   
3.4.4.2 Differentially expressed genes in hnrnpa3-/- zebrafish brain 
 
Upon Hnrnpa3 KO NGS revealed 343 differentially expressed genes with a p-value smaller 
than 0.01 and a upwards or downwards fold change greater than one between mutants and 
wildtype siblings. Of these genes 263 are upregulated and 80 downregulated. hnrnpa3 itself is 
1.86 fold downregulated (p-adj.=3,50E-29) supporting the successful KO of hnrnpa1b 
previously shown by Western blot. Interestingly, 16 linc RNAs are changed.  
 
Gene Ensembl ID 
Human 
Orthologue 
log2fold 
change 
p-adjusted 
si:dkey-200c24.1 ENSDARG00000104305 n.a. 9.02 2.15E-10 
CR848784.1 ENSDARG00000096895 n.a. 7.96 1.45E-7 
myhc4 ENSDARG00000035438 MYH1 6.63 2.64E-3 
CABZ01002522.1 ENSDARG00000107775 n.a. 5.93 5.45E-3 
zgc:175177 ENSDARG00000102296 n.a. 3.27 2.63E-7 
slc16a5b ENSDARG00000102668 SLC16A5 3.21 7.31E-9 
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hsp90aa1.1 ENSDARG00000010478 HSP90 3.03 1.56E-3 
FO834829.1 ENSDARG00000099605 n.a. 2.98 2.22E-5 
hbaa2 ENSDARG00000069735 n.a. 2.83 6.33E-5 
slc6a5 ENSDARG00000067964 SLC6A 2.74 2.18E-11 
 
N.A. ENSDARG00000102915 HIN2 -7.06 4.72E-6 
BX000534.2 ENSDARG00000102489 n.a. -3.44 2.28E-7 
cryabb ENSDARG00000101380 CRYABB -3.41 5.89E-13 
CU856343.1 ENSDARG00000099073 n.a. -2.99 5.60E-3 
sesn2 ENSDARG00000070012 SESN2 -2.76 1.09E-3 
si:rp71-80o10.4 ENSDARG00000094316 n.a. -2.69 1.25E-4 
BX649622.2 ENSDARG00000105085 n.a. -2.54 6.41E-05 
slc1a4 ENSDARG00000000551 SLC1A4 -2.16 3.60E-3 
mars ENSDARG00000034396 MARS -2.06 8.75E-3 
asns ENSDARG00000016375 ASNS -2.03 3.75E-3 
Table 3.6 - Top 10 differentially expressed genes and the respective human orthologues in hnrnpa3-/- brains 
3.4.5 Hnrnpa1a and Hnrnpa1b compensate for each other loss of function, which is not 
compensated by Hnrnpa3 
 
Since hnrnpa1a and hnrnpa1b are duplicated genes and both orthologues of human 
HNRNPA1 (see Figure 3.2), the lack of a phenotype in single hnrnpa1a-/- and hnrnpa1b-/- 
mutant zebrafish could be due to compensational mechanisms. Hnrnpa1b could take over the 
function of Hnrnpa1a upon Hnrnpa1a KO or vice versa. Alternatively, there could be 
functional compensation within the larger Hnrnpa family and Hnrnpa3 could take over the 
function of the Hnrnpa1 proteins. To investigate potential crossregulatory mechanisms, I 
performed immunoblotting of Hnrnpa1a and Hnrnpa3 on brain samples of the hnrnpa1a-/-, 
hnrnpa1b-/- and hnrnpa3-/- mutants. Due to the lack of a Hnrnpa1a specific antibody, 
compensation of Hnrnpa1a protein in hnrnpa1b-/- and hnrnpa3-/- mutants could not be 
addressed. Instead, hnrnpa1a mRNA levels were measured in hnrnpa1b-/- and hnrnpa3-/- 
zebrafish brain samples by qRT-PCR. The analysis revealed significant upregulation of 
hnrnpa1a mRNA upon KO of Hnrnpa1b or Hnrnpa3 (see Figure 3.20A). Hnrnpa1b protein 
levels showed no change in Hnrnpa1a or Hnrnpa3 deficient zebrafish brain samples by 
immunoblotting (see Figure 3.20B). Interestingly, Hnrnpa1b levels were highly increased in 
brains derived from hnrnpa1a-/- mutants compared to age-matched wildtype (see Figure 
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3.20B). This upregulation was observed in two independent KO lines, hnrnpa1a∆16 and 
hnrnpa1ains10 pointing to the specificity of the upregulatory effect (see Figure 3.20B). 
Immunoblotting for Hnrnpa3 revealed no change in protein levels in brain samples of 
hnrnpa1a-/- or hnrnpa1b-/- mutants compared to age matched wildtype (see Figure 3.20C). 
 
 
 
Figure 3.20 – Hnrnpa1a and Hnrnpa1b compensate for each others loss of function, which is not 
compensated by Hnrnpa3. A: mRNA levels of hnrnpa1a were significantly upregulated in brains of hnrnpa1b-/- 
(***p<0.001; n=4) and hnrnpa3-/- (***p<0.001; n=4) mutants. . Normalized to rflp13a and elf1a2. Error bar 
indicates SEM. Student’s t-test. Results by qRT-PCR were reproduced twice using the same cDNA. B: 
Hnrnpa1b levels were significantly upregulated in brains of hnrnpa1a mutants (hnrnpa1a∆16-/-: ***p<0.0001, 
n=8; hnrnpa1ains10-/-: ***p<0.0001, n=8) and not changed in brains of hnrnpa3-/- mutants (p>0.69, n=4) 
compared to their wildtype siblings. C: Hnrnpa3 levels were not changed in brains of hnrnpa1a-/- mutants 
(p>1.1, n=8) and hnrnpa1b-/- mutants (p>0.64, n=8) compared to their wildtype siblings. Student’s t-test. Error 
bars indicate S.E.M. Calnexin served as a loading control. 
It can be concluded that Hnrnpa3 protein levels are not changed upon hnrnpa1a or hnrnpa1b 
KO. Upon KO of Hnrnpa1a a high increase in Hnrnpa1b protein was observed, which was 
confirmed in two independent hnrnpa1b KO lines. Vice versa, hnrnpa1a mRNA levels were 
upregulated upon hnrnpa1b KO. Moreover, slight hnrnpa1a mRNA upregulation was 
observed upon Hnrnpa3 KO. 
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3.5 Analysis of hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
Hnrnpa1a, Hnrnpa1b, and Hnrnpa3 have multiple functions of which some are overlapping 
but others are specific to one particular protein. The previous analysis revealed 
crossregulation among Hnrnpas shown by upregulation of Hnrnpa1b upon loss of Hnrnpa1a 
protein and vice versa. While Hnrnpa3 protein levels were not changed upon Hnrnpa1a or 
Hnrnpa1b loss of function, Hnrnpa1b was slightly upregulated upon Hnrnpa3 loss of function. 
In order to address potential Hnrnpa redundancy and functional compensation in single KO, I 
generated double KO fish. 
3.5.1 hnrnpa1a-/-; hnrnpa3-/- and hnrnpa1b-/-; hnrnpa3-/- mutants are viable 
 
Double homozygous KO fish obtained from a homozygous hnrnpa1a-/-; hnrnpa3-/- or 
hnrnpa1b-/-; hnrnpa3-/- incross were viable and did not show any obvious morphological 
phenotype (see Figure 3.21). Also, these fish reached adulthood and showed Mendelian 
inheritance pattern (data not shown).  
It can be concluded that combined loss of Hnrnpa1a or Hnrnpa1b and Hnrnpa3 protein 
function does not result in obvious morphological abnormalities in zebrafish. This result 
points to either non-essential functions of these proteins or further redundancy in the zebrafish 
genome. 
 
 
Figure 3.21 - hnrnpa1a-/-; hnrnpa3-/- and hnrnpa1b-/-; hnrnpa3-/- mutants show no obvious morphological 
phenotype. Representative images of 5 dpf old wildtype, hnrnpa1a-/-; hnrnpa3-/-, and hnrnpa1b-/-; hnrnpa3-/- 
embryos. Lateral view. Anterior to the left. Images were taken Axio Scope A1. Scalebar represents 500 µm.  
3.5.2 hnrnpa1a-/-; hnrnpa1b-/- mutants are not viable 
 
Interestingly, no adult hnrnpa1a-/-; hnrnpa1b-/- fish were obtained from an incross of 
hnrnpa1a+/-; hnrnpa1b+/- mutant fish. The Mendelian ratios obtained from genotyping adult 
offspring from this incross show that all possible genotypes are present in the expected ratio 
apart from hnrnpa1a-/-; hnrnpa1b-/- fish, of which no fish was obtained (see Table 3.7). To 
address the question whether hnrnpa1a-/-; hnrnpa1b-/- fish die while breeding them to 
adulthood, or as embryos until they are transferred to the breeding system at 5 dpf, or whether 
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Incross of hnrnpa1a +/-; hnrnpa1b +/-, (n=4) 
Genotype a+/+ 
; b+/+ 
a+/-
;b+/+ 
a+/+; 
;b+/- 
a+/-
;b+/- 
a-/- 
;b+/+ 
a+/+ 
;b-/- 
a-/- 
;b+/- 
a+/- 
;b-/- 
a-/- 
;b-/- 
Examined 
Ratio 
(%, s.d.) 
3.92  
± 0.01 
13.30 
± 0.03 
13.71
± 0.03 
33.38 
± 0.03 
7.70  
±0.01 
4.94  
± 0.02 
10.33 
± 0.06 
12.73 
± 0.05 
0  
 
Expected 
ratio (%) 
6.25 12.5 12.5 25 6.25 6.25 12.5 12.5 6.25 
Table 3.7 - hnrnpa1a-/-; hnrnpa1b-/- mutants do not reach adulthood. Clutch number of minimum 40 eggs. 
n=number of clutches analyzed. 
they are not even born, offspring obtained from a hnrnpa1a+/-; hnrnpa1b+/- incross were 
genotyped at 2 dpf. At this point all genotypes were present in the expected ratios (data not 
shown) showing that hnrnpa1a-/-; hnrnpa1b-/- mutants are born but die before reaching 
adulthood (see Table 3.7). Careful analysis of newborn embryos obtained from a hnrnpa1a+/-; 
hnrnpa1b+/- incross from 0 hpf until 5 dpf showed that some embryos have reduced blood 
flow, a thinned yolk extension, cell death, and develop severe heart edema at 4 dpf until they 
die at around 5 dpf (see Figure 3.22). Those embryos were present at the expected ratio of 
around 6.25% pointing towards loss of both Hnrnpa1a and Hnrnpa1b causing the 
morphological abnormalities. This was confirmed by genotyping the phenotypic embryos 
from the clutch. 
 
 
 
Figure 3.22 - hnrnpa1a-/-; hnrnpa1b-/- mutants are embryonically lethal and show blood circulation defects. 
After 48 hpf hnrnpa1a-/-; hnrnpa1b-/- mutants show reduced blood flow and a thinned yolk extension (left panel). 
After 72 hpf hnrnpa1a-/-; hnrnpa1b-/- mutants develop severe heart edema (right panel). Scalebar represents 
200 µm. 
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3.5.2.1 hnrnpa1a-/-; hnrnpa1b-/- mutants are full loss of protein function mutants 
 
While no antibody is available that specifically detects Hnrnpa1a, full protein loss of function 
in hnrnpa1a-/-; hrnnpa1b-/- mutants was assessed by immunoblot with an antibody that detects 
 
 
Figure 3.23 - hnrnpa1a-/-; hnrnpa1b-/- mutants are loss of protein mutants. The antibody HA1-CT (VM) 
AN351 detects Hnrnpa1a and Hnrnpa1b since a band at the expected size of Hnrnpa1a and Hnrnpa1b appears in 
wildtype, hnrnpa1a-/- and hnrnpa1b-/- zebrafish brains. Slight upregulation of Hnrnpa1b in hnrnpa1a-/- mutants is 
also detected as previously observed. No band appears at the expected size in hnrnpa1a-/-, hnrnpa1b-/- embryos. 
Tubulin serves as a loading control. 
Hnrnpa1 and Hnrnpa1b (kind gift from Julia Nikolic, Douglas black lab). Immunoblotting 
showed a band at the expected size on brain samples obtained from Hnrnpa1a and Hnrnpa1b 
single KO showing that the antibody detects both proteins. Moreover, the antibody could 
detect Hnrnpa1a and Hnrnpa1b in 30 hpf wildtype embryos and can hence be used already in 
early developmental stages. No band was detected in hnrnpa1a-/-; hrnnpa1b-/- whole embryo 
samples demonstrating loss of Hnrnpa1a and Hnrnpa1b protein in the double mutants (see 
Figure 3.23). Concluding, it was shown that hnrnpa1a-/-; hrnnpa1b-/- mutants do not express 
Hnrnpa1a or Hnrnpa1b protein and are thereby full double protein loss of function mutants. In 
combination with the phenotypic analysis of these mutants, this finding further shows that 
loss of these two proteins leads to the observed phenotypes.  
3.5.2.2 Further characterization of hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
hnrnpa1a-/-; hnrnpa1b-/- mutants are not viable and die around 5 dpf with a severe heart 
edema. The cellular abnormalities causing premature death are though unknown. For further 
analysis I focused on the difference of morphologically affected hnrnpa1a-/-; hnrnpa1b-/- 
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mutants and morphologically wildtype looking siblings, obtained from an hnrnpa1a+/-; 
hnrnpa1b-/- incross. hnrnpa1a-/-; hnrnpa1b-/- mutant embryos become first distinguishable 
from their wildtype looking siblings at 30 hpf. At this point wildtype looking embryos start to 
have blood flow, whereas hnrnpa1a-/-; hnrnpa1b-/- mutants do not have developed blood flow 
yet (data not shown). Furthermore, hnrnpa1a-/-; hnrnpa1b-/- mutants have a thinned yolk 
extension (see Figure 3.27A), whereas wildtype looking embryos have a healthy looking yolk 
extension with a roundish shape. Lastly, apoptotic tissue can be observed in the entire body in 
hnrnpa1a-/-; hnrnpa1b-/- mutants (data not shown). The phenotype is progressive and 
accompanied by secondary effects due to advanced cell death (data not shown). In order to 
minimize secondary morphological and cellular phenotypes, the timepoint at 30 hpf when 
hnrnpa1a-/-; hnrnpa1b-/- mutants can be firstly morphologically distinguished from their 
siblings, was chosen for further analysis. Three criteria were developed to reproducibly 
identify hnrnpa1a-/-; hnrnpa1b-/- mutants and to minimize missorting. The criteria are the 
following: absence of blood flow, thinned yolk extension, and indication of cell death.  
3.5.2.2.1 hnrnpa1a-/-; hnrnpa1b-/- mutants are developmentally delayed 
 
Several points of evidence suggest involvement of Hnrnpa1 in development [214] [162]. The 
developmental stage of the embryos was assessed using the head-trunk angle that was firstly 
described by Kimmel et al. [198]. The head trunk angle is assessed by drawing a line through 
the middle of the ear and the eye, and a second line from the middle of the ear to the point 
where the yolk extension grows out from the yolk (see Figure 3.24A). The head-trunk angle 
increases throughout development between 20 hpf and 70 hpf as a consequence of 
morphogenesis of the embryo. Upon identification of the head-trunk angle a specific 
developmental stage can be determined given that the embryos were kept at 28.5° [198]. At 
30 hpf the head-trunk angle accounts 90° under normal conditions and was averaged at 86° in 
age matched wildtype, and 81° in hnrnpa1a-/-; hnrnpa1b-/- mutants. At 48 hpf the head-trunk 
angle accounts 138° under normal conditions and was averaged at 139° in wildtype controls 
and 121° in hnrnpa1a-/-; hnrnpa1b-/- mutants (see Figure 3.24B). At both time points the angle 
was significantly smaller hnrnpa1a-/-; hnrnpa1b-/- mutants than in age matched controls 
pointing to developmental delay of hnrnpa1a-/-; hnrnpa1b-/- mutants (see Figure 3.24D). 
Developmental delay in hnrnpa1a-/-; hnrnpa1b-/- mutants is further evidenced by a delay in 
melanin pigmentation (see Figure 3.24B).  
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Figure 3.24 - hnrnpa1a-/-; hnrnpa1b-/- mutants are developmentally delayed. A: Schematic illustration of the 
head-trunk angle and its dependency on developmental stage. B: At 30 hpf the head angle of wildtype embryos 
was measured at 86° and for hnrnpa1a-/-; hnrnpa1b-/- mutants at 81°. The reference angle at 30 hpf is 90°. C: At 
48 hpf the head angle of wildtype embryos was measured at 139° and for hnrnpa1a-/-; hnrnpa1b-/- mutants at 
121°. The reference angle at 48 hpf is 138°. Lateral view. Anterior to the left. Images taken by Axio Scope A1 
microscope. D: The head trunk angle is significantly smaller in hnrnpa1a-/-; hnrnpa1b-/- mutants at 30 hpf 
(p<0.02; n=6) and 48 hpf (p<0.02; n=6) compared to age matched wildtype. Student’s t-test. Error bar indicates 
S.E.M. 
3.5.2.2.2. hnrnpa1a-/-; hnrnpa1b-/- mutants have shortened SpMN axon length  
 
SpMN of hnrnpa1a-/-; hnrnpa1b-/- mutants were visualized as previously described for single 
KOs (see section 3.4.2.1). The SpMN axonal length was measured and quantification 
revealed that hnrnpa1a-/-; hnrnpa1b-/- mutants have significantly shorter SpMN axons (see 
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Figure 3.25). However, no abnormal migration pattern or aberrant branching was observed in 
hnrnpa1a-/-; hnrnpa1b-/- mutants.  
 
 
 
Figure 3.25 - hnrnpa1a-/-; hnrnpa1b-/- mutants show impaired SpMN axon outgrowth. Examples of whole-
mount IF stainings of 30 hpf wildtype and hnrnpa1a-/-; hnrnpa1b-/- embryos stained with znp-1 antibody. The 
four SpMN axons anterior to the end of the yolk extension are shown. Images are taken with the spinning disk 
cell observer. Maximum intensity projection. Lateral view. Anterior to the left. Scale bar: 25 µm. A comparison 
of the SpMN axon lengths of wildtype (orange) and hnrnpa1a-/-; hnrnpa1b-/- mutants (red) at 30 hpf revealed 
reduced SpMN axon outgrowth in hnrnpa1a-/-; hnrnpa1b-/- mutants (**p(1)<0.001; ***p(2-4)<0.0001; n=16;. 
Error bar indicates S.E.M. Two-way ANOVA. Bonferroni post-test. 
3.5.2.2.3 hnrnpa1a-/-; hnrnpa1b-/- mutants show muscle defects 
 
Muscle integrity of hnrnpa1a-/-; hnrnpa1b-/- embryos was analyzed since muscle degeneration 
is a pathological hallmark of ALS [40]. Muscle fibers of hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
 
 
Figure 3.26 - hnrnpa1a-/-; hnrnpa1b-/- mutants show morphological muscle defects A: Antibody staining of 
30 hpf wildtype and hnrnpa1a-/-; hnrnpa1b-/- mutants with the α-actinin specific antibody (green). B: Antibody 
staining of 30 hpf wildtype and hnrnpa1a-/-; hnrnpa1b-/- mutants with the myosin specific antibody ZE-BO-1F4 
(green). A and B: White arrow indicates areas that show loss of muscle integrity. Pictures taken by confocal 
laser-scanning microscopy using the 488 nm laser. Lateral view. Anterior to the left. Scale bar represents 25 µm. 
Results 
 91  
were visualized as described in section 3.4.2.2. Loss of muscle integrity can be observed at 
30 hpf at variable sites of the trunk. Immunohistochemical analysis with the α-actinin 
antibody and the myosin specific antibody ZE-BO-1F4 shows defects in muscle integrity (see 
Figure 3.26). From the actin staining it becomes evident that the thin filaments in fast muscle 
fibers are disorganized. Likewise the thick muscle filaments in fast muscle fibers stained by 
the myosin specific antibody are disarrayed.  
3.5.2.2.4 hnrnpa1a-/-; hnrnpa1b-/- mutants have yolk extension and lipid uptake defects  
 
A prominent feature of the hnrnpa1a-/-; hnrnpa1b-/- mutants is the abnormally thinning yolk 
extension during development This phenotype becomes first detectable at 24 hpf as the yolk 
 
 
 
Figure 3.27 - hnrnpa1a-/-; hnrnpa1b-/- mutants have a thinned yolk extension. A: Images of wildtype (upper 
panel) and hnrnpa1a-/-; hnrnpa1b-/-  (lower panel) mutants at 24 hpf, 30 hpf, and 48 hpf. At 24 hpf hnrnpa1a-/-; 
hnrnpa1b-/- mutants can be hardly distinguished from their wildtype siblings apart from a small bulge in the yolk 
extension. After 30 hpf the yolk extension of hnrnpa1a-/-; hnrnpa1b-/- embryos starts to thin, which becomes 
more severe over time resulting in an severely reduced yolk extension after 48 hpf up to 72 hpf. Lateral view. 
Anterior to the left. Images were taken with Axio Scope A1. Scalebar represents 200 µm. B: Schematic 
illustration of the measured area of the yolk extension (indicated in red) at 30 hpf. C: Quantification of the two-
dimensional yolk extension area at 30 hpf shows significant reduction in yolk extension area in hnrnpa1a-/-; 
hnrnpa1b-/- mutants compared to wildtype. Student’s t-test (n=13; ***p<0.0001). Error bars indicate S.E.M. 
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extension shows a small bulge at the site where it connects to the yolk. Over time (30 hpf to 
48 hpf) the yolk extension becomes thinner until it is almost completely absent at 72 hpf (see 
Figure 3.27A). Quantification of two-dimensional area of the yolk extension (see Figure 
3.27B) revealed a significant reduction in size in 30 hpf hnrnpa1a-/-; hnrnpa1b-/- mutants (see 
Figure 3.27C). In order to assess a potential lipid phenotype in further detail ORO staining, 
which labels neutral lipids, was performed. Upon staining neutral fat distribution can be 
detected. ORO stain was detectable in the wildtype embryos in the yolk, the yolk extension, 
and the head. This lipid staining pattern correlates with previously reported ORO staining 
[215]. In contrast, in the hnrnpa1a-/-; hnrnpa1b-/- mutants strikingly lower levels of lipid were 
detected in the yolk extension. Additionally, more neutral lipid staining appeared to be 
present in the embryo`s body (see Figure 3.28).  
It can be concluded that loss of Hnrnpa1 leads to thinning of the yolk extension, which 
initiates at 24 hpf and becomes more severe during development. Also, neutral lipids are 
detected more prominently in the body compared to age matched wildtype embryos. 
 
 
 
 
 
 
Figure 3.28 - hnrnpa1a-/-; hnrnpa1b-/- mutants show altered neutral lipid distribution. ORO stained the head 
structures, the yolk, yolk extension and around the spinal cord. Reduced amounts of neutral lipids in the yolk 
extension are present in hnrnpa1a-/-; hnrnpa1b-/- mutants at 30 hpf. Additionally, hnrnpa1a-/-; hnrnpa1b-/- 
mutants show increased amounts of neutral lipid in the trunk (black arrow). Lateral view. Anterior to the left. 
Images were taken with Axio Scope A1 microscope. Scalebar represents 200 µm. 
3.5.2.2.5 hnrnpa1a-/-; hnrnpa1b-/- mutants show no alteration in pkma splicing 
 
The yolk sac extension thinning and the increased uptake of neutral lipids from the yolk 
extension to the zebrafish trunk point to misregulated metabolic pathways, such as fatty acid 
(FA) and amino acid metabolism. As a potential molecular candidate responsible for this 
phenotype we tested Pyruvate kinase muscle 2 (PKM2), which is a limiting glycolytic 
enzyme that catalyzes the final step in glycolysis. This protein is not only involved in tumor 
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metabolism and growth, which could explain the potential metabolic phenotype in hnrnpa1a-/-
; hnrnpa1b-/- mutants, but it was also previously shown that HNRNPA1 and HNRNPA2/B1 
bind and control PKM1 alternative splicing giving rise to PKM1 and PKM2 [216] [217].  
In human PKM1 is mainly expressed in adult tissues, while PKM2 is expressed in embryonic 
and adult tissues and is also enriched in many cancers . PKM1 is predominantly active and 
expressed in terminally differentiated tissues, which require a large supply of ATP. In 
contrast, PKM2 is expressed in proliferating cells, which have anabolic function. In zebrafish 
two isoforms exist, pkma202 and pkma201, which were identified to have high conservation 
in gene structure with human PKM1 and PKM2 isoforms, respectively [219]. The zebrafish 
pkma202 and pkma201 isoforms share the mutually exclusive exons 10 and 11 with the 
human PKM1 and PKM2, which have mutually exclusive exons 9 and 10 (see Figure 3.29A).  
Semiquantitative PCR was performed on hnrnpa1a-/-; hnrnpa1b-/- mutants and wildtype 
siblings to amplify pkma exon 202 and exon 203. No significant difference in expression of 
the two transcripts was detected upon Hnrnpa1 KO (see Figure 3.29B+C).  
 
 
 
Figure 3.29 - hnrnpa1a-/-; hnrnpa1b-/- mutants show no alteration in pkma splicing. A: Schematic illustration 
of alternative splicing pattern of pkma exon 202 (Primer pair: LJ-D03 + LJ-D04) and exon 203 (Primer pair: LJ-
D01 + LJ-D02) usage. B: Semiquantitative PCR products produced by exon 202 and exon 203 specific primer 
on cDNA of 30 hpf hnrnpa1a-/-; hnrnpa1b-/- mutants and wildtype siblings. C: pkma exon 202 inclusion was not 
changed in hnrnpa1a-/-; hnrnpa1b-/- mutants compared to their wildtype siblings (p>0.78, n=4). Student’s t-test. 
Error bars indicate S.E.M. Pools of 20 embryos of independent clutches at 30 hpf were used. 
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One can conclude that the mechanism whereby HNRNPA1 controls the splicing of PKM1 is 
not conserved in zebrafish as depletion of Hnrnpa1 does not have an effect on the alternative 
splicing of pkma exon 10 or 11 of in zebrafish.  
3.5.2.2.6 hnrnpa1a-/-; hnrnpa1b-/- mutants show increased cell death 
 
Death of the upper and lower motoneurons is the ultimate cause for muscle wasting, muscle 
weakness, and aberrant motor unit activity in ALS patients [40]. Given the shortened SpMN 
axon length, the muscle impairment, and the lethality of the hnrnpa1a-/-; hnrnpa1b-/- mutants, 
I assayed for cell death via the incorporation of the DNA intercalating dye Acridine Orange, 
which marks apoptotic and necrotic cells and serves as a marker to detect cell death in 
zebrafish in vivo [202]. The dye was applied at 30 hpf. The spinal cord was imaged and the 
Acridine Orange positive cells in this region were counted using Fiji. Quantification identified 
a significantly increased number of Acridine Orange stained cells in hnrnpa1a-/-, hnrnpa1b-/- 
mutants compared to wildtype (see Figure 3.30). 
 
 
 
Figure 3.30 - hnrnpa1a-/-; hnrnpa1b-/- mutants show increased cell death in the spinal cord. Images of 
wildtype and hnrnpa1a-/-; hnrnpa1b-/- mutants stained with Acridine Orange (green), which is taken up by 
apoptotic and necrotic cells (only part of the spinal cord is shown). Lateral view. Anterior to the left. Maximum 
intensity projection of stacks of ten 0.9 µm images. Images were taken with laser scanning confocal microscope 
using the 488 nm laser. Quantification of Acridine Orange positive cells within the spinal cord of wildtype and 
hnrnpa1a-/-; hnrnpa1b-/- mutants. Number of Acridine Orange positive cells is significantly increased in 
hnrnpa1a-/-; hnrnpa1b-/- mutants. Error bars indicate S.E.M; n=9 embryos per experiment; ***p<0.0001; 
Student’s-t-test. Scalebar represents 40 µm. 
It can be concluded that loss of Hnrnpa1 increases cell death in the spinal cord illustrated by 
an increased number of Acridine Orange stained cells. This provides further evidence for 
neuronal cell death, which could explain the shortened SpMN axons in the hnrnpa1a-/-; 
hnrnpa1b-/- mutants. Furthermore, the high levels of cell death may be the cause of the 
ultimate lethality of the hnrnpa1a-/-; hnrnpa1b-/- mutants. 
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3.5.2.2.7 hnrnpa1a-/-; hnrnpa1b-/- mutants show vascular mispatterning 
 
Some ALS patients were described to show signs of dysfunctional circulation effects like 
hypoperfusion [220] [221]. Moreover, tardbp-/-; tardbpl-/- mutants display vascular 
mispatterning. 
 
Figure 3.31 - hnrnpa1a-/-; hnrnpa1b-/- mutants show vascular outgrowth delay and mispatterning. 
Representative whole mount images of single wildtype and hnrnpa1a-/-; hnrnpa1b-/- mutants. The shown 
embryos are Tg(fli1a:EGFP) highlighting the vasculature. The area dorsal of the yolk sack extension is 
displayed. A: Schematic illustration of the assayed region (red box) B: At 30 hpf the hnrnpa1a-/-; hnrnpa1b-/- 
mutants display reduced length of intersomitic vessels compared to their wildtype siblings but the correct 
number of sprouts is formed. Scale bar represents 25 µm. Anterior to the left. Lateral view. Maximum intensity 
projection. Images were taken with cell observer spinning disc microscope C: At 46 hpf the hnrnpa1a-/-; 
hnrnpa1b-/- mutants display vascular mis-patterning reflected by intersomitic vessels that are misconnected 
(white arrow) or ISVs that are still unconnected (black arrow). Scale bar represents 25 µm. Anterior to the left. 
Lateral view. Maximum intensity projection. Images were taken by confocal laser scanning microscopy. D: 
Quantification of the number of sprouts that have formed per somite at 30 hpf in wildtype and hnrnpa1a-/-; 
hnrnpa1b-/- mutants. No difference in sprout number was observed. No statistical analysis was performed as 
always one sprout formed per somite in all analyzed embryos.  
Results 
 96 
I therefore investigated vessel morphology in hnrnpa1a-/-; hnrnpa1b-/- mutants by crossing 
them to the transgenic line Tg(fli1a:EGFP). In this line the blood vessels are visible as the line 
expresses GFP under the control of the blood vessel specific promoter fli1a [194]. hnrnpa1a-/-
; hnrnpa1b-/- mutants and their wildtype siblings were PFA fixed to keep the analysis time 
points among the embryos as similar as possible, and imaged at 30 hpf and 46 hpf. In contrast 
to tardbp-/-; tardbpl-/- mutants, hnrnpa1a-/-; hnrnpa1b-/- mutants form the correct number of 
sprouts per somite (see Figure 3.31D). However, growing sprouts extend lateral lamellipodia, 
which correctly form a lumen and expand, and are developmentally delayed resulting in 
reduced length of intersomitic vessels (ISV) compared to wildtype at 30 hpf (see Figure 
3.31B). The growing sprouts occasionally fail to connect with their neighboring sprouts or 
misconnect to other sprouts (see Figure 3.31B+C). To better follow the vasculature 
development, age matched embryos obtained from a hnrnpa1a-/-; hnrnpa1b+/- incross were 
recorded in a movie for 20 h starting at 24 hpf and were afterwards genotyped. The movie 
showed that endothelial sprouts follow their physiological path, but that this process is 
delayed, which becomes evident already at the beginning of the recording (24 hpf). 
Ultimately, the endothelial sprouts divert their physiological path and fail to connect or 
misconnect.  
In summary, hnrnpa1a-/-; hnrnpa1b-/- mutants and tardbp-/-; tardbpl-/- mutants have distinct 
vascular mispatterning defects in early development. They share the vascular defect of 
mislead lamellipodia that ultimately misconnect or stay unconnected. However, the vascular 
phenotype is more severe in tardbp-/-; tardbpl-/- mutants with the additional defect of 
increased endothelial sprouting from the dorsal aorta at the very early event of sprout 
formation.  
3.5.2.2.8 hnrnpa1a-/-; hnrnpa1b-/-  and tardbp-/-; tardbpl-/- mutants show significantly 
increased levels of fn1b 
 
It was previously shown that vascular defects, represented by hypersprouting, in tardbp-/-; 
tardbpl-/- mutants arise from increased levels of the extracellular matrix protein fibronectin1b 
(fn1b). FN1A and Vascular cell adhesion molecule 1 (VCAM1) signal through the 
INTEGRIN ALPHA4 4 (ITGA4) receptor. Genes for these three proteins were identified to 
be highly upregulated upon TDP-43 KD in Human umbilical vein endothelial cells (HUVEC) 
[222]. I therefore tested whether a member of this ligand-receptor complex is also responsible 
for the vascular defects observed in hnrnpa1a-/-, hnrnpa1b-/- mutants. To address changes in 
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mRNA levels of these genes I performed qRT-PCR on hnrnpa1a-/-, hnrnpa1b-/- mutants using 
fn1a, fn1b, itga4, or vcam1 specific primer pairs.  
 
 
Figure 3.32 - mRNA expression of fn1b is increased in hnrnpa1a-/-; hnrnpa1b-/- mutants. Relative mRNA 
expression of fn1b (*p<0.04; n=4), but not fn1a (p>0.06; n=4), itg4 (p>0.44; n=4), or vcam1 (p>0.79; n=4) is 
increased in hnrnpa1a-/-; hnrnpa1b-/- embryos (red) compared to their wildtype siblings (orange). n=4 pools of 
embryos of independent clutches at 30 hpf, Student’s t-test. Results by qRT-PCR were reproduced twice using 
the same cDNA. Error bars indicate S.E.M. 
While fn1a, itga4 and vcam1 mRNA levels are not significantly changed in hnrnpa1a-/- and 
hnrnpa1b-/- mutants, fn1b levels are significantly upregulated (see Figure 3.32). The same 
result was previously obtained in tardbp-/-; tardbpl-/- mutants [222]. It can be concluded that 
Hnrnpa1 and Tdp-43 both control fn1b mRNA levels and loss of Tdp-43 or Hnrnpa1 leads to 
increased fn1b mRNA levels.  
3.5.2.3 Differentially expressed genes and proteins in hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
In order to identify differentially expressed genes and proteins upon Hnrnpa1 deficiency, 
which potentially lead to the observed phenotype in hnrnpa1a-/-; hnrnpa1b-/- mutants, two 
unbiased approaches were chosen. As hnrnpa1a-/-; hnrnpa1b-/- mutants are not viable, 30 hpf 
old embryos were used for NGS and proteomic analysis. The mutant embryos were selected 
according to the criteria described in section 3.5.2.2. 
3.5.2.3.1 Differentially expressed RNAs of hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
NGS (total RNA, transcriptome sequencing, paired end, 35 Million reads/sample) revealed 
615 differentially expressed genes of an adjusted p-value smaller than 0.01 and an up- or 
downregulated fold change greater than one. 235 of these genes were upregulated and 282 
were downregulated. Genes of a p-value smaller than 0.001 and with a more than 2 fold 
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change in expression were analyzed in further detail. Functional annotation clustering using 
the annotation tool DAVID (david.ncifcrf.gov/home.jsp) revealed that many of the total 517 
differentially expressed genes are involved in “cell cycle”, “p53 signaling”, “FoxO 
signaling”, or “Notch signaling” (see Figure 3.33).  
 
Gene Ensembl ID 
Human 
Orthologue 
log2fold 
change 
p-adjusted 
BX323459.3 ENSDARG00000115555 n.a. 6.10 2,28E-06 
drd6b ENSDARG00000040765 n.a. 5.26 1,07E-04 
isg15 ENSDARG00000086374 ISG15 4.58 1,08E-12 
cdkn2a/b ENSDARG00000037262 CDKN2A 4.53 5,91E-23 
ifit8 ENSDARG00000057173 IFIT3 4.37 3,21E-13 
btr07 ENSDARG00000105558 n.a. 4.33 4,50E-06 
cacna2d4b ENSDARG00000023886 CANA2D4 4.32 6,03E-19 
si:dkey-
145c18.3 
ENSDARG00000078738 NAMPT 4.06 5,74E-14 
CT583625.5 ENSDARG00000110288 n.a. 3.98 5,74E-05 
si:ch211-
132b12.8 
ENSDARG00000055250 CNTD2 3.72 8,42E-15 
 
si:ch211-
256m1.8 
ENSDARG00000055172 n.a. -3.74 4.06E-18 
lctla ENSDARG00000036139 LCTL -3.21 1.64E-10 
apoda.1 ENSDARG00000060345 APOD -3.16 2.24E-15 
defbl1 ENSDARG00000075161 n.a. -3.15 9.75E-11 
crygm2d15 ENSDARG00000069826 n.a. -3.11 1.40E-04 
crygm2d2 ENSDARG00000086917 CRYGD -2.98 3.25E-05 
crygm2d16 ENSDARG00000076790 n.a. -2.97 2.61E-06 
cyb561a3b ENSDARG00000028257 CYB561A3 -2.77 6.17E-10 
cryaa ENSDARG00000053502 CRYAA -2.66 4.34E-15 
cpa5 ENSDARG00000021339 CPA1 -2.62 2.40E-04 
Table 3.8 - Top 10 differentially expressed genes and the respective human orthologues in hnrnpa1a-/-; 
hnrnpa1b-/- mutants 
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Figure 3.33 – Top affected pathways based on RNA sequencing in hnrnpa1a-/-; hnrnpa1b-/- mutants. The 
numbers represent gene numbers involved in the process. 
The top genes with interesting function and potential disease relevance were analyzed by 
qRT-PCR to confirm differential gene expression in hnrnpa1a-/-; hnrnpa1b-/- mutants. 
Decreased expression of apoda.1 (~6 % remaining apoda.1) and glycoprotein nonmetastatic 
melanoma b (gpnmb) was verified by qRT-PCR, while increased expression of nampt could 
not be reproduced by qRT-PCR (see Figure 3.34). gpnmb encodes Gpnmb ,which is a type I 
transmembrane protein and is involved in a variety of processes including osteoplast 
differentiation and function, and regulation of autoimmune responses [223]. GPNMB was 
shown to exert a neuroprotective role and was linked to ALS due to its higher expression 
levels in sporadic ALS patients [224]. 
 
 
  
 
Figure 3.34 - mRNA expression of apoda.1 and gpnmb is decreased in hnrnpa1a-/-; hnrnpa1b-/- mutants. 
Relative mRNA expression of apoda.1 (***p<0.0001) and gpnmb (***p<0.0001), is decreased in hnrnpa1a-/-, 
hnrnpa1b-/- mutants (red) compared to their wildtype siblings (orange) while nampt (p>0.83) expression is not 
changed. n=4 pools of embryos of independent clutches at 30 hpf, Student’s t-test. Results by qRT-PCR were 
reproduced twice using the same cDNA. Error bars indicate S.E.M. 
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The expression of genes linked to ALS and/or FTD were only mildly changed in hnrnpa1a-/-, 
hnrnpa1b-/- mutants and were mostly not significant (see Table 3.9). grn2 shows the largest 
change with a 4.23 fold decrease, which is though not significant. fus and ccnf show 
significant changes, though with a small fold change of approximately 0.7. 
 
Gene Ensembl ID log2 fold change p-adjusted 
c9orf72 ENSDARG00000011837 0.32 0.21 
ccnf ENSDARG00000105046 -0.71 5.12E-5 
ewsr1a ENSDARG00000113252 n.a. n.a. 
ewsr1b ENSDARG00000117011 -0.53 0.35 
grn1 ENSDARG00000089362 -0.31 0.88 
grn2 ENSDARG00000088641 -4.23 0.69 
fus ENSDARG00000037968 -0.78 5.96E-9 
sod1 ENSDARG00000043848 -0.30 0.08 
taf15 ENSDARG00000070019 -0.33 0.015 
tardbp ENSDARG00000040031 -0.24 0.09 
tardbpl ENSDARG00000004452 -0.40 0.82 
tia ENSDARG00000052536 -0.46 0.01 
vapb ENSDARG00000070435 0.07 0.78 
vcp ENSDARG00000020008 0.13 0.50 
Table 3.9 - Expression of ALS and/or FTD related genes in hnrnpa1a-/-; hnrnpa1b-/- mutants. 
 
3.5.2.3.2 Expression of the cell cycle regulators cdk1a, cdk2a/b, gadd45, p53, and rbl2 is 
increased in hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
RNA sequencing hits involved in cell cycle were reanalyzed by qRT-PCR. As depicted in 
Figure 3.35 the levels of cdkn1a, cdkn2a/b, gadd45, p53 and rbl2, but not ccne1, were 
significantly increased in hnrnpa1a-/-; hnrnpa1b-/- mutants compared to their wildtype 
siblings. It can be concluded that the majority of genes, which were found by RNA 
sequencing to be differentially expressed in hnrnpa1a-/-; hnrnpa1b-/- mutants and are involved 
in cell cycle are upregulated. This finding makes it highly possible that cell cycle alterations 
contribute to the observed phenotypic abnormalities in hnrnpa1a-/-; hnrnpa1b-/- mutants. 
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Figure 3.35 - mRNA expression of cdkn1a, cdkn2a/b, gadd45, p53, and rbl2 is increased in hnrnpa1a-/-; 
hnrnpa1b-/- mutants. Relative mRNA expression of cdkn1a (**p<0.004), cdkn2a/b (***p<0.0004), gadd45 
(**p<0.005), p53 (***p<0.0003), and rbl2 (***p<0.0007) but not ccne (p>0.40) is increased in hnrnpa1a-/-, 
hnrnpa1b-/- embryos (red) compared to their wildtype siblings (orange). n=4 pools of embryos of independent 
clutches at 30 hpf. Student’s-t-test. Results by qRT-PCR were reproduced twice using the same cDNA. Error 
bars indicate S.E.M. 
3.5.2.3.3 Splice analysis of hnrnpa1a-/-; hnrnpa1b-/- mutants  
 
A list of interesting potential splice targets of HNRNPA1 was analyzed for changes in 
splicing pattern in hnrnpa1a-/-; hnrnpa1b-/- mutants. The splice analysis was performed by 
Özge Pelin, a PhD student from our group. No splicing differences were detected in cell cycle 
related genes, such as ccne1, ccne2, or cdk2. Also, splicing of apod.a1, fn1b or pkma was not 
affected in hnrnpa1a-/-, hnrnpa1b-/- mutants (data not shown). While the splicing of tardbp 
was not affected, tardbpl was differentially spliced upon Hnrnpa1 KO. The analysis further 
revealed that one of the alternative 3’UTR of apoeb shows significantly higher expression 
levels in hnrnpa1a-/-; hnrnpa1b-/- embryos leading to higher usage of a longer 3’UTR version 
(personal communication with Özge Pelin). Interestingly, HNRNPA1 KO was previously 
shown to regulate Apolipoprotein E (APOE) promoter activity, which is important in the 
development of AD [142].  
3.5.2.4 Differentially expressed proteins of hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
To identify altered protein expression in hnrnpa1a-/-; hnrnpa1b-/- mutants quantitative mass 
spectrometry was performed. Due to the richness of yolk proteins, which may mask detection 
of other proteins at this early stage, the yolk was manually removed from the embryos. 
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Protein NCBI accession log2 fold change p-value 
vitellogenin 4 precursor NP_001038759 1.75 7.69E-3 
vitellogenin 1 precursor NP_001038362 1.54 3.18E-3 
retinoic acid receptor 
RXR-beta-A isoform X9 
XP_009292301 0.65 4.00E-3 
ADP-ribosylation 
factor-like protein 3 
isoform 2 
NP_001017827 0.58 5.75E-3 
tumor necrosis factor 
receptor type 1-
associated DEATH 
domain protein 
NP_571682 0.56 7.86E-3 
serine/threonine-protein 
kinase tousled-like 1 
isoform X1 
XP_009302714 0.54 9.99E-3 
putative RNA-binding 
protein 15 
XP_001335820 0.53 5.53E-3 
N-lysine 
methyltransferase 
SMYD2-A 
NP_001013568 0.46 9.57E-3 
tumor protein D52 NP_001038486 0.41 4.65E-3 
S-formylglutathione 
hydrolase 
NP_001017796 0.41 6.59E-3 
 
heterogeneous nuclear 
ribonucleoprotein A1 
isoform X3 
XP_021335236.1 -6.16 6.88E-7 
hemoglobin embryonic 
subunit alpha 
XP_001333555.1 -5.35 4.49E-6 
GTP cyclohydrolase 1 NP_571742.1 -3.37 4.26E-4 
immunoglobulin 
superfamily DCC 
subclass member 3-like 
XP_009292645.2 -5,94 1.15E-6 
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wu:fc46h12 precursor NP_001278276.1 -2,16 6.89E-3 
proliferation marker 
protein Ki-67 isoform 
X1 
XP_021335806.1 -2.09 8.18E-3 
hemoglobin beta 
embryonic-3 
NP_001015058.1 -2.57 2.67E-3 
lymphoid-specific 
helicase 
NP_001032178.1 -2.60 2.53E-3 
40S ribosomal protein 
S30 
NP_957031.1 -2.76 1.74E-3 
ribonucleoside-
diphosphate reductase 
subunit M2 
NP_571525.1 -4.72 1.90E-5 
Table 3.10 - Top 10 differentially expressed proteins in hnrnpa1a-/-; hnrnpa1b-/- mutants.  
Only those samples were considered for further analysis that had a minimum coverage of 
4.000 proteins and had less than 10% remaining Hnrnpa1a protein. The p-value cut off was 
set to p<0.05 and only those values were included for further analysis that had an upwards or 
downwards fold change greater than one. The remaining 240 proteins met these criteria and 
were analyzed using the annotation tool DAVID (david.ncifcrf.gov/home.jsp), which revealed 
that most of the differentially expressed proteins are involved in the “ribosome”,  
 
 
Figure 3.36 - Top affected pathways based on proteomics in hnrnpa1a-/-; hnrnpa1b-/- mutants. The numbers 
represent protein numbers involved in the process. 
“spliceosome”, “cell cycle”, or “purine metabolism” pathway (see Figure 3.36). Even though 
these top pathways highly overlap with those found by RNA sequencing, the comparison with 
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the RNA sequencing data revealed little overlap of the most significant targets, most likely 
because the top RNA sequencing hits were below protein detection level. 
3.5.2.5 hnrnpa1a-/-; hnrnpa1b-/- mutants show no altered Pcna levels or distribution 
pattern 
 
Several lines of evidence point to cell cycle misregulation in the G1 to S-phase transition in 
hnrnpa1a-/-; hnrnpa1b-/- mutants. First, The RNA sequencing revealed the cell cycle as the 
most affected pathway in hnrnpa1a-/-; hnrnpa1b-/- mutants. I could further verify upregulation 
of the G1/S-phase related genes cdkn1a, cdkn2a/b, gadd45, p53, and rbl2 by qRT-PCR. 
Second, the proteome analysis of hnrnpa1a-/-; hnrnpa1b-/- mutants revealed cell cycle as one 
of the main affected pathways. Third, a previous study identified cell cycle S-phase as one of 
the top 10 affected processes upon Hnrnpa1 KO in mice [162]. To address cell cycle 
progression the protein levels and distribution pattern of Pcna in hnrnpa1a-/-; hnrnpa1b-/- 
mutants was investigated. PCNA is an evolutionary well-conserved protein, which is involved 
in many steps of cell division, such as processivity of DNA polymerase, chromatin 
remodeling, DNA replication control, and DNA repair. Furthermore, expression of the PCNA 
gene correlates with cell proliferation [225] [226] [227]. A decrease in Pcna in zebrafish 
mutants would thereby be an indicator of reduced cell proliferation [228]. Western blotting 
with a Pcna specific antibody on hnrnpa1a-/-; hnrnpa1b-/- mutants revealed unchanged Pcna 
protein levels compared to wildtype (see Figure 3.37A). Moreover, PCNA staining is suitable 
to discriminate the cell cycle stages G1 and S-phase. During G1-phase PCNA is equally 
distributed over the whole nucleus. In S-phase PCNA accumulates to small, equally 
distributed foci, which are located at the nuclear periphery or the center of the nuclei 
depending whether it is mid S-phase or late S-phase, respectively [229]. Upon whole mount 
staining of 30 hpf hnrnpa1a-/-; hnrnpa1b-/- mutants with Pcna, the embryos were imaged with 
the cell observer spinning disc microscope. The different Pcna staining patterns revealing the 
cell cycle stage (G1 and S-phase) of the specific cells are visible. There was no difference 
detected in cells undergoing G1 or S-phase between hnrnpa1a-/-; hnrnpa1b-/- mutants and 
wildtype (see Figure 3.37C).  
It can be concluded that Pcna protein levels are not changed upon Hnrnpa1 KO. Moreover, 
loss of Hnrnpa1 does not seem to alter the number of cells undergoing G1 or S-phase. 
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Figure 3.37 - hnrnpa1a-/-; hnrnpa1b-/- mutants show no change in Pcna levels or distribution pattern. A: 
Immunoblotting of Pcna on hnrnpa1a-/-; hnrnpa1b-/- mutants and wildtype embryos. Tubulin served as a loading 
control.  B: Quantification revealed no significant differences in Pcna levels among hnrnpa1a-/-; hnrnpa1b-/- 
mutants and wildtype embryos (p>0.20; n=8). Student’s t-test. Error bars indicate S.E.M. C: Pcna whole mount 
staining in wildtype and hnrnpa1a-/-; hnrnpa1b-/- mutants. In the enlarged view the cell stage can be detected by 
the Pcna pattern. Equally grey stained cells undergo G1-phase (white arrowhead) and cells with white punctae 
are in S-phase (black arrowhead). Lateral view of the tail. Anterior to the left. Scalebar represents 50 µm. Images 
were taken by cell observer spinning disc microscope using the 488 nm laser. 
 
3.5.2.6 Hnrnpa1 KO vs. Tdp-43 KO 
 
TDP-43 and HNRNPA1 belong to the HNRNP protein family, share similar protein structure, 
and mutations in these proteins were associated with ALS. Interestingly, the phenotype of 
hnrnpa1a-/-; hnrnpa1b-/- mutants is quite similar at first to that observed in tardbp-/-, tardbpl-/- 
mutant embryos. [12]. I therefore asked myself whether loss of function of these proteins in 
zebrafish causes similar phenotypes and overlapping molecular signatures.  
3.5.2.6.1 Phenotype analysis  
 
tardbp-/-; tardbpl-/- and hnrnpa1a-/-; hnrnpa1b-/- mutants share some phenotypic overlap, such 
as lethality, development of heart edema, shortened SpMN axons, muscle defects, and 
vascular development defects [12] [222]. However, the vascular phenotype shows distinct 
characteristics in the two mutants. hnrnpa1a-/-; hnrnpa1b-/- mutants develop lateral 
lamellopodia, diverting from their physiological migration path and misconnect, whereas 
ectopic sprouting from the dorsal aorta is characteristic for tardbp-/-; tardbpl-/- mutants. 
Results 
 106
Moreover, hnrnpa1a-/-; hnrnpa1b-/- mutants show a thinned yolk extension (see Figure 3.27), 
increased lipid uptake from the yolk extension to the trunk (see Figure 3.28), a higher number 
of dying cells in the spinal cord (see Figure 3.30) and developmental delay (see Figure 3.24) - 
all features that were so far not specifically addressed in tardbp-/-; tardbpl-/- mutants.  
 
 
 
Figure 3.38 - tardbp-/-; tardbpl-/- mutants are not developmentally delayed, show no changed neutral lipid 
distribution or cell death. A: Representative images of 30 hpf old wildtype and tardbp-/-; tardbpl-/- mutants 
with head trunk angle measurement. Lateral view. Anterior to the left. Images taken by Axio Scope A1 
microscope. Scalebar represents 200 µm. B: Quantification of head trunk angle of 30 hpf old wildtype (88°) and 
tardbp-/-; tardbpl-/- (88°) embryos revealed no significant difference; n=8 embryos; p>0.91; Student’s-t-test. 
Error bars indicate S.E.M. C: Representative images of 30 hpf wildtype and tardbp-/-; tardbpl-/- mutants stained 
with ORO. Slightly increased neutral lipid uptake is observed in tardbp-/-; tardbpl-/- mutants (black arrow) 
Lateral view. Anterior to the left. Scalebar represents 200 µm. D: Quantification of the 2-dimensional yolk 
extension area of wildtype and tardbp-/-; tardbpl-/- mutants reveals no significant difference. n=10 embryos; 
p>0.41; Student’s-t-test. Error bars indicate S.E.M. E: Representative images of 30 hpf wildtype and tardbp-/-; 
tardbpl-/- mutants stained with Acridine Orange (green), which is taken up by apoptotic and necrotic cells (only 
part of the spinal cord is shown). Lateral view. Anterior to the left. Maximum intensity projection. Images were 
taken with laser scanning confocal microscope using the 488 nm laser. Scalebar represents 40 µm. F: 
Quantification of Acridine Orange positive cells is unchanged in tardbp-/-; tardbpl-/- mutants. n=5 embryos per 
experiment; p>0.54; Student’s-t-test. Error bars indicate S.E.M.  
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Assessment of the head trunk angle revealed no significant change pointing to no or very little 
developmental delay in tardbp-/-; tardbpl-/- mutants (see Figure 3.38A+B). Upon staining of 
tardbp-/-; tardbpl-/- mutants with ORO, it becomes evident that tardbp-/-; tardbpl-/- mutants do 
neither have a thinned yolk extension nor do they show highly augmented neutral lipid uptake 
from the yolk extension to the body as depicted in hnrnpa1a-/-; hnrnpa1b-/- embryos (see 
Figure 3.38C+D). The occurrence of cell death was addressed by staining 30 hpf tardbp-/-; 
tardbpl-/- mutants with Acridine Orange. No increase in Acridine Orange positive cells was 
observed in tardbp-/-; tardbpl-/- mutants (see Figure 3.38E+F). 
3.5.2.6.2 Comparison between RNA sequencing datasets from tardbp-/-; tardbpl-/- and 
hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
In order to identify whether loss of Tdp-43 or Hnrnpa1 affect common downstream targets in 
zebrafish and to thereby determine whether they may act in similar pathways, I compared the 
RNA sequencing data obtained from hnrnpa1a-/-; hnrnpa1b-/- mutants to RNA sequencing 
data of tardbp-/-; tardbpl-/- mutants with bioinformatic help from Özge Pelin. The two data 
sets were analyzed in the same manner to allow for better comparison between the two data 
 
 
Figure 3.39 - Venn diagram showing shared and distinct differentially expressed genes upon Hnrnpa1 or 
Tdp-43 KO. 615 genes are differentially expressed in hnrnpa1a-/-; hnrnpa1b-/- mutants compared to their 
wildtype siblings. 56 genes are differentially expressed in tardbp-/-; tardbpl-/- mutants. 15 among these two data 
sets were found to overlap. p-value was adjusted to p<0.01. 
sets. The p-value was adjusted to 0.01 as the Tdp-43 dataset did not contain as many hits as 
the Hnrnpa1 data, and only those values were included that have an up- or downward fold 
change greater than one. With these settings 615 genes were differentially expressed in 
hnrnpa1a-/-; hnrnpa1b-/- mutants compared to wildtype. In tardbp-/-; tardbpl-/- mutants 56 
genes were differentially expressed compared to wildtype (see Figure 3.39). 15 genes were 
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changed in both datasets among which 8 genes were changed in the same direction (see Table 
3.11).  
 
 
Table 3.11 - Shared differentially expressed genes upon Hnrnpa1 or Tdp-43 KO. For explanation see text. 
 
3.6 KD of apoda.1 phenocopies the observed yolk extension thinning observed in 
hnrnpa1a-/-; hnrnpa1b-/- mutants in a dose-dependent manner 
 
apoda.1 was identified by RNA sequencing as one of the main downregulated genes in 
hnrnpa1a-/-; hnrnpa1b-/- mutants. One of the most striking phenotypes in hnrnpa1a-/-; 
hnrnpa1b-/- mutants is the thinned yolk extension and increased neutral lipid uptake, pointing 
to lipid metabolism defects. In order to test whether reduction in apoda.1 is involved in 
causing the lipid phenotype, I knocked down apoda.1 in AB wildtype fish using a splice site 
targeting MO as the KD efficiency can be easily assessed by PCR (see Figure 3.40A+B). 
Gene 
symbol 
Human gene 
log2 
foldchange 
hnrnpa1 
p-adj. 
hnrnpa1 
log2 fold 
change 
tardbp 
p-adj. 
tardbp 
Same 
direction 
ace AC113554.1 0,61 6,69E-06 -0,94 5,19E-04 no 
ankrd1a ANKRD1 0,69 4,54E-06 0,62 1,02E-4 yes 
chrng CHRNG -0,48 1,27E-04 1,16 5,29E-4 no 
ctgfa CTGF -2,50 1,16E-06 -0,61 2,18E-05 yes 
flnca FLNC 0,65 3,05E-07 1,92 3,44E-10 yes 
gli2b / 1,63 3,62E-07 -0,99 6,75E-10 no 
hspb11 / 1,03 7,16E-08 2,03 1,94E-22 yes 
mylpfb MYLPF 0,79 1,72E-05 1,02 7,74E-17 yes 
npr1a NPR2 -0,98 3,09E-04 1,18 2,64E-06 no 
plxnb3 PLXNB3 0,63 6,29E-07 1,01 5,46E-06 yes 
pvalb1 / 0,66 3,43E-04 1,12 9,77E-06 yes 
rnf44 RNF44 -4,32 3,67E-06 0,90 8,04E-05 no 
tcap TCAP -0,66 2,25E-05 1,24 4,33E-14 no 
wfikkn1 / 0,34 9,55E-3 -0,87 1,77E-03 no 
zmp:0000
001082 
ITGAX 0,62 1,08E-05 0,63 6,39E-04 yes 
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Binding of the apoda.1 MO leads to inclusion of intron 2 resulting in a longer RNA. This was 
verified by sequence analysis (data not shown) of the resulting higher band appearing in 
apoda.1 MO injected embryos at about 630 bp (see Figure 3.40B). Bands were cut, DNA  
 
 
 
 
Figure 3.40 – KD of apoda.1 mimics the yolk extension thinning observed in hnrnpa1a-/-; hnrnpa1b-/- 
mutants. A: Schematic illustration the four exons and three introns of apoda.1. Binding of the apoda.1 MO 
(indicated in red) leads to inclusion of intron 2 resulting in a longer RNA (see A). Primers used for amplification 
are indicated by black arrows. B: PCR products of cDNA from MO injected AB (+) embryos and uninjected 
siblings (-) shown in C. Injection of apoda.1 MO leads to appearance of a second, higher migrating band 
representing apoda.1 RNA with partial intron 2 inclusion. The lower band represents the normally spliced 
apoda.1 RNA. C: Images show the thinned yolk extension of AB embryos injected with 1 µM apoda.1 MO. 
Upper picture shows uninjected wildtype control with a normally developed roundish yolk extension. The 
middle picture shows an embryo with a mild phenotype showing little thinning of the yolk extension. The 
bottom picture shows an embryo with a severe phenotype characterized by a greatly thinned yolk extension. 
Lateral view. Anterior to the left. D: The two-dimensional yolk extension area is significantly reduced in 
embryos showing mild (n=11; ***p<0.0001) and severe (n=8; ***p<0.0001) thinning of the yolk extension 
caused by low and high KD levels of apoda.1, respectively. The analysis demonstrates that apoda.1 reduction 
phenocopies the yolk extension thinning observed in hnrnpa1a-/-; hnrnpa1b-/- mutants. Student’s t-test. Error 
bars indicate S.E.M. 
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purified and sent for sequencing, revealing a frameshift resulting from partial intron inclusion 
leading to a PTC at 79 aa. To quantify the phenocopy effect of apoda.1 KD in AB embryos, 
the average two-dimensional yolk area was measured at 30 hpf (see section 3.5.2.2.1). 
Strikingly, upon injection of the apoda.1 MO into wildtype embryos the majority of injected 
embryos showed a thinned yolk extension. Since the severity of this phenotype was variable 
among the injected embryos, embryos were divided into two classes (mild and severe) 
depending on the severity of the yolk extension thinning. Both groups showed a significantly 
smaller two-dimensional yolk extension area than wildtype embryos. Moreover, the 
efficiency of the MO KD correlates to the severity of the lipid phenotype (mild: 50% 
remaining apoda.1; severe: 25 % remaining apoda.1; see Figure 3.40 B+C+D).  
I conclude that reduction in apoda.1 phenocopies the lipid phenotype observed in hnrnpa1a-/-; 
hnrnpa1b-/- embryos in a dose dependent manner. This suggests that Apoda.1 reduction is 
causative for the lipid phenotype.  
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4 Discussion 
4.1 Evolution of HNRNPA proteins 
 
HNRNPA proteins are among the most abundant HNRNP proteins and are highly conserved 
across species [230]. In contrast to a single HNRNPA1 gene in mammals, two Hnrnpa1 
orthologues are present in zebrafish named Hnrnpa1 and Hnrnpa1b. The shared synteny of 
hnrnpa1a and hnrnpa1b with HNRNPA1 supports that these genes are orthologues. The 
presence of Hnrnpa1 and Hnrnpa1b can be explained by the TSD that lead to an additional 
round of WGD in zebrafish during evolution [231]. WGDs generates complexity by 
generating genes without preassigned essential function that can serve as genetic raw material 
for evolutionary innovation [232]. WGD-derived genes can undergo different fates: one of the 
duplicates may be lost (non-functionalization), both duplicates may acquire changes so that 
the ancestral gene’s function is shared by the duplicates (subfunctionalization), or one of the 
duplicated genes may acquire a new function (neofunction) [231]. These events are not 
mutually exclusive and each of them was observed in the past. Two questions arise in this 
context: First, whether Hnrnpa1a and Hnrnpa1b share common functions and second, which 
one of them better resembles Human HNRNPA1. Interestingly, no orthologue of HNRNPA2 
is described in zebrafish whereas it is found in lamprey and coelacanth. Since Hnrnpa1 is 
duplicated in zebrafish it is possible that Hnrnpa2 is lost due to functional redundancy [203] 
as it has been previously suggested that upon WGD many genes are deleted so that the gene 
content is only slightly increased [233]. Alternatively, Hnrnpa1a and/or Hnrnpa1b may have 
taken over HNRNPA2 functions. 
Regarding the first question whether Hnrnpa1a and Hnrnpa1b share common functions, the 
lab of J. Trimarchi shed more light on Hnrnpa1a and Hnrnpa1b function by studying their 
expression pattern in zebrafish. They found hnrnpa1a and hnrnpa1b to be expressed mainly 
in the head with a fainter expression in the trunk and in the retina at 2 dpf, 3 dpf and 4 dpf. 
hnrnpa1a showed ubiquitous expression in the head, while hnrnpa1b was only expressed in a 
subset of cells at these development stages. hnrnpa1a was slightly detected in the trunk at 
2 dpf and 3 dpf, while it was strongly expressed at 4 dpf. hnrnpa1b was absent at 2 dpf and 
was only faintly expressed in the trunk at 3 dpf and 4 dpf [234]. The in situ hybridization 
(ISH) expression pattern points to an important role of hnrnpa1a and hnrnpa1b in brain 
development [234]. The different temporal and spatial expression pattern of hnrnpa1a and
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 hnrnpa1b imply unique functions in zebrafish development, whereas the partial overlap in 
localization also suggests shared functions. The latter could speak in favor of compensatory 
mechanisms. Functional compensation is supported by the finding that Hnrnpa1b protein 
levels are significantly upregulated in hnrnpa1a-/- mutants. Correspondingly, hnrnpa1a 
mRNA levels were significantly upregulated in hnrnpa1b-/- mutants. These findings clearly 
show that Hnrnpa1a and Hnrnpa1b compensate for one another’s function by upregulating 
their protein or mRNA levels, respectively. Similarly, the Hnrnp family member tardbp 
shows compensational mechanisms by alternative splicing of tardbpl upon KO of its paralog 
tardbp [12]. Moreover, HNRNPA1 was shown to compensate for HNRNPA2/B1 function in 
mouse spinal cord, and HNRNPA2/B1 upregulation was observed upon HNRNPA1 loss of 
function in HeLa cells but not mice [235] [102] [162]. This could be because regulation of 
HNRNPA2/B1 upon HNRNPA1 may be much more complicated in an animal than a cell. It 
seems that in the mouse HNRNPA1 has a unique function that cannot be compensated by 
HNRNPA2/B1. The compensation among Hnrnpa1a and Hnrnpa1b observed in zebrafish 
presents a different scenario as these genes are both orthologues and are likely to both possess 
HNRNPA1 related function and/or acquired new ones. As zebrafish lack the Hnrnpa2 
orthologue compensation among Hnrnpa1 and Hnrnpa2 cannot be addressed. Furthermore, 
single hnrnpa1a-/- or hnrnpa1b-/- mutants lack any morphological abnormalities. More 
detailed analysis of ALS related phenotypes revealed neither a change in SpMN axon length 
nor muscle defects. Based on this finding it seems unlikely that one of these genes became 
nonfunctional as in this case the double KO would have been also phenotypically normal, but 
instead these mutants were embryonically lethal. We hypothesize that these genes became 
subject of subfunctionalization with each gene taking over essential functions in zebrafish 
development. The functions are though not fully complementary as in this scenario loss of 
either of them would result in a phenotype.  
In order to address the second question, which hnrnpa zebrafish orthologue is more closely 
realted to human HNRNPA1, sequence homology analysis using UniProt was performed and 
revealed a higher sequence homology of Hnrnpa1a and Hnrnpa1b to HNRNPA1-B, which is 
the minor isoform, than to HNRNPA1-A. Moreover, the full-length gene sequence of 
hnrnpa1a shows greater similarity with HNRNPA1-B than with hnrnpa1b. These findings 
imply that rather hnrnpa1a correlates with HNRNPA1 on a structural basis, while no 
conclusions on the functional relation can be drawn.  
Hnrnpa3 is highly identical to Human HNRNPA3 in its sequence and seems to be 
functionally more distinct from Hnrnpa1, based on the following observations. First, Hnrnpa3 
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RNA and protein levels in hnrnpa1a-/- and hnrnpa1b-/- single mutants are unchanged. Second, 
hnrnpa1a-/-; hnrnpa3-/- and hnrnpa1b-/-; hnrnpa3-/- double mutants were viable and did not 
show phenotypic abnormalities. Hnrnpa3’s sequence differs more from Hnrnpa1a and 
Hnrnpa1b than Hnrnpa1a and Hnrnpa1b to each other. The function of Hnrnpa3 is not well 
characterized in the literature. However, there is some evidence that points to a distinct 
function of HNRNPA3 compared to HNRNPA1 and HNRNPA2B1. He et al. showed that the 
levels of HNRNPA1 and HNRNPA2B1, but not HNRNPA3 are modulated during cell cycle 
in Colo16 squamous carcinoma cells, suggesting that HNRNPA1 and HNRNPA2B1 are 
required at specific stages of the cell cycle, while HNRNPA3 functions in a more generalized 
manner [236]. While no KO or KD animal was generated so far and no study did address 
compensation by HNRNPA3 upon loss of another HNRNP family member, the finding that 
Hnrnpa3 KO fish are viable but not Hnrnpa1 deficient zebrafish, gives further evidence that 
Hnrnpa3 is functionally distinct from Hnrnpa1.  
Taken together the expression pattern and sequence homology analysis shows that Hnrnpa1a 
and Hnrnpa1b have functional overlap while also having distinct roles. This suggests that 
subfunctionalization split the HNRNPA1 function to Hnrnpa1a and Hnrnpa1b. Hnrnpa1a and 
Hnrnpa1b have the greatest sequence similarity with the human minor form HNRNPA1-B. 
There is no HNRNPA2 homologue in zebrafish and only one HNRNPA3 homologue.  
4.2 What underlying mechanisms may cause the different phenotypes observed 
upon Hnrnpa1 KO or KD? 
 
KD studies are a powerful tool to study the physiological function of genes in zebrafish 
during development [237]. KD of hnrnpa1b by MO injection in zebrafish embryos was 
previously shown by Liu et al. to result in abnormalities of the dorsal axis and vessels, and 
development of heart edema. Upon usage of a higher MO concentration 77.7% of the 
hnrnpab1 MO injected embyos were lethal before 24 hpf [162]. In contrast, MO induced 
hnrnpa1b KD in zebrafish described by Cartealy et al. resulted in three different classes of 
phenotypes: (I) small and underdeveloped embryos, (II) kinked body and disorganized 
somites, and (III) lack of midbrain-hindbrain boundary. From the diversity of observed 
phenotypes upon KD of the same gene using two different MOs (one against the ATG, the 
other targeting the 5’UTR) a high level of discrepancy is observed. Contrasting these KD 
studies, the KO of Hnrnpa1a or Hnrnpa1b by CRISPR/Cas9 did not result in any 
developmental abnormalities. Discrepancies among the observed KD or KO phenotypes were 
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also previously observed for other genes [238]. In the following the potential underlying 
reasons for the observation of different phenotypes upon hnrnpa1b KD or KO are discussed. 
The usage of MOs to transiently KD genes has been highly criticized over the past years due 
to the high rate of divergent phenotypes upon KO of the same gene by genome editing. The 
high frequency of off-target effects makes it difficult to determine how much of an antisense 
mediated phenotype results from the KD of the actual gene of interest, and how much derives 
from the KD of other genes [237]. To validate MO specificity, Stanier et al. provided 
guidelines for the usage of MO in the generation of genetic KDs and recommended the 
following: Usage of multiple MOs, rescue experiments, control MOs, dose-response curves, 
comparison with existent mutant, loss of protein confirmation, and minimization of off-target 
effects. 
Both hnrnpa1b KD studies used a translation blocking MO by either targeting the ATG 
directly or the 5’UTR. The gold standard to address efficient MO KD is the usage of a 
specific antibody [237]. Both MO hnrnpa1b KD studies lack a verification of Hnrnpa1b 
protein loss by Western blot using an antibody that specifically recognizes the protein of 
interest. Cartealy et al. used the approach of coinjecting a plasmid containing GFP tagged to 
5’UTR including the target site of the MO and take the relative decrease in GFP signal as an 
indicator of the overall genetic MO KD efficiency [163]. This approach was determined to be 
of little value, as suppression of GFP expression was observed to be a general phenomenon 
[239]. Liu et al. performed qRT-PCR using hnrnpa1b specific primer to determine the 
hnrnpa1b MO KD efficiency and showed 50% reduction in hnrnpa1b mRNA [162]. To 
control for toxicity effects both studies used scrambled MO. However, none of the studies 
performed rescue experiments by which specificity of the MO could be determined.  
Another possible explanation for the phenotype in MO induced KD of hnrnpa1b could be the 
simultaneous translation blocking of maternal RNA, whereas mutants derived from a 
heterozygous hnrnpa1a or hnrnpa1b incross contain remaining maternal RNA. As incrosses 
from homozygous KO mutants gave healthy offspring the possibility that maternal 
contribution rescues the early phenotype can be ruled out for single Hnrnpa1a or Hnrnpa1b 
KOs. Moreover, a study by Carla Neugebauers lab states that translation blocking MO usage 
is not applicable. Due to the large maternal contribution of Hnrnpa1a and Hnrnpa1b protein 
the maternally deposited Hnrnpa1a or Hnrnpa1b protein may still be sufficient carry out 
essential functions preventing sufficient KD efficiency [214]. Another explanation for the 
existence of a phenotype in hnrnpa1b morphants are off target effects. Both studies lack 
thorough analysis using an unbiased approach or analyzing educated guesses due to sequence 
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similarity, to identify off target effects. Due to the high sequence similarity of hnrnpa1a and 
hnrnpa1b the MO directed to hnrnpa1b could target hnrnpa1a as well, blocking the 
translation of both genes and leading to generation of a double KD. To clarify KD specificity 
and uncover compensatory mechanisms, it would have been interesting to see whether 
hnrnpa1a levels are reduced upon KD of hnrnpa1b and whether the hnrnpa1b morphant 
phenotype can be observed upon hnrnpa1a KD. Lastly, we cannot rule out that the lack of 
compensatory upregulation of hnrnpa1a upon KD of hnrnpa1b (as seen in the KO) and vice 
versa might be causing the discrepancy seen in KD vs. KO.  
It can be concluded that zebrafish mutants provide several advantages over morphants, such 
as reduction of hitting off targets. Outcrossing can eliminate mutations introduced in other 
loci than the gene of interest. Furthermore, mutants possess complete long-lasting KO of a 
gene, compared to MO generated KD models, which are mostly only partial loss of function 
and restricted to the first days of development. Taken together the discrepancy among 
hnrnpa1b KD models and the lack of appropriate controls raises concerns about the 
specificity of the described MOs. The lack of any phenotypic abnormalities in the generated 
hnrnpa1a-/- and hnrnpa1b-/- mutants again confirms this. As hnrnpa1a and hnrnpa1b were 
targeted with two different gRNAs and several alleles were raised to homozygosity, which all 
lack a phenotype, this observation can be considered to be specific. 
4.3 Is there evidence for ALS associated phenotypes in hnrnpa1a-/-; hnrnpa1b-/- 
mutants? 
 
Having identified compensatory mechanisms among Hnrnpa1a and Hnrnpa1b but not 
Hnrnpa3, and having observed lethality only upon Hnrnpa1a and Hnrnpa1b double KO, we 
focused our further analysis on hnrnpa1a-/-; hnrnpa1b-/- mutants. Moreover, in contrast to 
HNRNPA3, HNRNPA1 was directly linked to ALS and MSP patients by mutations that are 
causative for these diseases. The identification of HNRNPA1 mutations and the associated 
HNRNPA1 cytoplasmic mislocalization in ALS and MSP patients suggest that animal models 
lacking HNRNPA1 might recapitulate ALS and MSP associated phenotypes, which I 
analyzed in the hnrnpa1a-/-; hnrnpa1b-/- mutants. ALS is defined by the degeneration of upper 
and lower motoneuron, ultimately leading to muscle degeneration [38] [40] [40]. In some 
cases ALS patients were described to show signs of dysfunctional circulation effects like 
hypoperfusion [220] [221]. Muscle integrity is hereby particularly relevant as MSP patients 
suffer from myopathies and HNRNPA1 KO mice show a prominent muscle phenotype [162].  
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4.3.1 hnrnpa1a-/-; hnrnpa1b-/- and  tardbp-/-, tardbpl-/- mutants show partially 
overlapping phenotypes  
 
The identified phenotypes, such as shortened motoneuron axons, muscle defects, and to a 
limited extend vasculature mispatterning in hnrnpa1a-/-; hnrnpa1b-/- mutants are similarly 
present in tardbp-/-; tardbpl-/- mutants [12] and suggest common underlying mechanisms upon 
loss of these proteins. Both proteins belong to the HNRNP family, have similar structure, and 
were shown to functionally and physically interact with one another to regulate RNA 
metabolism [240] [149] [150]. Also, HNRNPA1 and HNRNPA2/B1 MSP patients show 
nuclear clearance and cytoplasmic inclusions of TDP-43 in muscle tissue next to HNRNPA1 
or HNRNPA2/B1 pathology [101]. Therefore, we compared our Hnrnpa1 KO model to the 
previously established Tdp-43 KO zebrafish regarding their phenotypes and molecular 
signature. 
4.3.1.1 Shortened SpMN in hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
The HNRNPA1 KO mouse was not analyzed for neurodegeneration phenotypes specifically. 
However, several findings suggest a role of HNRNPA1 in neuron development. The top 
affected process comparison based on differentially expressed genes between wildtype, 
homozygous and heterozygous HNRNPA1 KO mice revealed “developmental neurogenesis”, 
“axonal guidance”, “synaptogenesis”, “neurophysiological processes”, and 
“neurotransmission” among the top 10 affected pathways. Likewise, top 10 process network 
analysis based on alternative splicing genes of these mice revealed neurodevelopment specific 
pathways, such as “neurogenesis”, “neurohormone signaling”, “neuropeptide signaling”, and 
“axonal guidance” [162]. As HNRNPA1 has its highest expression levels in the mouse CNS, 
followed by the liver and placenta, HNRNPA1 seems to play a crucial role in neuronal 
processes. Likewise, a role for Hnrnpa1 in neurodevelopment in zebrafish is supported by the 
expression pattern analysis by J. Trimarchi, who found that hnrnpa1a and hnrnpa1b are 
mainly expressed in the zebrafish head. Also, Cartealy et al. previously showed that hnrnpa1b 
mRNA is mainly localized to the brain, the forebrain, midbrain, hindbrain, and spinal cord 
neurons at 24 hpf [163]. Moreover, hnrnpa1a-/-; hnrnpa1b-/- mutants show vascular 
mispatterning accompanied by reduced blood flow, which leads us to the assumption that 
cerebral blood flow is similarly dysregulated. This finding is in line with the observation that 
hypoperfusion is present in ALS patients and models, which correlates with disease severity 
[241] [242] [243]. 
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Our finding that hnrnpa1a-/-; hnrnpa1b-/- mutants have shortened SpMN can be explained by 
the previously identified role of Hnrnpa1 in neurodevelopment, which seems to be conserved 
among zebrafish and mice. It remains though elusive at this point what mechanism underlies 
the neuronal impairment. Alternatively, the developmental delay observed in hnrnpa1a-/-; 
hnrnpa1b-/- mutants could account for the reduced SpMN axon length.  
4.3.1.2 Loss of muscle integrity in hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
HNRNPA1 heterozygous KO mice show muscle development defects, such as irregular 
tongue muscle, and diaphragm skeletal muscles with fibrous tissue infiltration. The muscle 
phenotype is further supported by global expression changes in genes related to muscle and 
an exon array study that identified muscle contraction as the second most affected process 
[162]. Moreover, alternative splicing pattern of muscle development-related genes was 
changed upon heterozygous KO of HNRNPA1 in mice. Likewise, hnrnpa1a-/-; hnrnpa1b-/- 
zebrafish mutants show muscle disintegrity at 30 hpf pointing to a conserved role of Hnrnpa1 
in muscle development. Altogether these findings point to a crucial role of HNRNPA1 in 
muscle development. An additional role of HNRNPA1 in muscle maintenance could 
contribute to muscle wasting later in life as observed in HNRNPA1 associated ALS patients 
due to loss of HNRNPA1 function. 
From the observed neuronal impairment and loss of muscle integrity upon Hnrnpa1 and Tdp-
43 KO paired with findings from previous studies, it seems plausible that these proteins play a 
vital role in neuronal and muscle development. Due to the drastic phenotype in both mutants 
leading to premature death after few days, these morphological abnormalities may though not 
be highly specific to Hnrnpa1 or Tdp-43 loss of function. The hnrnpa1a-/-; hnrnpa1b-/- 
mutants shows high levels of cell death in the spinal cord at the time analyzed, which is not 
present in tardbp-/-; tardpl-/- mutants. It is therefore difficult to say whether these 
developmental defects are a direct consequence of Hnrnpa1 loss of function or whether the 
apoptotic tissue environment disrupts the correct formation of muscles and neurons. 
Motoneuron shortening especially is a commonly observed phenotype upon KD of genes, and 
is in most cases accompanied by general atrophy in the developing embryo or a 
developmental delay due to toxicity [244] [245] [246] [247]. Our previous study in tardbp-/-; 
tardbpl-/- mutants linked these phenotypes to upregulation of Filamin C (FLNC), which codes 
for FLNC, an actin cross-linking protein that provides anchors for membrane proteins and 
structural components, has important signaling functions, and was linked to FTLD-TDP 
patients due to its upregulation in these patients’ brains [12] [248]. Strikingly, flnca 
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upregulation was likewise found in hnrnpa1a-/-; hnrnpa1b-/- mutants. The link between 
upregulated flnca upon TDP-43 or HNRNPA1 loss of function paired with Filamin C 
upregulation in ALS patients supports loss of function disease mechanisms and common 
pathomechanisms leading to HNRNPA1 and TDP-43 pathology. It will be relevant in the 
future to determine whether upregulated Filamin C levels are also found in HNRNPA1 
associated ALS/MSP cases. 
Concluding, Filamin C is a molecular link between Hnrnpa1 and Tdp-43 KO muscle 
phenotype and muscle deficits in ALS patients in line with a potential common 
pathomechanism.  
4.3.1.3 Vasculature abnormalities hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
Vascular phenotypes were not investigated in HNRNPA1 KO mice, but the network analysis 
between wildtype and heterozygous or homozygous HNRNPA1 KO mice revealed regulation 
of angiogenesis and development of blood vessels among the top 10 affected processes. 
Moreover, recent research suggests a role of HNRNPA1 in vascular smooth muscle cell 
(VSMC) function by regulating VSMC-specific gene expression, proliferation, and migration 
[249]. Similarly, hnrnpa1a-/-; hnrnpa1b-/- mutants show vascular mispatterning with impaired 
and delayed sprouting starting at 30 hpf. A vascular phenotype is also present in tardbp-/-; 
tardbpl-/- mutants sharing certain commonalities and differences with hnrnpa1a-/-; hnrnpa1b-/- 
mutants. Both mutants show vasculature misspatterning displayed by supernumerous sprouts 
that leave their physiological path, and ultimately misconnect or stay unconnected. However, 
in hnrnpa1a-/-; hnrnpa1b-/- mutants this hypersprouting is restricted to the intersegmental 
vessels dorsal to the horizontal mypseptum and the correct number of one sprout from the 
dorsal aorta per somite ventral to the horizontal myoseptum is formed (see Figure 3.31D). In 
contrast, tardbp-/-; tardbpl-/- mutants grow approximately 1.5 sprouts per somite and 
hypersprout also ventral to the horizontal myoseptum [222]. Moreover, the intersegmental 
sprouts of hnrnpa1a-/-; hnrnpa1b-/- mutants that extend along their physiological path up to 
the horizontal myoseptum and form a lumen, while the sprouts of tardbp-/-; tardbpl-/- mutants 
hyperbranch already ventral to the horizontal myoseptum show a thinned lumen restricting 
constant blood flow.  
Sprouting blood vessels are formed by angiogenesis, a process that includes regulation of 
endothelial cells (EC) migration, proliferation, and adhesion. The leading cell senses stimuli 
that cause extension of one lamellipodium and several filopodia to the direction of migration. 
Thus, pro-angiogenic signaling cues have to be provided locally at the correct time and place 
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to ensure sprout growth along defined paths at distinct sites and developmental stages [250]. 
In hnrnpa1a-/-; hnrnpa1b-/- mutants the high level of cell death may disrupt this highly 
specialized signaling pattern. Also, vascular sprouting starts later in development than in 
wildtype embryos since the mutants are generally developmentally delayed.  
Concluding, the delay in vasculature formation and the mispatterning of ISV upon Hnrnpa1 
KO are in accordance with previous findings that suggest an essential role for Hnrnpa1 in 
vasculature development. As the observed phenotype may be additionally influenced by cell 
death and developmental delay that is present in these mutants, we cannot determine whether 
the vascular phenotype is a primary or secondary effect. Lastly, the vascular phenotype is for 
the most part distinct to that observed in Tdp-43 deficient embryos, suggesting distinct 
underlying mechanisms leading to vascular mispatterning. 
 
fn1b upregulation: a potential link to vasculature defects observed upon Hnrnpa1 or 
TDP-43 KO 
 
Endothelial hypersprouting in tardbp-/-; tardbpl-/- mutants was linked to upregulation of fn1b, 
vcam1 and itgα4/β1. Likewise, hnrnpa1a-/-; hnrnpa1b-/- mutants show increased fn1b levels 
potentially linking the commonalities of the vascular phenotype present in Hnrnpa1 and Tdp-
43 deficient embryos. Interestingly, vcam1 and itgα4/β were not upregulated in hnrnpa1a-/-; 
hnrnpa1b-/- mutants. FN1 is a high molecular weight glycoprotein of 250 kDa and is involved 
in cell adhesion, growth, and migration [251]. FN1 KO mice are embryonically lethal with 
heart defects in heart and blood vessel development, pointing to an essential role of FN1 
during embryonic development [252] [253] [254]. Zebrafish have two FN1 genes, fn1a and 
fn1b [255], which were both shown to be required for somite boundary formation and 
maintenance [256]. While having overlapping functions, loss of fn1a or fn1b function point to 
distinct roles during zebrafish embryo development. fn1a deficiency results in mild somite 
boundary defects in the anterior somites, whereas fn1b KD zebrafish show normal somite 
formation but tail extension defects and disruption of the regular somite morphology by the 
15-20 somite stage [257]. Correct formation of somite boundaries is particularly important 
during development [256]. Once the somites are formed, distinct areas of each somite are 
subregionalized in various tissues and cell types, which are important for bone, musculature, 
and nervous system development [258]. Any disruption of somite formation can hence result 
in anomalies affecting various tissues, such as vasculature or muscle. 
Upregulation of fn1b, vcam1 and itgα4/β1 in tardbp-/-; tardbpl-/- mutants was causative for the 
vasculature hypersprouting, and increased FN1 expression was detected deposited around 
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ectopically sprouting EC. The contribution of fn1b, vcam1 and itgα4/β1  to the phenotype 
could be further verified by a partial MO KD to wildtype levels in these mutants that were 
sufficient to rescue the phenotype. Moreover, FN1 was found among the top 30 bound 
transcripts by individual nucleotide resolution cross-linking immunoprecipitation-high-
throughput sequencing (iCLIPs) [259]. Prominent binding of TDP-43 to the entire RNA of 
FN1 suggests regulation of transcript stability or translation [260] [261]. It remains elusive 
how fn1b upregulation causes the vasculature mispatterning in hnrnpa1a-/-; hnrnpa1b-/- 
mutants as the phenotype is different than that observed in tardbp-/-; tardbpl-/- mutants, which 
additionally show hypersprouting ventral to the horizontal myoseptum. As Fn1b has a direct 
role in extracellular matrix (ECM) signalling and somite formation, Fn1b upregulation may 
contribute to common characteristics of the vascular phenotypes, such as hypersprouting 
dorsal to the horizontal myoseptum and mispatterning of ISV, in several ways. FN1 is 
secreted by EC, deposited in the ECM and functions in multiple aspects of EC behavior [262]. 
The ECM-EC interaction induces several signaling events, which are crucial for directed 
migration of EC during vascular development. Upon increased levels of fn1b the ECM-EC 
signaling may be impaired leading to impaired EC migration and sprout formation. 
Alternatively, somite boundaries, which are key for shaping the basic structure for later 
vasculature formation, may be disrupted due to FN1’s importance in somite formation. As a 
consequence growing sprouts lack their guidance, divert from their physiological path, and 
misconnect.  
It would be interesting to perform FN1 staining in these mutants as performed previously in 
tardpb-/-; tardbpl-/- mutants to detect Fn1 expression pattern and determine potential 
differences observed in Tdp-43 and Hnrnpa1 KO zebrafish that could explain the distinct 
vascular phenotypes with common increase in fn1b. Moreover, a MO rescue approach could 
be performed to identify whether reduced fn1b is sufficient to restore normal vasculature 
development also in hnrnpa1a-/-; hnrnpa1b-/- mutants. While no direct binding between FN1 
and HNRNPA1 was described yet, it is possible that these two proteins either directly or 
indirectly interact via TDP-43, as HNRNPA1 and TDP-43 are direct interaction partners 
[149]. Alternatively, the different vascular phenotypes may arise from secondary effects as 
both HNRNPA1 and TDP-43 have hundreds of targets that may influence vasculature 
development.  
One can conclude that Hnrnpa1 or Tdp-43 causes largely different vascular phenotypes but 
share the upregulation of fn1b, which could contribute to the few common aspects of the 
phenotype. 
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4.3.2 Shared genes that are differentially expressed genes in hnrnpa1a-/-; hnrnpa1b-/- 
mutants 
 
We wondered if besides fn1b and flnca there are more shared misregulated genes contributing 
to the partially overlapping phenotypes of hnrnpa1a-/-; hnrnpa1b-/- and tardpb-/-; tardbpl-/- 
mutants. We performed RNA sequencing of hnrnpa1a-/-; hnrnpa1b-/- mutants and compared 
the dataset to the previously obtained RNA sequencing dataset of tardpb-/-; tardbpl-/- mutants 
in order to identify potential overlap of differentially expressed genes upon KO of Hnrnpa1 or 
Tdp-43. The overlap analysis revealed 15 genes whose expression is changed in both datasets 
of which 8 genes are changed in the same direction. It has to be noted that RNA sequencing 
of hnrnpa1a-/-; hnrnpa1b-/- mutants revealed far more differentially expressed genes (615 in 
total) with a more than one fold change and a p-value<0.01 than RNA sequencing data 
obtained from tardpb-/-; tardbpl-/- mutants (56 in total). Interestingly, the majority of 
commonly differentially expressed genes encode proteins that are present in the ECM or 
encode membrane proteins pointing to overlapping differentially expressed genes related to 
structure. Other genes were related to muscle integrity, which links HNRNPA1 and TDP-43 
loss of function with the muscle phenotype observed upon their KO and muscle deficits in 
ALS patients.  
4.3.3 Regulation among Hnrnpas and Tdp-43 
 
The overlapping findings of shared phenotypes and common differentially expressed genes 
upon Hnrnpa1 or Tdp-43 deficiency, prompted us to investigate whether protein levels of any 
of the three Tdp-43 zebrafish paralogues are changed upon Hnrnpa KO. Upon single loss of 
Hnrnpa1a, Hnrnpa1b, or Hnrnpa3 no differences in Tardbp, Tardbpl or Tardbpl_tv1 protein 
levels were detected. Similar results were obtained in hnrnpa1a-/-; hnrnpa1b-/- mutants. Apart 
from TDP-43 and HNRNPA1 being well-known splicing factors that control the expression 
of many different target genes, and the finding that HNRNPA1 and TDP-43 control their own 
splicing and/or transcript levels in zebrafish [12], there is also evidence that they regulate the 
splicing of each other. It was previously shown that upon loss of nuclear TDP-43 the splicing 
pattern of HNRNPA1 is altered resulting in a longer and more aggregation prone HNRNPA1 
isoform, named HNRNPA1-B [150]. We could further determine that upon loss of Hnrnpa1, 
tardbpl is alternatively spliced leading to the integration of a longer exon 6 isoform, most 
probably functioning as an alternative 3’UTR, which plays a crucial role in transcript 
stability, control of gene expression, or nuclear export [263]. Differentially used 3`UTRs 
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upon Hnrnpa1 KO may therefore have widespread effects and contribute to disease 
pathogenesis. The finding needs further research to determine whether the alternative 3’ UTR 
usage is linked to increased expression of Tardbpl_tv1 or Tardbp protein. While the 
proteomic analysis revealed no difference in Tardbp or Tardbpl levels, the changes may be 
either too subtle to detect or be restricted to the Tardbpl_tv1 isoform, which was neither 
identified by mass spectrometry nor studied on Western blot. It will be of relevance to 
determine whether HNRNPA1 loss of function in ALS leads to such alterations in TDP-43 as 
it has been described vice versa.  
One can conclude that Hnrnpa1 and Tdp-43 control their own splicing/transcription, which 
results in compensatory mechanisms among the different paralogues. Moreover, Hnrnpa1 and 
Tdp-43 influence each other by controlling each other’s splicing and we could show here for 
the first time that loss of Hnrnpa1 has an effect on Tdp-43 splicing. 
 
 
 
Figure 4.1 - Schematic illustration of transcriptional and alternative splicing regulation between Hnrnpa1 
and Tdp-43. Hnrnpa1 (depicted in orange) has two different orthologues in zebrafish, Hnrnpa1a and Hnrnpa1b, 
that regulate each other on transcriptional level. Upon loss of Tardbp, Tardbpl is differentially spliced resulting 
in another transcript variant, tardbpl_tv1. Alternative splicing regulation among Hnrnpa1 and Tardbp in 
zebrafish and human could be also shown. Upon Loss of Hnrnpa1, tardbpl is differentially spliced resulting in 
expression of a variant possessing a longer exon 6, which likely resembles an alternative 3’UTR. Vice versa, 
upon TDP-43 depletion in human cells, HNRNPA1 is differentially spliced causing inclusion of exon 8 that 
results in higher levels of the HNRNPA1-B isoform. Red indicates transcriptional regulation. Turquoise 
indicates alternative splicing regulation. Dashed line represents findings from human samples.  
 
4.3.4 What causes the partial overlap in phenotype and differentially expressed genes 
upon Hnrnpa1 or Tdp-43 loss of function? 
 
HNRNPA1 and TDP-43 both belong to the HNRNP family, are nuclear shuttle proteins, and 
are ubiquitously expressed. The high degree of complexity among HNRNPs and their splicing 
targets results in some combinations of HNRNPs that exhibit significant synergy while others 
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act antagonistically [264]. While having many overlapping features regarding structure and 
function, certain characteristics are unique to HNRNPA1 and TDP-43, respectively. 
HNRNPA1 does not contain a classical nuclear localization signal (NLS) as TDP-43, but a 
specialized M9 domain and a PY-NLS like FUS [265]. RNA specificity is particularly 
determined by the terminal region of the RMM and the variable regions of the loops that give 
structure to the beta strands [266]. Also the binding motif preferences of HNRNPA1 and 
TDP-43 are different. While HNRNPA1 binds preferentially to AU-rich sequences with its 
most prominent binding motif being UUAGGG, TDP-43 binds to UG repeats [267]. The 
binding of TDP-43 mostly occurs in introns and 3`UTRs [268, 269], while HNRNPA1 
preferentially associates with exons and introns [270] [271]. Their binding in most cases leads 
to splicing repression, but no studies have compared the effect of HNRNPA1 or TDP-43 loss 
of function on their overall effect on their target genes to identify potential overlap and 
differences. While we could identify 15 commonly differentially upregulated genes upon 
Hnrnpa1 or Tdp-43 loss of function, it will be interesting to determine if and how these genes 
contribute to disease pathogenesis and whether some of these genes can be verified in other 
model systems to show conservation.  
It can be concluded that the majority of the underlying mechanisms upon Hnrnpa1 or Tdp-43 
deficiency are diverse while some overlap is present shown by some common differentially 
expressed genes.  
4.4 Could metabolic impairment be the underlying cause of premature death of 
hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
The most striking phenotype in hnrnpa1a-/-; hnrnpa1b-/- mutants is the thinned yolk extension 
phenotype, which is not present in tardbp-/-; tardbpl-/- mutants and points to a specific 
phenotype upon Hnrnpa1 KO. Paired with the significant developmental delay we 
hypothesize metabolic deficits upon Hnrnpa1 KO.  
4.4.1 Developmental delay in hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
Apart from being lethal after 5 dpf, hnrnpa1a-/-; hnrnpa1b-/- mutants are developmentally 
delayed. Likewise, HNRNPA1 KO mice are partially embryonically lethal, which was shown 
by a reduced number of homozygous HNRNPA1 KO mice after incrossing HNRNPA1 
heterozygous mice. Genotyping of E18.5 embryos showed that HNRNPA1 KO mice develop 
in the expected numbers but die before being born [162]. Early lethality of HNRNPA1 
deficient mice and zebrafish points to a crucial role of HNRNPA1 in early development. The 
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lab of Karla Neugebauer performed a detailed study on the role of Hnrnpa1 (Hnrnpa1a and 
Hnrnpa1b) in early developing zebrafish as it was found among other nuclear pre-mRNA 
processing factors to be highly enriched before zygotic genome activation (ZGA). As 
embryos are transcriptionally silent at the preZGA state an unconventional function of 
Hnrnpa1 during this phase was suggested. Hnrrnpa1 plays a role in RNA metabolism during 
embryogenesis as is regulates poly(A) tail length before ZGA through 3’ UTR binding and 
encourages translation of maternal transcripts [214]. Based on the finding of the Karla 
Neugebauer’s lab one can assume that upon loss of Hnrnpa1 translation of maternal 
transcripts is decreased, which may have widespread consequences on general protein 
synthesis. Given the dependence of early embryos on RNA-based regulation of gene 
expression, major roles for RBPs in developmental transitions are anticipated. RBPs are of 
critical importance to regulate every step of RNA metabolism through their association with 
RNA sequences [261] [272]. Despic et. al further reported a developmentally essential nuclear 
function of Hnrnpa1 at ZGA. Hnrnpa1 was found to bind basal, single-stranded segments of 
pri-miR-430a and thereby regulates miR-430 biogenesis [214]. miR-430 comprises an 
evolutionary conserved miRNA family, whose absence results in disrupted neural tube 
formation and brain morphogenesis [273] [274].  
It can be concluded that Hnrnpa1 plays a vital role already in very early development, 
especially before ZGA, which fits to our finding that hnrnpa1a-/-; hnrnpa1b-/- mutants are 
developmentally delayed and die at larval stage. It remains to be determined whether embryos 
become developmentally delayed and go down the detrimental path already before ZGA due 
to lack of transcription of maternal RNAs or after ZGA. Moreover, it is not clear which 
precise mechanism leads to developmental delay, but a previous study could show that 
developmental delay may arise from slowed down cell cycle [275]. It may be therefore 
interesting to assess cell cycle progression in these mutants. This model may be further used 
to better identify the role of Hnrnpa1 in preZGA state and to thereby elucidate how Hnrnpa1 
regulates poly(A) tail length and controls transcription.  
4.4.2 Alterations in pkma splicing do not cause metabolic defects in hnrnpa1a-/-; 
hnrnpa1b-/- mutants 
 
A potential molecular candidate that links HNRNPA1 loss of function and metabolic defects 
is PKM. The two isoforms, PKM1 and PKM2, are generated by alternative splicing of the 
primary RNA transcript of the PKM gene, by differential usage of exon 9 and 10, 
respectively. The non-allosteric isoform PKM1 is constitutively active, and expressed in 
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terminally differentiated tissues, including the muscle and the brain, which require a large 
supply of ATP. PKM2 is expressed in tissues with anabolic functions, including proliferating 
cells and cancer cells. The OE of PKM2 in cancer cells is controlled by the oncoprotein c-
Myc, which activates the transcription of HNRNPA1 and HNRNPA2/B1 [276]. Upon binding 
of these HNRNPA proteins to exon 9 of PKM1, the splicing of PKM1 mRNA is inhibited, 
which allows the synchronous expression of the PKM2 isoform [216] [217]. Upon loss of 
HNRNPA1 function splicing is no longer inhibited and less PKM2 is expressed. The effect of 
HNRNPA1 KD in HeLa cells was previously reported to result only in minor changes in 
PKM splicing pattern. In contrast, depletion of both HNRNPA1 and HNRNPA2/B1 resulted 
in an increase in PKM1 mRNA from 2% to 29%, and a concomitant decrease in PKM2 
mRNA [277]. PKM2 is a limiting glycolytic enzyme that catalyzes the final step in 
glycolysis, which is key in growth. Reduced expression of PKM2 due to loss of HNRNPA1 
could thereby explain the developmental delay observed in hnrnpa1a-/-; hrnnpa1b-/- mutants. 
In zebrafish two PKM orthologues exist: Pkma and Pkmb. Of these pkma is alternative 
spliced resulting in different isoforms of which pkma202 and pkma201 were identified to 
have a high conservation in gene structure and sequence with human PKM1 and PKM2 
isoforms, respectively [219]. 
We did not observe alternative splicing of pkma in zebrafish upon Hnrnpa1 KO, which 
indicates that this splice regulation is not conserved between human cells and zebrafish. The 
growth retardation seems therefore not result from changes in expression of pkma201 and 
pkma202. Interestingly, upon generation of a liver tumor zebrafish model the pkm2 isoform 
was found to be highly enriched and hnrnpa1 (no information available whether this refers to 
hnrnpa1a or hnrnpa1b or both) was greatly upregulated [219]. Discrepancies between these 
findings can be explained in several ways: potentially, loss of Hnrnpa1 function is not enough 
to induce increased pkm201 expression in zebrafish as only minor changes were observed in 
HeLa cells and the tumor zebrafish represents a quite aggressive model. Alternatively, gain 
and loss of Hnrnpa1 function might not simply have opposite function in zebrafish or pkma 
alternative splicing may highly depend on the developmental stage and may thus not occur at 
30 hpf. Furthermore, increased PKM2 expression was only observed in HeLa cells after 
depletion of both HNRNPA1 and HNRNPA2/B1. Since zebrafish lack an HNRNPA2/B1 
orthologue, other genes may be involved to control pkma splicing in zebrafish.  
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4.4.3 Identification of dysregulated candidate genes by NGS 
 
Having excluded expression alterations in the candidate gene pkma as being responsible for 
the impaired metabolism phenotype in hnrnpa1a-/-; hnrnpa1b-/- mutants, I aimed for an 
unbiased approach to identify differentially expressed genes involved in metabolism upon 
Hnrnpa1 KO. NGS revealed 615 differentially expressed genes with more than a two-fold 
change in differential expression and a p-value smaller than 0.01 in 30 hpf hnrnpa1a-/-; 
hnrnpa1b-/- mutants. The only other RNA sequencing data available for HNRNPA1 KO 
comes from a mouse study. The number of genes with altered expression upon HNRNPA1 
KO in mouse and zebrafish are quite different. While Liu et al. report 4355 upregulated genes 
and 4968 downregulated genes in HNRNPA1 KO mouse (foldchange>3; p-value<0.05), with 
the same settings only 121 genes were downregulated and 174 genes upregulated in 
hnrnpa1a-/-; hnrnpa1b-/- mutants. HNRNPA1 dependent regulation of specific mRNAs seems 
to vary in different tissues, organisms, and stages of development. While differentially 
expressed genes upon HNRNPA1 KO were analyzed from the mouse heart, for the analysis of 
zebrafish genes the whole embryos were taken. Moreover, the mouse study compared 
heterozygous HNRNPA1 KO mice to wildtype, while we compared hnrnpa1a-/-; hnrnpa1b-/- 
mutants to wildtype looking embryos, which are a mix of the genotypes of hnrnpa1a+/- and 
hnrnpa1a+/+. 
Functional annotation clustering revealed that the majority of the differentially expressed 
genes in zebrafish are involved in “cell cycle”, “p53 signaling pathway”, “FoXo signaling”, 
and “Notch signaling pathway”. As p53 signaling, FoXo signaling [278], and Notch signaling 
[279] all affect cell cycle progression, I focused on the cell cycle for further analysis.  
4.4.4 Could impaired cell cycle at G1/S-phase be responsible for the metabolic slow 
down in hnrnpa1a-/-; hnrnpa1b-/- mutants? 
 
RNA sequencing of hnrnpa1a-/-; hnrnpa1b-/- mutants revealed cell cycle as one of the most 
altered processes based on differentially expressed genes. The differentially expressed genes 
involved in cell cycle are ccne1, cdkn1a, cdkn2a/b, gadd45, p53, and rbl2. Their increased 
mRNA expression could be verified by qRT-PCR, with the exception of ccne1, which was 
found to be unchanged. Interestingly, genetic profiling studies of ALS patients and ALS 
animal models revealed gadd45, cdkn1a, and rb1 among the top upregulated genes, which 
were also detected in G86R SOD1 mice before symptom onset or motoneuron death [280] 
[281]. The corresponding proteins are all involved in G1/S-phase transmission pointing to 
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impairment of this specific cell cycle step upon Hnrnpa1 KO. Impairment of the cell cycle is 
further supported by the developmental delay and the increased cell death observed in 
hnrnpa1a-/-; hnrnpa1b-/- mutants. Moreover, additional lines of evidence support a role of 
Hnrnpa1 in cell cycle progression. First, Hnrnpa1 has been highly linked to cancer due to the 
finding of increased Hnrnpa1 levels in colorectal cancers and lymphoma [282]. Furthermore, 
one study reported cell cycle arrest at G2/M stage [158], while others showed cell cycle arrest 
at G0/G1 phase upon HNRNPA1 KD [146]. Even though current studies reveal non-
overlapping results, it can be agreed on that reduced HNRNPA1 levels are associated with 
low proliferating or resting cells [283].  
The G1/S transition is tightly controlled by the tumor suppressor protein RB and the E2F 
family of transcription factors. E2F family members bind cell cycle gene promoters and 
thereby control the temporal expression of genes required for the G1/S transition. 
Phosphorylated RB results in the release of the transcription factor E2F and the transcription 
of target genes. In contrast, unmodified RB binds to the E2F transcription factor preventing 
the transcription of target genes [284]. The RBL2/E2F2 is controlled by the p53 pathway. 
During G1/S-phase transition p53 levels are below the threshold that induces activation of 
Cdkn1a and Cdkn1b, which are potent inhibitors of the Ccne/Cdk2 complex. The active 
Ccne/Cdk2 complex phosphorylates Rbl2 upon which it dissociates from E2F2, which 
becomes free and shuttles into the cytoplasm where it binds promoters that initiate 
transcription of S-phase genes. Upon Hnrnpa1 KO, p53 levels are highly upregulated causing 
transcriptional enhancement of cdkn1a and cdkn2b, whose encoded proteins are active 
inhibitors of Cdk2. At the same time p53 directly regulates transcription of gadd45, which is a 
tumor suppressor gene, and induces upregulation that causes inhibition at G1/S-phase by 
interaction with Cdkn1a and Cdkn2b [285]. The inhibition of Cdk2 activity prevents 
phosphorylation of Rbl2 and hence dissociation of E2F2. As a result, E2F2 does not shuttle to 
the cytoplasm to initiate transcription of its target genes and the cell remains in G1 phase (see 
Figure 4.2) [286]. Reduced G1/S-phase transition can occur in response to several initiators, 
such as cellular stress or DNA damage.  
We addressed cell cycle progression of hnrnpa1a-/-; hnrnpa1b-/- mutants by analyzing the 
protein levels of Pcna, which was previously reported to label actively dividing cells, and did 
not observe any difference between hnrnpa1a-/-; hnrnpa1b-/- and wildtype looking siblings. 
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Figure 4.2 - Scheme illustrating the hypothetical cell cycle impairment in G1/S-phase transition in 
hnrnpa1a-/-; hnrnpa1b-/- mutants. For explanation see text.  
 
Likewise, Western blotting with a Pcna specific antibody was not substantially altered in the 
mutants. However, for the analysis of Pcna protein levels the whole embryo was taken. 
Therefore, lower levels of Pcna in a specific region that may be affected by reduced 
proliferation could be masked by other region showing greater proliferation. The changes in 
cell proliferation may also be below detection limit and small changes in the size of the 
analyzed embryos may cover subtle changes in Pcna protein levels. The staining pattern of 
Pcna is not clear, as many cells cannot be assorted to a specific cell cycle phase according to 
their staining. Quantification of cells undergoing a specific cell cycle phase is therefore not 
possible and no conclusion can be drawn whether more cells remained in G1 phase upon 
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Hnrnpa1 KO. For a more detailed and clear analysis, the transgenic Dual Fucci zebrafish 
carrying reporters that permit in vivo imaging of the cell cycle by labeling each cell cycle 
stage at a different fluorescence would be a more suitable model [287]. The finding of 
differentially expressed cell cycle associated genes upon Hnrnpa1 loss of function suggest a 
crucial role of Hnrnpa1 in controlling important mediators of the cell cycle, which is 
particularly important during development. However, functional impairment of the cell cycle 
in hnrnpa1a-/-; hnrnpa1b-/- mutants could not be directly shown and would require further 
crossings to a transgenic reporter fish. The upregulation of some genes in cell cycle control 
upon Hnrnpa1 KO can also promote apoptotic pathways, which also plays an important role 
during normal development. It remains to be determined whether p53 activation is a direct 
effect of Hnrnpa1 loss of function. As a follow up one could examine when p53 activation 
starts by measuring p53 RNA levels throughout embryo development at various time points 
earlier than the currently selected 30 hpf. Moreover, it would be interesting to examine if the 
expression of p53 and its target genes is localized to specific regions in the hnrnpa1a-/-; 
hnrnpa1b-/- mutants by performing an ISH and if MO mediated KO of p53 rescues the 
developmental delay or apoptosis.  
4.4.5 Lipid metabolism defects in hnrnpa1a-/-; hnrnpa1b-/- mutants 
 
While we could not pinpoint cell cycle defects to the observed metabolic deficits we aimed 
for other pathways that may be altered and ultimately lead to cell cycle impairment. The 
thinned yolk extension of hnrnpa1a-/-; hnrnpa1b-/- mutants points to impaired lipid 
metabolism upon Hnrnpa1 KO. There is so far little evidence of involvement of HNRNPA1 
in lipid metabolism and no alterations in lipid related genes were reported upon HNRNPA1 
KO in mice [162]. One study revealed an indirect role of HNRNPA1 in metabolism as the 
liver of high-fat-diet fed mice contained decreased nuclear HNRNPA1 compared to the liver 
of standard-diet-fed mice. The authors propose endoplasmatic reticulum (ER) stress related 
HNRNPA1 translocation to the cytosol where it mediates the activation of the transcription 
factor SREBP-1, which modulates expression of several enzymes involved in lipid synthesis 
[288]. Due to the fact that dysregulated energy metabolism is frequently linked to ALS, we 
focused on the phenotype in more detail. Hyperlipidaemia in particular was proposed as one 
of the reasons for energy imbalance in ALS patients and current literature suggests that the 
lipid metabolism plays a crucial role in ALS progression. However, the findings are still 
controversial and the underlying mechanisms linking lipid metabolism defects and ALS 
remain unclear.  
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A standard approach to assess lipid expression in the developing zebrafish embryo is to 
perform ORO staining that labels the neutral lipids and triglycerides. Under healthy 
conditions ORO staining in the yolk gradually decreases over time, meaning that less neutral 
lipids are present in the yolk. The lipids were then either used up by the embryo or were 
stored in the embryo body. In hnrnpa1a-/-; hnrnpa1b-/- mutants, ORO stain revealed lower 
amount of neutral lipids in the yolk extension and increased uptake from the yolk extension to 
the zebrafish trunk, suggesting that the yolk extension thinning arises from increased uptake 
of lipids. This finding implies an important role for Hnrnpa1 in lipid transport and metabolism 
during zebrafish development. The underlying mechanisms remain unclear raising the 
question how increased neutral lipid transport is mediated.  
During the first four days of development, zebrafish are lecithotrophic and rely on their yolk 
sac for the nutrients needed to sustain growth and survival. The developing embryo receives 
vital fat-solube vitamins from the yolk, as well as triacylglyerol and cholesterol, which is an 
essential component of cell membranes. The yolk syncytial layer (YSL) is implicated in yolk 
lipid metabolism and lipoprotein biogenesis, to transport yolk nutrients to the developing 
embryos [289]. Upon formation of the circulatory system, lipoproteins transport the yolk 
lipids to their specific target site via the bloodstream [290]. Defective lipoprotein assembly 
during embryogenesis was demonstrated to result in unabsorbed yolk phenotype suggesting 
that yolk lipids are assembled into lipoproteins for transport to the developing embryo [291] 
[292] [293].  
It is of particular interest to identify how lipids are being transported through the living 
embryo and at what point of development lipid usage becomes impaired in hnrnpa1a-/-; 
hnrnpa1b-/- mutants. As a next step, to assess lipid absorption and metabolism during 
zebrafish development, one can inject BODIPY labeled fluorescent FA analogs that closely 
resemble native FAs.  
4.4.6 Identification of a lipid transporter gene as the main hit 
 
Analysis of differential expression of genes that may be responsible for lipid processing in 
hnrnpa1a-/-; hnrnpa1b-/- mutants revealed the genes apoda.1, nampt and gpnmb as promising 
candidates. qRT-PCR confirmed downregulation of gpnmb and apoda.1, but not nampt. The 
reduction in apoda.1 and gpnmb paired with their involvement in metabolism suggest that 
reduction the corresponding proteins could be responsible for the metabolic defects observed 
in hnrnpa1a-/-, hnrnpa1b-/- mutants. Since Apoda.1 is a lipid processing protein and the 
hnrnpa1a-/-, hnrnpa1b-/- mutants show striking lipid processing defects, I focused my further 
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analysis on Apoda.1. APOD belongs to the lipocalin family of glycoproteins, binds small 
hydrophobic ligands, and was associated with lipid metabolism and metabolic syndrome 
[294] [295] [296] [297]. These studies clearly indicate an important role of APOD in energy 
and lipid homeostasis. However, the precise role of APOD remains unclear. No splicing 
alteration of apoda.1 mRNA was detected, indicating regulation of transcription itself or 
RNA degradation by Hnrnpa1.  
4.5 Apoda.1 as a potential link of the distinct lipid phenotype in hnrnpa1a-/-; 
hnrnpa1b-/- mutants 
 
Apoda.1 is downregulated by 8.9 fold upon KO of HNRNPA1 in zebrafish and is involved in 
lipid transport. Due to the lack of a zebrafish specific antibody, the protein levels of Apoda.1 
could not be analyzed. If decreased expression of apoda.1 is responsible for the metabolic and 
lipid phenotype observed in hnrnpa1a-/-; hnrnpa1b-/- mutants, KD of apoda.1 in AB wildtype 
embryos should mimic the Hnrnpa1 associated loss of function phenotype. Upon MO KD we 
could not only identify a specific role for apoda.1 to cause a similar lipid phenotype as upon 
Hnrnpa1 deficiency, but also determine a dosage dependent phenotype severity. Moreover, 
we could show that a certain threshold of at least 75% apoda.1 reduction has to be reached in 
order to fully phenocopy the observed thinning of the yolk extension in hnrnpa1a-/-; 
hnrnpa1b-/- mutants. For making the final link between the phenotype observed upon Hnrnpa1 
KO and Apoda.1 loss of function it will be interesting to determine whether Apoda.1 
overexpression can rescue the lipid phenotype in the hnrnpa1a-/-; hnrnpa1b-/- mutants.  
4.5.1 How could reduced Apoda.1 cause increased lipid transport across the YSL? 
 
Having identified apoda.1 as one of the most downregulated genes upon Hnrnpa1 KO the 
question remains whether and how apoda.1 is involved in causing the observed lipid 
phenotype. APOD is a small glycoprotein of 29 kDa with a high degree of sequence 
conservation among different species. It is a soluble carrier protein and has many functions 
including protection from oxidative stress and lipid transport. Both the different structure of 
APOD compared to the other apolipoprotein family members, such as APOB and APOC, as 
well as its allocation to the lipocalin family suggest a distinct role of APOD in lipid transport. 
While the APOD gene has been thoroughly studied in humans and mice, linking its abnormal 
expression to human diseases, such as PD and AD, only little is known about the role of 
APOD in zebrafish [298] [299] [300]. In zebrafish there are three copies of the apod gene: a1, 
a2, and b2. apoda.1 KD in AB wildtype embryos results in a thinned yolk extension, 
indicating that Apoda.1 is required for proper lipid processing in zebrafish. Moreover, KO 
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studies from mice demonstrated a correlation between APOD expression and healthy plasma 
lipid profiles. We can only speculate about its role in the developing embryo based on our 
findings and other previous animal studies. The hnrnpa1a-/-; hnrnpa1b-/- mutants show 
increased neutral lipid transport from the yolk extension to the trunk combined with highly 
decreased levels of Apoda.1. A direct role for Apoda.1 in YSL mediated lipid transport seems 
therefore unlikely as one would expect decreased YSL transport upon Apoda.1 loss of 
function as observed in mutants for typical apolipoproteins, such as ApoB and ApoC [301] 
[302]. The KO zebrafish mutant stalactite, lacking the gene encoding microsomal triglyeride 
transfer protein (mtp), which is involved in biosynthesis of apolipoproteinB (ApoB)-
containing lipoproteins, shows defects in yolk absorption pointing to decreased neutral lipid 
transport (characterized by retention of yolk volume and a reduction in neutral lipids in the 
body) and dies after approximately 6 dpf. A similar phenotype is observed upon KD of apoc2 
in zebrafish. No difference in these genes was found in hnrnpa1a-/-; hnrnpa1b-/- mutants, 
implying that lipid transport across the YSL is not directly impaired. It remains though 
unclear whether other proteins are similarly involved in this process. It should be noted at this 
point that the stalactite and apoc2 mutant show, apart from their delay in yolk consumption, 
also an underdeveloped vasculature or ectopic hypersprouting through up- or downregulation 
of vasculature endothelial growth factor (vegf), respectively. These mutants provide a link 
between the lipid impairment and vasculature mispatterning, as observed in hnrnpa1a-/-; 
hnrnpa1b-/- mutants. In contrast, Ear et al. developed a MO KD of the ribosomal protein L11 
(RPL11) that shows a similar thinned yolk extension as hnrnpa1a-/-; hnrnpa1b-/- mutants and 
developmental delay through an increased p53 dependent apoptotic response [303]. It is not 
clear how reduction of RPL11 leads to increased lipid uptake. It is though plausible that due 
to the function of RPL11 in ribosome biogenesis, a process, which is a key component in 
cellular growth [304], RPL11 indirectly regulates the p53 pathway leading to impairment of 
cell cycle progression and metabolic processes, hence providing a phenotypic overlap to the 
hnrnpa1a-/-; hnrnpa1b-/- mutants. The levels of rpl11 are not changed in hnrnpa1a-/-; 
hnrnpa1b-/- mutants, suggesting another link to the p53 pathway activation. Alternatively, 
RPL11 expression may be changed due to alternative splicing or posttranslational 
modifications, both features that were not addressed in our analysis.  
Increased lipid transport and cell cycle impairment may be connected in the following way: 
During embryonic development the yolk, containing mainly lipids, serves as an energy source 
to support growth by keeping the cell cycle going once they are transported to the zebrafish 
body. As a cell divides it undergoes a highly energy demanding transformation, which it will 
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only continue in the presence of the required nutrients, such as lipids that provide the basis for 
membranes. We could show that neutral lipids are effectively transported to the embryo body, 
but we speculate that due to Apoda.1 downregulation these are not being metabolized or 
transported to their target locations and thus accumulate leading to cell cycle progression 
impairment. Lipids are taken up as triglycerides from the yolk, are transported through the 
body, and need to be broken down to FAs for further processing. In case that Apoda.1 is 
required for transport through the body, triglycerides that are taken up from the yolk will 
remain at the YSL where they cannot be further processed. Alternatively, the lipid processing 
itself may be impaired leading to successful lipid transport through the body but ineffective 
break down to FAs. A previous study showed increased peroxisome proliferator-activated 
gamma (PPARγ) mRNA levels, which is a key regulator of lipid metabolism [305], in mice 
overexpressing APOD. The interaction between PPARγ and APOD is directly mediated by 
arachidonic acid (AA), the main ligand of APOD [306]. Likewise, we can assume that upon 
KD of APOD, PPARγ activity is reduced leading to a slow down of lipid metabolism and 
reduced FA uptake and/or processing. The inability of efficient nutrient usage upon APOD 
loss of function is further supported by an APOD KO mouse that shows augmented food 
intake without increase in body weight pointing to enhanced energy expenditure [307]. We 
assume that a similar phenomenon is present in hnrnpa1a-/-; hnrnpa1b-/- mutants. In order to 
compensate the nutrient deficiency more lipids are transported to the zebrafish body from the 
yolk and the embryo uses up its yolk nutrient reservoir ultimately starving to death. Lastly, it 
may be possible that a higher rate of beta-oxidation and usage of fats as a primary energy 
source is present resulting in increased lipid mobilization from the yolk to the trunk. The 
detected increase in neutral lipids in the trunk may reflect the lipids being transported to their 
sites of further processing. The ability of Apoda.1 deficient embryos/larvae to grow and 
survive to 5 dpf suggests that some lipid must be successfully transported to their target sites 
and are effectively used or that other nutrient sources keep the metabolism going at a reduced 
rate.  
We can conclude that Apoda.1 seems to play a distinct role in lipid metabolism compared to 
other apolipoproteins and seems to be not involved in yolk to body lipid transport directly but 
potentially in transporting lipids through the body to the organs. In this scenario, loss of Apod 
function may lead to cells lacking essential nutrients in form of lipids leading to increased 
lipid uptake from to embryonic yolk and ultimate starvation of the embryo. 
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4.5.2 Possible effects of dysregulated APOD in HNRNPA1 ALS/MSP patients 
 
apoda.1 is downregulated upon loss of Hnrnpa1 and seems to be indirectly causative for 
increased lipid transport from the yolk extension to the zebrafish trunk. A loss of HNRNPA1 
function disease mechanism in HNRNPA1 associated ALS is supported by several lines of 
evidence. First, HNRNPA1 essentiality was shown by the lethality of previous loss of 
function animal models. Second, HNRNPA1 has widespread functions by regulating various 
RNAs, and third, HNRNPA1 is cleared from nuclei in cells of HNRNPA1 ALS mutation 
carriers. Likewise, misregulation of apoda.1 may also contribute to disease causing 
mechanisms. The resulting possible effects in the context of neurodegeneration are discussed 
below. APOD is the most robust age dependent upregulated gene in the brain and several 
lines of evidence support a highly neuroprotective role, such as decrease in the number of 
cortex neurons in APOD KO mice [308]. Moreover, APOD is among the top 10 most 
significantly upregulated proteins in CSF obtained from AD, HD, and PD patients [309]. Due 
to its involvement in a variety of cellular functions, APOD may be neuroprotective on several 
levels, e.g. protecting from reactive oxygen species, sustaining lipid transport to neurons, and, 
maintaining astrocyte health.  
First, APOD was shown to protect the aging brain from OS, which is supported by studies in 
mice and flies demonstrating APOD’s ability to decrease lipid peroxides, which are a major 
source of OS, in membranes. Likewise, KO of the APOD drosophila or plant homologue 
results in higher sensitivity to OS [310]. McCarthy et al. could further show a brain specific 
acute APOD upregulation in mice after induction of OS related neurodegeneration [311], 
suggesting a specific function of APOD in the response of the nervous system to oxidative 
injury [312]. These findings clearly support the hypothesis that APOD is an acute response 
protein with a protective function against physiological and pathological OS. Interestingly, 
OS is evident in sALS and fALS [313] [314], and often resembles an early contributor to 
pathology that promotes tissue damage ultimately leading to motoneuron degeneration.  
Second, APOD has a well-established function in transport and modification of lipids, which 
play a critical role in CNS structure, particularly at the cell membrane as lipids control 
membrane fluidity, improve transmission of electric signals, and stabilize synapses [315]. As 
membrane fluidity is directly determined by enrichment of sphingolipids and cholesterol, 
which are known transport targets of APOD, reduced APOD levels are linked to impaired 
membrane integrity [316], a characteristic that was shown to precede ALS disease onset in 
G93A SOD1 mice [317]. Lipid transport becomes particularly important upon exposure to 
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OS, as damaged peroxidized lipids need to be removed from neurons and be transported to 
astrocytes that can oxidize these and generate energy [318].  
Third, APOD was shown to control astrocytes’ reactivity upon stress since lack of APOD 
renders astrocytes more vulnerable to OS [319] and APOD KO mice have higher levels of 
reactive astrogliosis in the cortex [320]. These data suggest that APOD is important to 
maintain astrocyte health, particularly upon exposure to OS, possibly by promoting removal 
of peroxidized lipids. Protecting astrocytes against OS is important as OS triggers astrocyte 
reactivity, lowering neuronal protection over time [321] [319]. In ALS astrocytes change their 
shape and molecular expression pattern indicating a reactive astrocyte state, and interaction 
between motoneurons and astrocytes was shown to be impaired (reviewed in [322]). The 
involvement of APOD in astrogliosis paired with reactive astrocytes in ALS provides a direct 
link between APOD loss of function and motoneuron degeneration by impaired astrocytic 
support.  
Taken together, APOD loss of function is linked to aging, degeneration, and injury of the 
nervous system, all features that are present in ALS patient brains. Due to its neuroprotective 
function APOD plays a vital role in maintaining brain metabolism and loss of APOD function 
may resemble a very early event in disease pathology leading to impaired lipid transport and 
membrane integrity, which over time causes motoneuron degeneration in ALS. Owing to the 
high evolutionary conservation of APOD and its neuroprotective effects, the downregulation 
of APOD upon HNRNPA1 KO may resemble the failure of HNRNPA1 deficient brains to 
protect themselves against age-dependent challenges. It is unlikely that APOD loss of 
function alone causes ALS, but that other environmental or pathological events contribute to 
disease progression. As previously proposed by Dorman et al. as the “two hit model” one 
pathogenic event may not be enough to cause the disease even in the presence of a disease 
associated mutation [323]. In HNRNPA1 ALS cases, the combinatory effect of loss of 
HNRNPA1 function due to mislocalization and aggregation in the cytoplasm resulting in loss 
of neuroprotective APOD function and increased OS may provide the detrimental 
combination leading to ALS pathogenic process initiation. Currently, the late diagnosis allows 
disease mechanism to override regenerative mechanisms leading to accelerated motoneuron 
death.  
Like APOD, the AD associated APOE protein, is a member of the apolipoprotein family, and 
highly expressed in the mammalian system. [324]. As lipid transporters are considered to play 
a role in the nervous system metabolic homeostasis, our findings prompted us to think 
whether APOD may play a similarly important role in ALS as APOE does in AD. In humans 
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three allelic variants of APOE are present, of which the APOE4 allele is the most common 
AD susceptibility locus [325], while APOE2 is considered to be neuroprotective as it 
decreases an individual’s risk for developing AD [326]. While APOD neuroprotection is 
dependent on its expression levels, the presence of one or the other APOE variant determines 
neuroprotective effects in AD patients. Overall, APOD seems to mostly resemble APOE2 
function in AD, since both proteins are beneficial through neuroprotection. 
4.5.3 Therapy 
 
In this study we could identify APOD, which was previously found to have neuroprotective 
capacity, as an interesting highly downregulated gene upon Hnrnpa1 loss of function. The 
identification of the underlying pathogenic mechanisms in ALS, will provide essential 
support in developing effective therapies against this devastating disease. In case that 
decreased APOD levels are an early cause of mutated HNRNPA1 one can design therapies 
much earlier and support regenerative mechanisms. In order to abolish one of the two hits, 
therapeutic approaches could on the one hand aim to reduce OS either by increasing 
endogenous levels of antioxidants or by lowering the generation of OS by stabilizing 
mitochondrial energy production [327]. On the other hand compensation of the lipid 
metabolism defects by providing nutritional support could prevent onset of or at least alleviate 
ALS symptoms. The second approach has been previously realized by providing high caloric 
diet to ALS patients and animal models leading to delayed disease onset and extended 
survival [328] [329] [330].  
Moreover, restoring APOD function seems to be a realistic approach. An interesting link 
between APOD and clozapine, which binds to multiple neurotransmitter receptors and is 
currently used in Schizophrenia treatment, was found [331]. Upon clozapine treatment of 
mice, APOD increased both at the mRNA and protein level in the mouse brain [332]. In the 
case that, as we propose, HNRNPA1 ALS/MSP patients lack APOD upregulation as a 
neuroprotective effect, it will be interesting to determine whether clozapine can restore 
endogenous or increase APOD levels to enhance neuroprotective mechanisms. As a first step, 
we could perform a drug screen in the hnrnpa1a-/-; hnrnpa1b-/- mutants and determine 
whether decreased APOD levels can be upregulated resulting in rescue of the loss of function 
phenotypes of these mutants.  
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5 Conclusion and Outlook 
 
Currently suggested disease pathomechanisms for HNRNPA1 related ALS and MSP include 
loss of HNRNPA1 function due to nuclear clearance or gain of function by HNRNPA1 
deposits that are neurotoxic in ALS and MSP patients. Resolving that question is of 
fundamental importance for understanding the underlying cellular mechanisms of ALS and 
MSP, but also to better develop future therapeutic strategies. My findings demonstrate that 
Hnrnpa1 plays an important role in zebrafish development. We identify a crucial 
physiological requirement of Hnrnpa1 in vessel patterning, muscle maintenance, and 
motoneuron integrity, ultimately leading to premature death if missing. This is in line with 
previous HNRNPA1 KO models in mice and flies, which also showed early lethality or 
reduction in life span, respectively [162] [333]. Due to the early lethality of the HNRNPA1 
KO mouse the consequences of HNRNPA1 loss of function in mammalian development is 
difficult to address. The wide range of cells affected in different HNRNPA1 KO animal 
models associated with cellular toxicity is consistent with a loss of function pathomechanism. 
It will be therefore interesting to determine whether HNRNPA1 patient mutations cause a full 
or partial loss of protein function, or lead to toxic gain of function as previously shown for 
HNRNPA2B1 mutations [102]. The next step will be to rescue the mutant phenotype with 
either wildtype or mutant HNRNPA1 to determine whether mutant HNRNPA1 is sufficient to 
carry out essential functions in zebrafish development. Furthermore, novel animal models 
with KI of the patient mutations need to be developed to additionally address the possibility 
of (toxic) gain of function mechanisms. Alternatively, a combination of loss and gain of 
function could synergistically lead to disease.  
The most striking finding is that Hnrnpa1 regulates lipid transport from the yolk extension to 
the trunk in zebrafish. The direct or indirect mediator of this function is Apoda.1, which is an 
important transporter of lipids and is among the top 10 downregulated genes upon Hnrnpa1 
KO. Interestingly, APOD is highly upregulated upon injury and is greatly expressed in ALS 
and AD patients suggesting a neuroprotective role. It will be interesting to find out whether 
HNRNPA1 directly binds to APOD to regulate its expression levels or which alternative 
pathway connects Hnrnpa1 loss of function to apoda.1 downregulation. To examine whether 
lack of APOD induced neuroprotection is involved in the disease mechanism of ALS/MSP, 
the following questions need to be addressed. First, do HNRNPA1 ALS/MSP lack the APOD 
neuroprotection observed in other neurodegenerative diseases such as AD? Second, are the 
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identified HNRNPA1 targets also differentially expressed in HNRNPA1 ALS patients? So far 
only few HNRNPA1 ALS/MSP cases were identified making it difficult to obtain patient 
material and to address whether they show increased levels of ROS, impaired membrane 
integrity, or defects in their lipid metabolism. The second question can be answered by the 
examination of APOD expression levels and expression pattern of neurons derived from 
HNRNPA1 ALS/MSP patients. Alternatively, one can perform RNA sequencing on 
HNRNPA1 ALS/MSP derived spinal cord/brain tissue or iPSC derived motoneurons to 
determine whether the identified HNRNPA1 targets are also up- or downregulated upon 
HNRNPA1 induced pathology [334]. With the advanced technology it would further be 
possible to utilize cells from healthy individuals and induce HNRNPA1 patient mutations by 
CRISPR/Cas9 technology. These experiments will reveal a potential involvement of APOD in 
HNRNPA1 associated ALS/MSP disease pathomechanisms and provide a new step for the 
ultimate goal of developing a drug for HNRNPA1 specific ALS and potentially sALS.  
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Figure 5.1- Sequences of CRISPR/Cas9 induced mutations that were detected in the F1 generation. A: Offspring from founder fish injected with gRNA 
targeting hnrnpa1a exon1 9 different mutations were identified. B: Offspring from founder fish injected with gRNA targeting hnrnpa1a exon9 resulted in 5 
different mutations C: In offspring from founder fish injected with gRNA targeting hnrnpa1b exon2 5 different mutations were identified D: Offspring from 
founder fish injected with gRNA targeting hnrnpa1b exon9 3 different mutations were identified E: Offspring from founder fish injected with gRNA targeting 
hnrnpa3 exon2 4 different mutations were identified  +: deletion, + insertion, green: ATG start codon, red: mutations (deletion/insertion), blue: ORF 
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Figure 5.2 – Alignement of Hnrnpa1a, Hnrnpa1b and Hnrnpa3. Hnrnpa1a388 (ENSDART00000018131.8), Hnrnpa1a411 (NP_001349307.1), Hnrnpa1b422 
(ZFIN:ZDB-GENE-030912-14), Hnrnpa1b403 (ENSDART00000053267.6), and Hnrnpa3340 (ENSDART00000102934.4) were aligned with CLC Main 
Workbench. Red highlighted letters: aa that are different.  
 
